Cytokine IL-2 prodrugs comprising a cleavable linker

Abstract

This disclosure relates to protease-cleavable cytokine prodrugs. In some embodiments, the prodrugs comprise a targeting sequence. In some embodiments, the prodrugs comprise a pharmacokinetic modulator.

Description

CYTOKINE PRODRUGS COMPRISING A CLEAVABLE LINKER CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority of US Provisional Patent Application No. 62 / 961,537, filed January 15, 2020, which is incorporated herein by reference in its entirety for all purposes. INTRODUCTION AND SUMMARY

[0002] This disclosure relates to the field of cytokine therapeutics, particularly cytokine prodrugs comprising a cleavable linker.

[0003] Cytokines, such as IL-2, are powerful immune growth factors that play a significant role in sustaining an effective immune cell response. IL-2 has been reported to induce complete and durable regressions in cancer patients but immune related adverse effects have reduced its therapeutic potential. In some cases, however, systemic IL-2 administration can activate immune cells throughout the body. Systemic activation can lead to systemic toxicity and indiscriminate activation of immune cells, including immune cells that respond to a variety of epitopes, antigens, and stimuli. The therapeutic potential of IL-2 therapy can be impacted by these severe toxicities.

[0004] IL-2 therapies can also suffer from a short serum half-life, sometimes on the order of several minutes. Thus, the high doses of IL-2 that can be necessary to achieve an optimal immune-modulatory effect can contribute to severe toxicities.

[0005] As a result, cytokine therapeutics that overcome the hurdles of systemic or untargeted function, severe toxicity, and poor pharmacokinetics, are needed. The present disclosure aims to meet one or more of these needs, provide other benefits, or at least provide the public with a useful choice.

[0006] In some aspects, protease-activated pro-cytokines (also referred to as cytokine prodrugs) are provided, which can be administered to a subject in an inactive form. The inactive form can include a cytokine polypeptide sequence, a protease-cleavable polypeptide sequence, and an inhibitory polypeptide sequence capable of blocking an activity of the cytokine polypeptide sequence. Such prodrugs can become activated when the protease- cleavable polypeptide sequence is cleaved by a protease. Cleaving the protease-cleavable polypeptide can allow the inhibitory polypeptide sequence to dissociate from the cytokine polypeptide sequence.

[0007] Many tumors and tumor microenvironments exhibit aberrant expression of proteases. The present disclosure provides cytokine prodrugs that are activatable through proteolytic cleavage, such that they become active when they come in contact with proteases in a tumor or tumor microenvironment. In some cases, this can lead to an increase in active cytokines in and around the tumor or tumor microenvironment relative to the rest of a subject’s body or healthy tissue. One exemplary advantage that can result is the formation of cytokine gradients. Such a gradient can form when a cytokine prodrug is administered and selectively or preferentially becomes activated in the tumor or tumor microenvironment and subsequently diffuses out of these areas to the rest of the body. These gradients can increase the trafficking of immune cells to the tumor and tumor microenvironment. Immune cells that traffic to the tumor can infiltrate the tumor. Infiltrating immune cells can mount an immune response against the cancer. Infiltrating immune cells can also secrete their own chemokines and cytokines. The cytokines can have either or both of autocrine and paracrine effects within the tumor and tumor microenvironment. In some cases, the immune cells include T cells, such as T effector cells or cytotoxic T cells, or NK cells.

[0008] Also described herein are methods of treatment and methods of administrating the cytokine prodrugs described herein. Such administration can be systemic or local. In some embodiments, a cytokine prodrug described herein is administered systemically or locally to treat a cancer.

[0009] A further example of local administration is administration of a cytokine prodrug, such as an IL-2 cytokine prodrug, to boost T regulatory cells. In some cases, the local administration of an IL-2 cytokine prodrug is to an area of inflammation. Such a method can be used to treat chronic autoimmune and / or inflammatory diseases.

[0010] The following embodiments are encompassed.

[0011] Embodiment 1 is a protease-activated pro-cytokine comprising: a cytokine polypeptide sequence; a inhibitory polypeptide sequence capable of blocking an activity of the cytokine polypeptide sequence; a linker between the cytokine polypeptide sequence and the inhibitory polypeptide sequence, the linker comprising a protease-cleavable polypeptide sequence; and a targeting sequence, wherein the targeting sequence is configured to bind an extracellular matrix component, an integrin, or a syndecan; or is configured to bind, in a pH-sensitive manner, an extracellular matrix component, IgB (CD79b), an integrin, a cadherin, a heparan sulfate proteoglycan, a syndecan, or a fibronectin; or the targeting sequence comprises the sequence of any one of SEQ ID NOs: 180-662 or a variant having one or two mismatches relative to the sequence of any one of SEQ ID NOs: 180-662.

[0012] Embodiment 2 is the protease-activated pro-cytokine of the immediately preceding embodiment, further comprising a pharmacokinetic modulator.

[0013] Embodiment 3 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the pharmacokinetic modulator comprises an immunoglobulin constant domain.

[0014] Embodiment 4 is the protease-activated pro-cytokine of embodiment 2, wherein the pharmacokinetic modulator comprises an immunoglobulin Fc region.

[0015] Embodiment 5 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the immunoglobulin is a human immunoglobulin.

[0016] Embodiment 6 is the protease-activated pro-cytokine of any one of embodiments 4-5, wherein the immunoglobulin is IgG.

[0017] Embodiment 7 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the IgG is IgGl, IgG2, IgG3, or IgG4.

[0018] Embodiment 8 is the protease-activated pro-cytokine of embodiment 2, wherein the pharmacokinetic modulator comprises an albumin.

[0019] Embodiment 9 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the albumin is a serum albumin.

[0020] Embodiment 10 is the protease-activated pro-cytokine of any one of embodiments 8- 9. wherein the albumin is a human albumin.

[0021] Embodiment 11 is the protease-activated pro-cytokine of embodiment 2, wherein the pharmacokinetic modulator comprises PEG.

[0022] Embodiment 12 is the protease-activated pro-cytokine of embodiment 2, wherein the pharmacokinetic modulator comprises XTEN.,

[0023] Embodiment 13 is the protease-activated pro-cytokine of embodiment 2, wherein the pharmacokinetic modulator comprises CTP.

[0024] Embodiment 14 is the protease-activated pro-cytokine of any one of embodiments 2- 13, wherein the protease-cleavable polypeptide sequence is between the cytokine polypeptide sequence and the pharmacokinetic modulator.

[0025] Embodiment 15 is the protease-activated pro-cytokine of any one of embodiments 2- 13, wherein the pharmacokinetic modulator is between the cytokine polypeptide sequence and the protease-cleavable polypeptide sequence.

[0026] Embodiment 16 is the protease-activated pro-cytokine of any one of the preceding embodiments, comprising a plurality of protease-cleavable polypeptide sequences.

[0027] Embodiment 17 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the cytokine polypeptide sequence is flanked by protease cleavable polypeptide sequences.

[0028] Embodiment 18 is the protease-activated pro-cytokine of the immediately preceding embodiment, having the structure PM-CL-CY-CL-IN (from N- to C-terminus or from C- to N-terminus), where PM is the pharmacokinetic modulator, each CL independently is a protease-cleavable polypeptide sequence, CY is the cytokine polypeptide sequence, and IN is the inhibitory polypeptide sequence.

[0029] Embodiment 19 is the protease-activated pro-cytokine of any one of the preceding embodiments, comprising the targeting sequence, wherein the targeting sequence is between the cytokine polypeptide sequence and the protease-cleavable polypeptide sequence or one of the protease-cleavable polypeptide sequences.

[0030] Embodiment 20 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the cytokine polypeptide sequence comprises a modification to prevent disulfide bond formation, and optionally otherwise comprises wild-type sequence.

[0031] Embodiment 21 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the cytokine polypeptide sequence has at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of a wild-type cytokine polypeptide sequence or to a cytokine polypeptide sequence in Table 1.

[0032] Embodiment 22 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the cytokine polypeptide sequence is a wild-type cytokine polypeptide sequence.

[0033] Embodiment 23 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the cytokine polypeptide sequence is a monomeric cytokine, or wherein the cytokine polypeptide sequence is a dimeric cytokine polypeptide sequence comprising monomers that are associated covalently (optionally via a polypeptide linker) or noncovalently.

[0034] Embodiment 24 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the inhibitory polypeptide sequence comprises a cytokine-binding domain.

[0035] Embodiment 25 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the cytokine-binding domain is a cytokine-binding domain of a cytokine receptor or a cytokine-binding domain of a fibronectin.

[0036] Embodiment 26 is the protease-activated pro-cytokine of embodiment 24, wherein the cytokine-binding domain is an immunoglobulin cytokine-binding domain.

[0037] Embodiment 27 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the immunoglobulin cytokine-binding domain comprises a light chain variable domain and a heavy chain variable domain that bind the cytokine.

[0038] Embodiment 28 is the protease-activated pro-cytokine of any one of embodiments 26- 27, wherein the immunoglobulin cytokine-binding domain is an scFv, Fab, or VHH.

[0039] Embodiment 29 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the protease-cleavable polypeptide sequence is recognized by a metalloprotease, a serine protease, a cysteine protease, an aspartate protease, a threonine protease, a glutamate protease, a gelatinase, an asparagine peptide lyase, a cathepsin, a kallikrein, a plasmin, a collagenase, a hKl, a hK10, a hK15, a stromelysin, a Factor Xa, a chymotrypsin-like protease, a trypsin-like protease, a elastase-like protease, a subtilisin-like protease, an actinidain, a bromelain, a calpain, a caspase, a Mir 1-CP, a papain, a HIV-1 protease, a HSV protease, a CMV protease, a chymosin, a renin, a pepsin, a matriptase, a legumain, a plasmepsin, a nepenthesin, a metalloexopeptidase, a metalloendopeptidase, an ADAM 10, an ADAM17, an ADAM 12, an urokinase plasminogen activator (uPA), an enterokinase, a prostate-specific target (PSA, hK3), an interleukin-1b converting enzyme, a thrombin, a FAP (FAP-a), a dipeptidyl peptidase, or dipeptidyl peptidase IV (DPPIV / CD26), a type II transmembrane serine protease (TTSP), a neutrophil elastase, a proteinase 3, a mast cell chymase, a mast cell tryptase, or a dipeptidyl peptidase.

[0040] Embodiment 30 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the protease-cleavable polypeptide sequence comprises the sequence of any one of SEQ ID NOs: 700-741, or a variant having one or two mismatches relative to the sequence of any one of SEQ ID NOs: 700-741.

[0041] Embodiment 31 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the protease-cleavable polypeptide sequence is recognized by a matrix metalloprotease.

[0042] Embodiment 32 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the protease-cleavable polypeptide sequence is recognized by MMP- 1.

[0043] Embodiment 33 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the protease-cleavable polypeptide sequence is recognized by MMP- 2

[0044] Embodiment 34 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the protease-cleavable polypeptide sequence is recognized by MMP- 3

[0045] Embodiment 35 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the protease-cleavable polypeptide sequence is recognized by MMP- 7

[0046] Embodiment 36 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the protease-cleavable polypeptide sequence is recognized by MMP- 8.

[0047] Embodiment 37 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the protease-cleavable polypeptide sequence is recognized by MMP- 9

[0048] Embodiment 38 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the protease-cleavable polypeptide sequence is recognized by MMP- 12.

[0049] Embodiment 39 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the protease-cleavable polypeptide sequence is recognized by MMP- 13.

[0050] Embodiment 40 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the protease-cleavable polypeptide sequence is recognized by MMP- 14.

[0051] Embodiment 41 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the protease-cleavable polypeptide sequence is recognized by more than one MMP.

[0052] Embodiment 42 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the protease-cleavable polypeptide sequence is recognized by two, three, four, five, six, or seven of MMP-2, MMP-7, MMP-8, MMP-9, MMP-12, MMP-13, and MMP-14.

[0053] Embodiment 43 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the protease-cleavable polypeptide sequence comprises the sequence of any one of SEQ ID NOs: 80-94 or a variant sequence having one or two mismatches relative to the sequence of any one of SEQ ID NOs: 80-90.

[0054] Embodiment 44 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 80 or a variant sequence having one or two mismatches relative thereto.

[0055] Embodiment 45 is the protease-activated pro-cytokine of any one of embodiments 1- 43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 81 or a variant sequence having one or two mismatches relative thereto.

[0056] Embodiment 46 is the protease-activated pro-cytokine of any one of embodiments 1- 43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 82 or a variant sequence having one or two mismatches relative thereto.

[0057] Embodiment 47 is the protease-activated pro-cytokine of any one of embodiments 1- 43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 83 or a variant sequence having one or two mismatches relative thereto.

[0058] Embodiment 48 is the protease-activated pro-cytokine of any one of embodiments 1- 43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 84 or a variant sequence having one or two mismatches relative thereto.

[0059] Embodiment 49 is the protease-activated pro-cytokine of any one of embodiments 1- 43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 85 or a variant sequence having one or two mismatches relative thereto.

[0060] Embodiment 50 is the protease-activated pro-cytokine of any one of embodiments 1- 43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 86 or a variant sequence having one or two mismatches relative thereto.

[0061] Embodiment 51 is the protease-activated pro-cytokine of any one of embodiments 1- 43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 87 or a variant sequence having one or two mismatches relative thereto.

[0062] Embodiment 52 is the protease-activated pro-cytokine of any one of embodiments 1- 43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 88 or a variant sequence having one or two mismatches relative thereto.

[0063] Embodiment 53 is the protease-activated pro-cytokine of any one of embodiments 1- 43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 89 or a variant sequence having one or two mismatches relative thereto.

[0064] Embodiment 54 is the protease-activated pro-cytokine of any one of embodiments 1- 43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 90 or a variant sequence having one or two mismatches relative thereto.

[0065] Embodiment 55 is the protease-activated pro-cytokine of any one of embodiments 1- 43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 80-89 or 90.

[0066] Embodiment 56 is the protease-activated pro-cytokine of any one of embodiments 1- 43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 91.

[0067] Embodiment 57 is the protease-activated pro-cytokine of any one of embodiments 1- 43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 92.

[0068] Embodiment 58 is the protease-activated pro-cytokine of any one of embodiments 1- 43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 93.

[0069] Embodiment 59 is the protease-activated pro-cytokine of any one of embodiments 1- 43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 94.

[0070] Embodiment 60 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the targeting sequence comprises the sequence of any one of SEQ ID NOs: 180-662, or a variant having one or two mismatches relative to the sequence of any one of SEQ ID NOs: 180-662.

[0071] Embodiment 61 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the targeting sequence comprises the sequence of any one of SEQ ID NOs: 180-662.

[0072] Embodiment 62 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the targeting sequence binds to denatured collagen.

[0073] Embodiment 63 is the protease-activated pro-cytokine of any one of embodiments 1- 61, wherein the targeting sequence binds to collagen.

[0074] Embodiment 64 is the protease-activated pro-cytokine of any one of embodiments 62- 63, wherein the collagen is collagen I.

[0075] Embodiment 65 is the protease-activated pro-cytokine of any one of embodiments 62- 63, wherein the collagen is collagen II.

[0076] Embodiment 66 is the protease-activated pro-cytokine of any one of embodiments 62- 63, wherein the collagen is collagen III.

[0077] Embodiment 67 is the protease-activated pro-cytokine of any one of embodiments 62- 63, wherein the collagen is collagen IV.

[0078] Embodiment 68 is the protease-activated pro-cytokine of any one of embodiments 1- 61, wherein the targeting sequence binds to integrin.

[0079] Embodiment 69 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the integrin is one or more of a1p1 integrin, 021 integrin, a3p1 integrin, a4p1 integrin, a5p1 integrin, a6P1 integrin, a7B1 integrin, a9P1 integrin, a4p7 integrin, avp3 integrin, avp5 integrin, olIbB3 integrin, allIbP3 integrin, aMP2 integrin, or oIIbB3 integrin.

[0080] Embodiment 70 is the protease-activated pro-cytokine of any one of embodiments 1- 61, wherein the targeting sequence binds to von Willebrand factor.

[0081] Embodiment 71 is the protease-activated pro-cytokine of any one of embodiments 1- 61, wherein the targeting sequence binds to IgB.

[0082] Embodiment 72 is the protease-activated pro-cytokine of any one of embodiments 1- 61, wherein the targeting sequence binds to heparin.

[0083] Embodiment 73 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the targeting sequence binds to heparin and a syndecan, a heparan sulfate proteoglycan, or an integrin, optionally wherein the integrin is one or more of al1p1 integrin, a2B1 integrin, a3p1 integrin, 04P1 integrin, a5P1 integrin, a6P1 integrin, a7p1 integrin, a9B1 integrin, a4P7 integrin, avP3 integrin, avP5 integrin, alIbB3 integrin, alllbB3 integrin, «MP2 integrin, or oIIbB3 integrin.

[0084] Embodiment 74 is the protease-activated pro-cytokine of any one of embodiments 72- 73, wherein the syndecan is one of more of syndecan-1, syndecan-4, and syndecan-2(w).

[0085] Embodiment 75 is the protease-activated pro-cytokine of any one of embodiments 1- 61, wherein the targeting sequence binds to a heparan sulfate proteoglycan.

[0086] Embodiment 76 is the protease-activated pro-cytokine of any one of embodiments 1- 61, wherein the targeting sequence binds to a sulfated glycoprotein.

[0087] Embodiment 77 is the protease-activated pro-cytokine of any one of embodiments 1- 61, wherein the targeting sequence binds to hyaluronic acid.

[0088] Embodiment 78 is the protease-activated pro-cytokine of any one of embodiments 1- 61, wherein the targeting sequence binds to fibronectin.

[0089] Embodiment 79 is the protease-activated pro-cytokine of any one of embodiments 1- 61, wherein the targeting sequence binds to cadherin.

[0090] Embodiment 80 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the targeting sequence is configured to bind its target in a pH-sensitive ‘manner.

[0091] Embodiment 81 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the targeting sequence has a higher affinity for its target at a pH below normal physiological pH than at normal physiological pH, optionally wherein the pH below normal physiological pH is below 7, or below 6.

[0092] Embodiment 82 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the targeting sequence has a higher affinity for its target at a pH in the range of 5-7, e.g., 5-5.5, 5.5-6, 6-6.5, or 6.5-7, than at normal physiological pH.

[0093] Embodiment 83 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the targeting sequence comprises one or more histidines, e.g., 1, 2, 3, 4,5,6,7,8,9, or 10 histidines.

[0094] Embodiment 84 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the targeting sequence comprises the sequence of any one of SEQ ID NOs: 641-662, or a variant having one or two mismatches relative to the sequence of any one of SEQ ID NOs: 641-662.

[0095] Embodiment 85 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the targeting sequence comprises the sequence of any one of SEQ ID NOs: 641-662.

[0096] Embodiment 86 is the protease-activated pro-cytokine of any one of embodiments 80- 86, wherein the targeting sequence is configured to bind, in a pH-sensitive manner, an extracellular matrix component, IgB (CD79b), an integrin, a cadherin, a heparan sulfate proteoglycan, a syndecan, or a fibronectin.

[0097] Embodiment 87 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the extracellular matrix component is hyaluronic acid, heparin, heparan sulfate, or a sulfated glycoprotein.

[0098] Embodiment 88 is the protease-activated pro-cytokine of embodiment 86, wherein the targeting sequence is configured to bind a fibronectin in a pH-sensitive manner.

[0099] Embodiment 89 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the cytokine polypeptide sequence is an interleukin polypeptide sequence.

[00100] Embodiment 90 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the cytokine polypeptide sequence is capable of binding a receptor comprising CD132.

[00101] Embodiment 91 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the cytokine polypeptide sequence is capable of binding a receptor comprising CD122.

[00102] Embodiment 92 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the cytokine polypeptide sequence is capable of binding a receptor comprising CD25.

[00103] Embodiment 93 is the protease-activated pro-cytokine of any one of the preceding embodiments, wherein the cytokine polypeptide sequence is an IL-2 polypeptide sequence.

[00104] Embodiment 94 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the IL-2 polypeptide sequence has at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of any one of SEQ ID NOs: 1-4.

[00105] Embodiment 95 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the IL-2 polypeptide sequence comprises the sequence of any one of SEQ ID NOs: 1-4.

[00106] Embodiment 96 is the protease-activated pro-cytokine of any one of embodiments 93-95, wherein the IL-2 polypeptide sequence is a human IL-2 polypeptide sequence.

[00107] Embodiment 97 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the IL-2 polypeptide sequence comprises the sequence of SEQID NO: 1.

[00108] Embodiment 98 is the protease-activated pro-cytokine of any one of embodiments 93-95, wherein the IL-2 polypeptide sequence comprises the sequence of SEQ ID NO: 2.

[00109] Embodiment 99 is the protease-activated pro-cytokine of any one of embodiments 93-98, wherein the inhibitory polypeptide sequence comprises an IL-2 binding domain of an IL-2 receptor (IL-2R).

[00110] Embodiment 100 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the inhibitory polypeptide sequence comprises an amino acid sequence having at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of any one of SEQ ID NOs: 10-19.

[00111] Embodiment 101 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the IL-2R is a human IL-2R.

[00112] Embodiment 102 is the protease-activated pro-cytokine of any one of embodiments 93-98, wherein the inhibitory polypeptide sequence comprises an IL-2-binding immunoglobulin domain.

[00113] Embodiment 103 is the protease-activated pro-cytokine of any one of embodiments 93-98, wherein the IL-2-binding immunoglobulin domain is a human IL-2- binding immunoglobulin domain.

[00114] Embodiment 104 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the IL-2-binding immunoglobulin domain comprises a VL region comprising hypervariable regions (HVRs) HVR-1, HVR-2, and HVR-3 having the sequences of SEQ ID NOs: 33, 34, and 35, respectively, and a VH region comprising HVR-1, HVR-2, and HVR-3 having the sequences of SEQ ID NOs: 36, 37, and 38, respectively.

[00115] Embodiment 105 is the protease-activated pro-cytokine of any one of embodiments 102-104, wherein the IL-2-binding immunoglobulin domain comprises a VL region comprising an amino acid sequence having at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of SEQ ID NO: 32 and a VH region comprising an amino acid sequence having at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of SEQ ID NO: 33.

[00116] Embodiment 106 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the IL-2-binding immunoglobulin domain comprises a VL region comprising the sequence of SEQ ID NO: 32 and a VH region comprising the sequence of SEQ ID NO: 33.

[00117] Embodiment 107 is the protease-activated pro-cytokine of any one of embodiments 102-104, wherein the IL-2-binding immunoglobulin domain is an scFv.

[00118] Embodiment 108 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the IL-2-binding immunoglobulin domain comprises an amino acid sequence having at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of SEQ ID NO: 30 or 31.

[00119] Embodiment 109 is the protease-activated pro-cytokine of the immediately preceding embodiment, wherein the IL-2-binding immunoglobulin domain comprises the sequence of SEQ ID NO: 30 or 31.

[00120] Embodiment 110 is the protease-activated pro-cytokine of embodiment 1, comprising the sequence of any one of SEQ ID NOs: 803-852.

[00121] Embodiment 111 is a pharmaceutical composition comprising the protease- activated pro-cytokine of any one of the preceding embodiments.

[00122] Embodiment 112 is the protease-activated pro-cytokine or pharmaceutical composition of any one of the preceding embodiments, for use in therapy.

[00123] Embodiment 113 is the protease-activated pro-cytokine or pharmaceutical composition of any one of the preceding embodiments, for use in treating a cancer.

[00124] Embodiment 114 is a method of treating a cancer, comprising administering the protease-activated pro-cytokine or pharmaceutical composition of any one of the preceding embodiments to a subject in need thereof.

[00125] Embodiment 115 is a use of the protease-activated pro-cytokine or pharmaceutical composition of any one of embodiments 1-110 for the manufacture of a medicament for treating cancer.

[00126] Embodiment 116 is the method, use, or protease-activated pro-cytokine for use of any one of embodiments 113-115, wherein the cancer is a solid tumor.

[00127] Embodiment 117 is the method, use, or protease-activated pro-cytokine for use of the immediately preceding embodiment, wherein the solid tumor is metastatic and / or unresectable.

[00128] Embodiment 118 is the method, use, or protease-activated pro-cytokine for use of any one of embodiments 113-117, wherein the cancer is a PD-L1-expressing cancer.

[00129] Embodiment 119 is the method, use, or protease-activated pro-cytokine for use of any one of embodiments 113-118, wherein the cancer is a melanoma, a colorectal cancer, a breast cancer, a pancreatic cancer, a lung cancer, a prostate cancer, an ovarian cancer, a cervical cancer, a gastric or gastrointestinal cancer, a lymphoma, a colon or colorectal cancer, an endometrial cancer, a thyroid cancer, or a bladder cancer.

[00130] Embodiment 120 is the method, use, or protease-activated pro-cytokine for use of any one of embodiments 113-119, wherein the cancer is a microsatellite instability-high cancer.

[00131] Embodiment 121 is the method, use, or protease-activated pro-cytokine for use of any one of embodiments 113-120, wherein the cancer is mismatch repair deficient.

[00132] Embodiment 122 is a nucleic acid encoding the protease-activated pro- cytokine of any one of embodiments 1-110.

[00133] Embodiment 123 is an expression vector comprising the nucleic acid of embodiment 121.

[00134] Embodiment 124 is a host cell comprising the nucleic acid of embodiment 121 or the vector of embodiment 122.

[00135] Embodiment 125 is a method of producing a protease-activated pro-cytokine, comprising culturing the host cell of embodiment 124 under conditions wherein the protease- activated pro-cytokine is produced.

[00136] Embodiment 126 is the method of the immediately preceding embodiment, further comprising isolating the protease-activated pro-cytokine.

[00137] Embodiment 127 is a method of boosting T regulatory cells and / or reducing inflammation or autoimmune activity, comprising administering the protease-activated pro- cytokine of any one of embodiments 1-110 to an area of interest in a subject, e.g., an area of inflammation in the subject.

[00138] Embodiment 128 is a method of treating an inflammatory or autoimmune disease or disorder in a subject, comprising administering the protease-activated pro-cytokine of any one of embodiments 1-110 to an area of interest in a subject, e.g., an area of inflammation or autoimmune activity in the subject. FIGURE LEGENDS

[00139] FIG 1A shows an illustration of an exemplary cytokine prodrug structure and an SDS-PAGE gel characterizing a purified cytokine prodrug (Construct B). Abbreviations: PM, pharmacokinetic modulator; HMW, high molecular weight.

[00140] FIG 1B shows an illustration of an exemplary cytokine prodrug structure comprising human IL-2 and IL-2Ra sequences and an MMP-cleavable linker, and an SDS- PAGE gel and Western blot characterizing a purified cytokine prodrug (Construct E). Abbreviations: Hu, human; MMP, matrix metalloprotease; other abbreviations are as above.

[00141] FIG 1C shows an illustration of an exemplary cytokine prodrug structure comprising murine IL-2 and IL-2Ra sequences, an MMP-cleavable linker, additional linkers that include a targeting sequence (“RET Linker”), and an SDS-PAGE gel characterizing the indicated purified cytokine prodrugs.

[00142] FIG 1D shows an illustration of an exemplary cytokine prodrug structure comprising human IL-2 and IL-2Ra sequences, an MMP-cleavable linker, additional linkers that include a targeting sequence (“RET Linker”), and an SDS-PAGE gel characterizing the indicated purified cytokine prodrugs.

[00143] FIG 2A illustrates a cleavage reaction of a cytokine prodrug by a protease and shows Western blot evidence of cleavage of Construct A by MMP-9 at time points of 1, 2, and 4 hours and overnight. Each of the Western blots contains +MMP digestion lanes and - MMP mock-digestion lanes. Cleavage product was detectable at 1 hour, and the full-length cytokine prodrug was substantially undetectable at the overnight +MMP time point.

[00144] FIG 2B illustrates a cleavage reaction of a cytokine prodrug comprising a pharmacokinetic modulator by a protease and shows Western blot evidence of cleavage of Construct B by MMP-9 at time points of 1, 4, and 20 hours. Each of the Western blots contains +MMP digestion lanes and -MMP mock-digestion lanes. Cleavage product was detectable at 1 hour, and the full-length cytokine prodrug gave only a faint band at the 20 hour +MMP time point.

[00145] FIGs 2C-E illustrate cleavage reactions of a cytokine prodrug comprising a pharmacokinetic modulator by a protease and shows Western blot evidence of cleavage of Construct E by MMP-9 at time points of 1, 4, and 22 hours (2C); and cleavage of the indicated constructs at 18 hours (2D and 2E). Constructs BBB, CCC, and FFF in Fig. 2E that did not show substantial cleavage had scrambled MMP sites. Each of the Western blots contains +MMP9 digestion lanes and -MMP9 mock-digestion lanes. Cleavage product was detectable at 1 hour, and the full-length cytokine prodrug gave essentially no band at the 22 hour +MMP time point.

[00146] FIG 3A shows results of a CTLL-2 proliferation assay with Construct A or cleavage products thereof. Construct A was cleaved by MMP-9 and the resulting products were incubated with CTLL-2 cells. The data shows that MMP-9 treated Construct A stimulates CTLL-2 cell proliferation in a dose dependent manner and exhibits 10-fold greater activity than untreated Construct A (EC50 comparison). EC50 values are shown in nM.

[00147] FIG 3B shows results of a CTLL-2 proliferation assay with Construct B or cleavage products thereof. Construct B was cleaved by MMP-9 and the resulting products were incubated with CTLL-2 cells. For comparison, mIL2 was also incubated with CTLL-2 cells. The data show that MMP-9 treated Construct B stimulates CTLL-2 cell proliferation in a dose dependent manner. Uncleaved Construct B was minimally stimulatory. EC50 values are shown in nM.

[00148] FIG 3C-FIG 3J show HEK-Blue™ IL2 assay results. Cells were treated with various concentrations Construct E, uncleaved or cleaved with mMMP9 for 22 hours (FIG 3C); human IL2 (FIG 3D); Construct B, uncleaved or cleaved with mMMP9 for 19 hours; Construct J, Construct K, Construct F, Construct L, or Construct I, each uncleaved or cleaved with mMMP?9 for 22 hours (FIGs 3E-J, respectively); and the EC50 was determined based on 0OD630 as a readout of IL-2 stimulation.

[00149] FIG 3K-FIG 3L show results of a CTLL-2 proliferation assay with Construct M, Construct N, or cleavage products thereof. Cleavage was by MMP-2 for 2 hr and the resulting products were incubated with CTLL-2 cells. The data show that MMP-2 treated Construct M and Construct N stimulate CTLL-2 cell proliferation in a dose dependent manner. EC50 values are shown in nM.

[00150] FIG 3M shows Coomassie-stained SDS-PAGE results comparing Construct E, Construct M, and Construct N. Construct M and Construct N showed decreased aggregation and greater stability and homogeneity.

[00151] FIG 3N-FIG 3P show results of a CTLL-2 proliferation assay with Construct 0, Construct P, Construct Q, or cleavage products thereof. Cleavage was by MMP2 for 2 hr and the resulting products were incubated with CTLL-2 cells. The data show that MMP2 treated Construct O, Construct P, and Construct Q stimulate CTLL-2 cell proliferation in a dose dependent manner. EC50 values are shown in nM.

[00152] FIG 3Q-FIG 3Y show results of a HEK-Blue™ IL2 assay with the indicated construct or cleavage products thereof. Cleavage was by MMP for either 18 hr or 22 hr and the resulting products were incubated with HEK-Blue™ IL2 cells. EC50 was determined based on OD630 as a readout of IL-2 stimulation. The data show that MMP? treated constructs stimulate IL-2 in a dose dependent manner. EC50 values are shown in nM.

[00153] FIG 4 illustrates a serum stability assay using Construct B and provides results thereof indicating that Construct B was stable when incubated with serum collected from control or tumor-bearing over a time course of 72 hours. Concentrations were measured by quantitative sandwich ELISA using an mIL2 capture antibody and mIL2Ra detection antibody.

[00154] FIG 5 shows a study design, graphical results, and pharmacokinetic (PK) parameters for Construct B in mice. PK parameters were calculated using WinNonlin 7.0 (non-compartmental model).

[00155] FIG 6A shows a study design and results for intratumoral dosing of Construct A in mice injected subcutaneously with MC38 cells at day -7 and then treated with Construct A, vehicle, or human IL-2 on each of days 0-4 and 7-11. Construct A substantially inhibited tumor growth. In contrast, human IL-2 adversely affected tumor control relative to vehicle. Necrosis attributable to tumor growth was observed in the control and human IL-2 groups.

[00156] FIG 6B shows a study design in which mice treated as in FIG 6A were re- challenged with 2x10 MC38 cells at day 40. Tumor growth was rejected, indicating that the treatment resulted in a durable response including anti-tumor immune memory.

[00157] FIG 7A shows a study design in mice injected subcutaneously with MC38 cells at day -10 where Construct B or vehicle was administered intravenously once per three days (Q3D) during a three week period (eight total administrations). Essentially no systemic toxicity was observed. Construct B-treated mice showed virtually no tumor growth after initiation of treatment, in contrast to vehicle-treated mice where tumor growth continued through day 21. Following day 21, several vehicle-treated mice were euthanized due to tumor volume exceeding 3000 mm? and accordingly subsequent tumor volume data for vehicle- treated mice is not shown as it would be biased toward mice with smaller tumor volumes relative to the population average through day 21.

[00158] FIG 7B shows body weight data for the same mice as in FIG 7A. Mouse body weight was substantially constant during treatment with Construct B, consistent with lack of any apparent toxicity.

[00159] FIG 8 shows immunohistochemistry results for tumor-infiltrating immune cells at day 21 for vehicle group tissues and at day 25 for Construct B treated tumors of the study described above for FIG 7A. Significantly more immune cells of all tested types were observed in Construct B-treated mice compared to vehicle-treated mice. Additionally, the proportion of cells with markers consistent with a effector T cell phenotype was substantially greater than the proportion of CD4+Foxp3+ (regulatory T) cells. Statistical analysis was performed using unpaired t test by Prism 5.0 software. P value between groups was calculated, and the differences with p value <0.05 were considered statistically significant. * p<0.05, ** p<0.01, *** p<0.001.

[00160] FIG 9 shows quantification of MMP activity in the indicated tumor-bearing mouse models by fluorescence intensity over time following MMPSense 680™ injection.

[00161] FIG 10A-FIG 10D show tumor volume over time for mice treated with vehicle or Construct B as indicated in the indicated cancer models.

[00162] FIG 11A-FIG 11D show tumor volume over time (11A) and levels of the indicated enzymes (11B-D) for mice treated with vehicle or Construct B as indicated in the B16F10 melanoma model.

[00163] FIG 12A-FIG 12D show tumor volume over time (12A) and levels of the indicated enzymes (12B-D) for mice treated with vehicle or Construct B as indicated in the RM-1 prostate cancer model.

[00164] FIG 13A shows MMP activity, measured as described for FIG 9, in the indicated groups.

[00165] FIG 13B-FIG 13C show tumor volume over time for mice treated with vehicle or Construct B as indicated in the indicated cancer models.

[00166] FIG 14A-B show schematic structures of the indicated linkers and binding of MMP linker peptides containing heparin binding motifs to heparin-agarose beads.

[00167] FIG 14C shows cartoons of the structures of the indicated constructs and heparin binding assay results for the indicated constructs. Assays were performed at pH 7.5 unless indicated as performed at pH 6.

[00168] FIG 14D shows schematic structures of the indicated linkers and binding of the indicated peptides to fibronectin at the indicated pH values.

[00169] FIG 14E shows fibronectin binding assay results for the indicated constructs. Assays were performed at pH 7.5 unless indicated as performed at pH 6.

[00170] FIG 14F shows schematic structures of the indicated linkers and binding of MMP linker peptides containing collagen binding motifs to beads associated with collagen Vv.

[00171] FIG 14G shows an anti-mIL2 Western blot of input (I), supernatant (S), collagen-bound (C) and control agarose bound (A) fractions from pulldown assays performed with the indicated constructs.

[00172] FIG 15A shows fluorescent images of mice treated with the indicated constructs as described in Example 15.

[00173] FIG 15B shows tumor-associated fluorescence measured in mice treated with the indicated constructs as described in Example 15.

[00174] FIG 15C-H show amounts of the indicated constructs present in tumor lysates prepared as described in Example 16. Here and throughout, mpk means mg / kg.

[00175] FIG 15I-K show amounts of the indicated constructs present in serum samples prepared as described in Example 16.

[00176] FIG 16A-B show tumor volume over time for groups treated with the indicated constructs as described in Example 17.

[00177] FIG 17A-B show IFN-y levels in tumors following treatment with the indicated constructs as described in Example 18.

[00178] FIG 18A-E show exemplary arrangements of elements in cytokine prodrugs comprising various combinations of a cytokine polypeptide sequence (CYTOKINE), a pharmacokinetic modulator (PK EXT), a protease-cleavable polypeptide sequence in a linker (PRO-LNK), an inhibitory polypeptide sequence (INHIBITOR), and in some cases one or more targeting sequences (RET LNK) or additional linkers (LNK). The targeting sequences are shown as white text on a dark background. In FIGs 18A and 18C, the pharmacokinetic modulator is on the same side of the protease-cleavable sequence as the inhibitory polypeptide sequence, so that it would not impact the pharmacokinetics of the cytokine polypeptide sequence. In FIGs 18B and 18D, the pharmacokinetic modulator is on the same side of the protease-cleavable sequence as the cytokine polypeptide sequence, so that it would impact the pharmacokinetics of the cytokine polypeptide sequence. In FIG 18E, a protease- cleavable sequence is present on each side of the pharmacokinetic modulator. This arrangement can produce intermediate results as the pharmacokinetic modulator would be separated from the cytokine polypeptide sequence more slowly than the inhibitory polypeptide sequence. DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

[00179] This specification describes exemplary embodiments and applications of the disclosure. The disclosure, however, is not limited to these exemplary embodiments and applications or to the manner in which the exemplary embodiments and applications operate or are described herein. The term “or” is used in an inclusive sense, i.e., equivalent to “and / or,” unless the context dictates otherwise. It is noted that, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the,” and any singular use of any word, include plural referents unless expressly and unequivocally limited to one referent. As used herein, the terms “comprise,” “include,” and grammatical variants thereof are intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that can be substituted or added to the listed items. Section divisions in the specification are provided for the convenience of the reader only and do not limit any combination of elements discussed. In case of any contradiction or conflict between material incorporated by reference and the expressly described content provided herein, the expressly described content controls. Overview

[00180] Provided herein are protease-activated pro-cytokines (also referred to herein as cytokine prodrugs) comprising a linker comprising a protease-cleavable linker and a targeting sequence described herein, e.g., a targeting sequence configured to bind an extracellular matrix component, an integrin, or a syndecan; or configured to bind an extracellular matrix component, IgB (CD79b), an integrin, a cadherin, a heparan sulfate proteoglycan, a syndecan, or a fibronectin in a pH-sensitive manner; or a targeting sequence comprising the sequence of any one of SEQ ID NOs: 180-662. The cleavable linker can be between a cytokine polypeptide sequence and an inhibitory polypeptide sequence, such that the ability of the cytokine polypeptide sequence to activate immune cells is reduced or eliminated compared to a free cytokine polypeptide sequence. Proteolysis of the linker can liberate the cytokine so that it can activate immune cells.

[00181] In some embodiments, the protease-cleavable linker is cleavable by a protease expressed at higher levels in the tumor microenvironment (TME) than in healthy tissue of the same type. In some embodiments, the protease-cleavable linker is a matrix metalloprotease (MMP)-cleavable linker, such as any of the MMP-cleavable linkers described herein. Without wishing to be bound by any particular theory, increased expression of proteases, including but not necessarily limited to MMPs, in the tumor microenvironment (TME) can provide a mechanism for achieving selective or preferential activation of the cytokine prodrug at or near a tumor site. Certain protease-cleavable linkers described herein are considered particularly suitable for achieving such selective or preferential activation.

[00182] In other embodiments, the cytokine prodrug comprises a targeting sequence, e.g., a targeting sequence that binds an extracellular matrix component, an integrin, or a syndecan, or is configured to bind fibronectin in a pH-sensitive manner. The targeting sequence can facilitate accumulation and / or increased residence time of the cytokine prodrug and / or the active cytokine in the ECM. In some embodiments, a targeting sequence is combined with a protease-cleavable linker cleavable by a protease expressed at higher levels in the TME and / or cleavable by an MMP.

[00183] In any of the foregoing embodiments, the cytokine prodrug may further comprise a pharmacokinetic modulator, e.g., which extends the half-life of the prodrug and which may optionally also extend the half-life of the active cytokine.

[00184] Sequences of exemplary cytokine prodrugs and components thereof are shown in Tables 1 and 2. In Table 1, “Xuy” designates a hydrophobic amino acid residue. In some embodiments, the hydrophobic amino acid residue is any one of glycine (Gly), alanine (Ala), valine (Val), leucine (Leu), isoleucine (Ile), proline (Pro), phenylalanine (Phe), methionine (Met), and tryptophan (Trp). In some embodiments, the hydrophobic amino acid residue is any one of Ala, Leu, Val, Ile, Pro, Phe, Met, and Trp. In some embodiments, the hydrophobic amino acid residue is any one of Leu, Val, Ile, Pro, Phe, Met, and Trp. In some embodiments, the hydrophobic amino acid residue is any one of Ala, Leu, Val, Ile, Phe, Met, and Trp. In some embodiments, the hydrophobic amino acid residue is any one of Leu, Val, Ile, Phe, Met, and Trp. “(Pip)” represents piperidine. “(Hof)” represents homophenylalanine. “(Cit)” represents citrulline. “(Et)” represents ethionine. “C(me)” represents methylcysteine. In certain sequences, underlining is used to indicate mutated positions.

[00185] This disclosure further provides uses of these cytokine prodrugs, e.g., for treating cancer. In some embodiments, the cytokine prodrug is selectively or preferentially cleaved in the tumor microenvironment, which may result in beneficial effects, e.g., improved recruitment and / or activation of immune cells in the vicinity of the tumor, and / or reduced systemic exposure to active cytokines. © - N 8 2g 3 2 Foo 2 = SES z 3 3523 = g o 2 £ 5 i 3 3 3s 3 2 = & 5 £ 5 5 S 2 £ £ wn = = ~ < nok — >= no wu Twig =Q Un) eX C <E UC oc Z Zk XE OO [4 [g- = Ww UF > un =n Lg gt 2 3 wa ASE ~ 22 — 0 3 => Ef 20 5 2 E> HOG 24Z of iL XH o£ O< az LEC Zn OC zd gE: za OU x 2 Zz Wf < =a 0 wo Oe Zz x > zd J OF — Th = WC HL = 2 ZF 0a SX nn 29S 232 43 Io] JZ» z52 —- = CO: ZO <L XC To ¥E LS ie bs 285 +H JIE I 3 on Zz oS =x Uk x JT uw 0 o o LW Qu u =w> oUF c nw A [FY=g v wv = Qyu 2 nQ< ag: T - = O = 4 Q a Jw o [28 3 wn <IOQ gu=s £ 2 o £ T(E £ 2 |= g " 8 E Hi a § |E=2 ==2 a 2= z= = £ @ © o_o $ «oa © =2a0 = 5222 22 Qc XE = 2 38 2 § EEE SE gg 85> SE SE SE: = = = = 3 I} Ss I} 3 x ] = S S S S = = = is = = = 5 8 § § § E £ E £ 5 3 3 3 = = = = no no oH no HH n>wn na J na J no J 42 Iwo Iwo Iwo Uz nex dH nea H nea H EITC noon woown wou own oz ZICH ZIEF ZIFF Z>Ju CT zw COzw CO zw SOTO FAX E FAEE FAXES >TO = Ud == Ud == wHZ J got PE Fx >uzo <9 <9 <0 ZX = Z oes oH LH: 25k ZSEX GEE eo RSS RSS RSS gJes X= > XZ>0 => > w0nx HQ HOOT Hoi Low Lyla xpua xywo sak xo OC x F< dH Ea Ea Ea Sux Owg oug © wg JWI Erg = gg FuIg YET ¥—=IQ YET LER Ux JO Ux JU Ux JO > JJ Lx sa Ln Ln h>z> Owe Ou Owe JT Wh Z x > Wl Z x > Ww Z x > Wl nna a Jon Zon Jon oug J HW ELSw HuSw EXZED FwSo Fwu>o Fw>o a OBL a Oo wa De wa De SH¥uW ues wee veel xX >I J Ya Fu ~ o ~ o oJ¥< xeZ5 xe a Rs a ZZ > <>2>0 <« a < @ LoS £955 $955 $955 52228 SEGE ©Eog SEGE <¥IOZ cE 3 3 FzZIY =zZ5UW EzSW EzSW gr <clw <xiw <iw a>FE=zn TEIO IEIO IEIO I Tq>a La La zigzz Hu HL Hv HL Hv HL [Cr -A=17] wwe woneo wwe ZI 20 own Qo Wn owen cZaon= aU oF oUF FEWET Qo cw oo<w ooqw oxi QUE OWE UWS Hoag agzu agzu agzw rLe8= CEify [CEify LEifr [Fuge ZSECT Z280a ZSE0T “nox = E Eo £ £ £8 £3 o so 22 fg 2 522} =§ 2% 29 Eos z2 =2 z2 Fd 2 EF 5 — — ~ wv wv I = LE SL 2 ,Ez5% [8% 25 535-8 = = =a = gE 88 fiz 28,555 2% E3228 [582 EES ERE — I~ — os bs 3 = 3 2 % 2 2 2 2 8 0 be 1 oO ° -= © 2, 2 z §28: [Ef : i: EZ 53 ES 5 2 i: 2388 ES 3 2st : = 23 5% 3 18 2 — 2 : Es &a8 £52 258 152 228, [|238x aT an kt EF |= =r B= wv wv a o 8 2 1283.58 2§ E5E28-5 E|5s2a|5% 58 [BE £58550 528 523 258 58 [98 REESEIEREEZEQE382 [SE |JE 3 2 2 2 3 2 i g gE BEE o = =) o 0 0 § § g § § § E E E E E E 2 g 3 3 3 3 = = = = = = TUE TU=Z pL TUE [TUZ (TUX nIx nx Ty nNIg |WIg [WI nok nok wn IT ox NOE VO VUE Zax Zax no Zoyx |Zzox |zox Oa [cpio zd x UJ0 |OJ0 [OJ0 Cag CaE OQ CRE G2E IG2F <E <E ~n I <E <= <= JO 29 YgE JO [JOE [2Q= EOXO EO¥O [29 EO0¥ [EO EO EYL gS axxo EY EY ZEY >0 Ja >0 29k JB > |aA> |B > hoh wn oh >0 |[nwgh |[ngh [hgh 02 uw 0 = Ww Ion zw zw OzW na na << WF Ww nog ag nag 225 £252 EAC [Sof |2af af — a H aH iH H H x2) sx [00d |E2xXUXxzxXxxxzxXU Fan WITH [EEE0 [XUTOLWUIAXWUIN 53k Gogh BEIPR [SESBBESEBESE gCed eC gE3k PLEneCeneEsa 02 >= Wi M¥O>W I¥M¥XV (Miedo >w Uw Owpa [UeE>w [UubauwbalUuwba ux Se Hoe Wubs Mxoplxosuxox Vo>0 VO>0 [U¥Ox QO>0V0O>00VO0>0 ZwOuw ZuQw [2030 (ZulWZuOWUZwWdwW Jw on Jwoh |JwWuw (Jwohs|lJwgaldwda HQ >» ZQa>u Zwoa (Ea >ruHL>0n=EZa>un HO FO>< |Fo>W0n |EFO><-O EPS VES o VEST [Worg (WESOLAESOVE SC wh-=0 WF=Z08 |Wa>0 (WEEAalWE-ZaupE-=0 XX > Ox ¥>Ox% EES X>OMIX>TMIX > >o0ouw >o0W _|I>>0% | >o0W>oouw>o0w I¥24g SEUoEgoUogEcHgESHIsESH =E>0> SF>2U0>EX2UW>EF>0EF>0EF>0 Seif goiowgia>ougEiagELagbLs ZT ZI La ZILYZzTL|YZTL Lx>o L>okzruuLe>oux>olex > EEHOVL EEHOWLIEZ>OLIEEHWEEHWEEHW LCE H ACF HICIEFHUHCC ECC XC CX TuWwn TVLWLWWICEFWIVWWINWWIGWW OWES LVEF VWWFOVES ONES OCNES HC WW HFESWWHANE SZ WHF <W(HF<W / HF<<W wows WQWU SWE u ou uwo|wy wo OZ E LOZHFERLQUWUOUHALOZHAOZHOAOZH a QWwo LQULgEOZF<aOWORLOWOR QW oo =H QO2HLIRLWULIOO3IHIOO3IHAOO 3H EEA End QIEH azo Jozd Jozi J Qo Ow -HooQuUoZzA JwWOoQo ooo gonad Ql U0 0 U=z00-0000-0U20010=200(0=00 hw oo SNWOOd aa OdnwoOdnwOldnwg| woe rH LOeFRUALUCRUVEF LIVE FLW FF s 8 < = = S = S > E-S os £ = <n = 5 5 a 2 a. a a ag s 9 5 a |=. |= 55 |B o> & x gg oo og = = HZ318 Fa |9Z23>|98 98 58 2388 2.8 [238323 23 23 S23 L= LO" = = = =T 327 ela» =n; |= = = Sef erm oN al oN oN N oN 8 ; 5 oo > 2B % Ia is - 8 S82 a TEx od HlIEaX 2 53 ZE-E2%Eg |Z EZ2 AESERZ ESE |B 228 5 = ws = 5 5 2 2 0 Q = = = =z o ° 0 0 = = a 5 w - 5 a a = < E = = = . x g 3 £2 g = § a (98325 [a 8 2 = hw > 2 8 EI8E(5 (5 &% =e =>e=elwm 3g (a @ = 2 = Ed I= Sle Q Q = |a = = > == c BE 2 =~ 59 2% 5 3 = 2 3 3 ir. 3 o g EE E « SE3Y db: — 2 x d wn < £r02 Eb gE % “ne ao. 38 0 © wn 4 g FE=F 9: Ef 3&IE 1% 25 EEE 53 Ox > ZYSY eS 53 So¥ 5% £3 dd as z Sz@8%s gc > 3 Q >< gs < oa 4 £3 XE z FES 24 ZUERIZY 3 ZLUEEES [2 zo vlzo Er PASE 2 5728557 [0% ShaE2sa at arulzar i rE. = AESRGAE SE VLG agaL 22 SEZ Y5E 2% OEZE0c 32 Cea gEd 75 EgRooEs 98 . BEEesEE BF . < ow ZL BE i g GLE <2|on [Cin z > eer x gu 3 g 3 > LOVEQLE £8 z : kB CE SEUSECE ong : g $222 Siu 3 g o z aa02Sa ° gE : . : c REE ie 0 a2 : ; 2 _ i G custo fuxse a SEE BESnEaEEEEY : z ES win : z : 2 < 2 SesdBBacuces [iE Egeiyegiicy 2 g La >EPGI28 EF bt id OQ E=(H Sey SREBHS RS 2 Fa E 22 sls 5 EE Jz 0 3 Zl Ely 2 i : : Lez S29 & : g z J |S = : : FEiBgnErge, EEL sols Ze 525 Sz Iz 5252525 £2 [28 52% 2% 2% [5 32% iz 2 |2F ~ © ao o < [vo [vo [= |e | | x x wn a fem fm en |e |; | ~ ~ ~ wv wv wv 2 a fa] ut Loi Ti 25 538557828 £28=25 & oS ESE|SELEloE ELEE E SELEn8REJEEE ELBE E 3 53Q 3519 3 2 3 5 } 5 3 AEeESESEXEREcElEREE 3 3 g 2 0 o 0 0 ~~ = 5 5 D3 |B zz 2z|] 5 5 5 5 E E E E 2 3 2 3 = = = = TU TU TU a HELE HE HELE nLE VO = vO nok nor Zax Zax Zo x Zax 5 JO oO J9 0 J9 Oa 2% C2& Cag Cag <= <= <= <= JO= “OZ “OZ 29 s§5 EE ger Es 0 meg 2o0 [Bon 28% 0 = Ww 0 = Ww OQ 2 uw C= uw wn OQ <C na < na << naa sof [gag ef, Ead x= ZU sx 2x0 xx WIT? WIV WT? WIT» EEsh BEE BESE [BESE eC eCEu |BLEn gCey Xo >= wl Mow (ed > 2 > Ww Uw wa wo Uwwo Own wy St ux ox Wx ux Se VO>0 VoO>0 VO>0 VoO>0 ZwOuw ZuwQWw (ZwQuw Zwouw dwn Jwde Jwda Jwoa B55 [E552 Esse pSse o> Va >0 LA >O va >o ¥55% ¥5&% [KEEL ¥55% TE3 (eTpiEny itn IESH IES SESH $ESH ILLo goit |gEio gLLic ZT ZI ZT ZI Lx>o LxE>o LxX>g Lx >o EEH® EEHW [EEHW EEHW Lx dx CCB Qa x= Tww TUWWw Tuww Tww Luk = CVE: BVEE LuE= Hb << HE<W |HEF<W Hb I LQ wv WQWO (Wyuo wo wo nw Z S080 e080 2880 e880 w > ™ QO 2H QO2H QO=2H QOH « wn Ess azo J EES EES I~ z 9 ~-Qo oO ooo dao o ~l00 wn 0 U =0 0 U=00 |U=00 U=00a 3 Oo 3 [Hw o JhWo [Jhwo Jw oo © i wwe = wnekE une wun © 3 - w _— Te < © = g |¢ cs 52s ESE: £8 zz 2 [2 8 ? § [25% 3 2% Za gz =z |§ = §g8 555% > > > = = SCA San = = 2.8 2.8527 > 2742 2T 8 T|2T|p [=F = 28|=TAad =" 2 > 2 © = |a wn [3 wy wv wy = |e mg a oo E 2 2 |E |? = Bk Iz EIB 2 12 |e » g a 28 LORE < < < wv a 3 8 : 8 o 28 lum lm g |B ES as Fg Sx oc 8 S - 8 S28 =o oS S| © o 2 S|T Coo (SE 2s 08 EIS QHSS 25 oE EB VEZ 7 E ~ EZ SEXES gn EQ EZ EE [EE = I 3 x 3 SE Za = 3x 2x2. 2 EF E|SE [JE [PEELS SElEREcE = = = = = = = 5 5 5 5 G 5 5 —- - =< = - = SE 2 2 g 2 2 2 2 = = = = = = o g § § § g § § E E E E E E E E 3 3 3 3 2 3 = = = = = = = IVUZ TUX TUX [TUX QED TU=ZE TUE NWI [WI Ig (Ix Ty nT in I & NOE MOE WVMOE VOR == wn Ok nO = Zox (zx (Zax (Zzdx VO Zax Zax UJ0 [DJ0 [DJdu [Ba zd v JO 5 JO C2 G2 G2 G2F OQ C2E C2Z <= <= <= <= =n <= <= JO |29= [29 |29= YEE JQ JO 25% 25% 25% 28% 28s ESE ES a — o o 25% R55 BEE R%: [Bf BEE Bes Uzw VsuW Vsw Gzuw Jon 0 = Ww 0 = Ww nig Mig [ME (MA w= Ww na ha < £55 Eof [Zab [af [E55 [Sad [sk SE [3% 23 [x3 OU x3 & SE CWT [WT [WUT [WT <= WT of WT SES BEZ jbE3 BEI BES BEI BES 2Ce |B2C2 BEd [ELE gF3 eC eC ME > MX > (MX > (XX x Xo > Xo > Ow VW Vw Vwi OZ > Uw Uw Lxy xg Wyo Uxg Wud Wxo Wxg Vos LO> LVO> UO> UX Vo > LO > zw (Zw |ZuWd (zwd ZO0> Zw Zw dwg dwg |Jwg Jwd (Jul dwg Jw 0 > (HOQ> (ZQ> (Za > wo HQ = 0 =F EA Pe Ei =o EO =O Oo Oo Oo oo OOo Oo Oo UESolWp-Solp-SajW-Sn (WE WE-So WE-So X¥>OXIX>OMIX>OX IX >OX EEL ¥>OX [X>0ON >o0W>o0W>o0W>o0W (>>0% >00W >o0W IX Zula ou <O0uw gy IXY ZF>OEF>UEF>0OEF>0 FEU =F>0 ZF>0 goLogcLagELagbLs IEpY (SELL SECS ZIL|MZzTIulYZTLuYZTL Lo ZI ZT L>olg>ouE>ouE>o bz LE>0 LX>g EFEHWEEHWEEHWEEHW EX>CO [EFEHW EEHW CAE HCC EFCCE-CCXEF AEH CX 4X TOLUWIVWWUWINWWINWW [TC (TUuw Tuuw LOVES LVESOLVESONES CUVWW DUVES DUVES HESWUHF<WHFSWUHFSW HOES HECSW HE<W WWOWYWOLWYWOLYWO Wal WQuWo Wyuwo SOECACECESECASEC BR0F BSE BoEt QOZHOOIHOOIHOOZH QUWL |092H OO 2H SZLJOZE JO ZE JSZE J agzgH |2Z2d >ZE ooo oNaaodonY OZ Jd 0QAQ Joao U=z0o00U=200lU=00Uz00 UOC U=200 U=s00 NWO INU INWOI NWO [12066 NWO |dnwo LnerFrllnerFUlnerFlner WAWO [WuekF LnekF S = £ £7 |2% | £ z £3 s sg By |B = 5 3 |= 2 Bo Br Bef Bot Bel Eat §2 | 88 SEQ REZxfEs [RES 27 [27 |23 |23% |#:83=:8 27% = |=T [=T [=A [2TH F=T2 (=A = wv 0 ~ 0 > o < < ~t + ee ~~ wv wv o ~ = 8 $23 ved EE = 5 o =8.. 8 EEE s § 5 £32 £2 3 og a5 2 23 «£5 2 S -- 2 g % oo 3 sg -23 = nag aged = FEE asd % ESS ES DE = S53 58 = Aan = I MNMDT a |= EE = © £ ° g 2 = i 2 2 5 z Z gs E E XE © 8 © § 08 ef £3 £ FZ £3 EF £3 3% 25 ER § 2 2 8 E 2 2 £ 2 g £ 2 oa =F Q - © = 3 2 £ |= = x oh 3 So 8. 1u 5 = 2 ° o Te c52[7lels ENESS leg a SoS [E22 |3 =~ SE888 [2|2¥z o Sle < AE = £l © £ ° 2 oO 3 22 5 £3 <5 y £35 << <Q 9 O ot 9 © © 2 < > = G G o 3 3 ol — - 2: 2 o a o a a 0 Oo 0 0 0 x a Q Q Q Q Q LQ - 003 = sm 0+. BE Bl: 5 2 EJs o o. 9 Ss 5g | — — eg FE a. a. a Oo Oo > Q Q Q Q o 8 8 < 3S <= -3 =~ EQ 02 9 EQ =] Mm ao maw mao [I] x 8&9 oY oe 0 YE 0 YE OYE a QL a QL a 29 a 29 a Qo —_ > 2 —_— 2 —_ > 2 —_— > 3 —_— 2 =%8 |z8 [88 |z88 |zt% © ad 0aad 0 eaed © ead 0a’ ° = 00 x b= © «© © © a == =e 2 152 53- 2 0 am] BE UA — = ~3a |[EE 3s |= |g I A ly vo 1 2p AAW HNYO J Hod dWOEUZ>0 er EAE Tr SCroauwoUrFgLlL> z awou ==> —>-WEa WW ¥>U8IgwasuLh UMIZW>202 WunnarkEFaz> EERE AxXQJEZZ-UOFSD EQQwua dong JHOZHE [i JHOZn¥a ao Ig <EQTLoLW>H xzogoUglZ4lL xz0LoUSET YLOhegaHT ZO JAQRER Jz JOhOLERE I> ¥=OOUoOWnAUG ZHOU WL >E0= ZHONG VL Kn >T LFAZIEF>¥0 ELOEXHOXDFT LOEYHOHFZ®Y SWOT zwWd> > ZEEEISLEZAS >ZOMOCEZE IM X >NOFO XT >Wi ZUQUZEa-FZIou zZWOQUZEat-Jd5FQ LOQUIEES XU SiSuRUEoECE BRSEADEEZne RIESdsglS BuoZFoydagy E052 EECSET Fogiss jure] NIE JEJUE IX NJE EIU EEX _J> I>=0 ~Frhgsigusy phen Esn =>0un>s—WOF JIFFOXF>0nE3 JL O¥Fafka> Xo JU ¥oa gd Dunod>wd>0Zz LDunod>wawna dl F>oNgURETI® CYHZXOnY WJ OXHZX DL Zz JL “ZUNXESOox I> JnHY OS ua xX JNHY OSL I>EL XHOHTNIvi>g gQoun>IHANXWLAOn QOUN>T HAL» LZzOxnUWAOHRZ EFQUunuUUVnAlQ ZFQOVUWUV>W>0 ZNOXII=Z IX salgaszigac Salzaszixea SIRGBCEEDD 2 ZLZH 2 z @Q Jag 0 So%SFEEHEES 592332258048 ZaBe2EEsE9a Ue>HLE>uh orn LU>HLE>nOXedT ZxO¥ETI%50 dT 2E>H0>0>0 JIT ZE>00IEa ST Hao OUx Joo TEXELOQONWOO TXXLOQO IAT Sue > SIZ 0nhneEdE oIZ2O0nucOa zJnhoue~afka SEpizliurogo Fo JUL AZYEFT JIFZ¥>wWouno QUL>U>WLOXYET SUL>uPULIIES HidJdoGunuzd JoWxionafFEa HT Jouxina>Yvd TZFEUOW Ix WpooI<>ggaT wpaegor<cyin>a SknfupsLe QpaI>JFI0C0T oppo I>Jda>HZWON JunHLOLDx>W SUE QUHLIUEXET QUFEQUHLADEZ J CoOHWOSU hud SO la>ZLEHIEZT Fla>ZxUONxUn JfpyEiFuaoga SON INEIVUSXYD UNIAN IESWa J dS: EEU QOoWUFLNIAWn>a QOWURFWNII>HQWV —_Z0ng nove Iolo >HZ® gio dUoUEZa Ox TJL=0E< IE coQuowxyakEUT coQuUoWeExZIZ0 LEIS odxg IXLNOIWOAaxIh gxTogzustalhe lH PEL<O WaoQz Yous woz XX Jw ow zu Xo ZX LWOOn >L HOV <WwoOOn ELSE JEEZ Hzss FELOunalu=a0x FELQualuluxuZz ooLzgZlua> ngLOZa FSC ZW nel Oa Fa Z>T EXJIEITOUL® nono JELLO == nwokEwnnadFong Jd ¥ JLag>aa>H NWXZOUZWOJIOLDT WEZOZUWOoJW>HIT M¥UWHOWHEZA OF FoLOoO0OxaS5S5<=2T FooQOOxaES>SI¥oWw Fu>uwneoUdx ndnOIUCLugLZ ndnOIUoLBnUnz UH FWAESW N>OOVUIE=FAWV>T n>VO0UITEF2>¥0 NAA Y==T =H L200 zwazFd NLYOZTzwa>> noo dcuWiEza EX JEFDOEQOSHO JL E~D win FOFQUYWSEXZL aug JEExXEod og JE ¥OU adwagzigia <=> ZxnowWT <=> z¥ Un «TQUVZWOOX J —~ ~~ ~ wv 1 w w + o = o 14 >) °8 2.1, 3 § “8 2, gd 2g .8 2 Bein Evans S Ee icgrota CEE Sf EEERRES Schr 525508850. EZER0EES Exo Fs98 DCE |Ex222588 0 Ex238589 Se SENG XIAET Ce ZEXS XA = Che] XS ¥=2 Cale 2d= EXC OCalESZA=£3 Caw EJAZAT _- Tt ~~! «< nS © =e uy 5s LE 2Z se L- \E& 528 | ao une _§ 8 oU np B= a gy ERESR8ES55e E2580 8%5Qw EQESRD 2X20 % O& HE £X2092 og £€x332 Ss gT=8S2 dy SE TEREX = SE 8=% CalE 2A= ELS OCalESZA=£3 Caw EQ 2 1:3 1:3 o < S SwoJZzHNLUA VL XSHOBLLDSES HSE L REx —>-WRaUWLNELZ 200% >2080« WiwnhaHEFaZ>T NL ZWZWOUZa EQUwa dong J LOT-UCcOWa0 IEQTUOLL>HZ QUGIZSRYF EL LOongaHIZaW SSEIZLOZCY Y¥EOOWUonnUnI LWSWZnda J=J0 C-VNZIE-F>X0E SSP IPNHgIR SWOT zWwh>>> eZFJdJdL OME >NOFAXZT>WLn SSHOWuLnLOW>W LOQUIEFESXOU FEDEORHEEOE |¥2gs2yssiNy Ho JQoun>IT HL Fogis? Esr= QUUL>SEZFOoVnWU®n => wu>=0zZ WeihI 0 dadn S>0n>s-UDFD ¥oUJDLSO>2 Xo J0UB¥oa odd UEFOJde ET F>0NQOUREING OZHLWU>-HLE>0n J1ZO8ESoxd> 2 JEFJdIzE200 XHOHShIn>o 2UZTEEOQC azZO0xnuWaHFZ 0 XxQFUQIxXxZxX0O0n ZNOXIIC-Z IX X Eh ¥HOLEL RED TW wn I al wu wv SELEZUEne zaBEEESEYae FH&ZowyaoI< ZxO¥EII5Sad Hoown@oSa I> Ho OUx Jo xav FA QuUEFEQUHL gaSumsrx> he JULo9 ig >zex ZJoQweFaka> SVESQUU INI IIFZ¥>wana dl C>20ZzgOWUFWUNIT HL J JOoDunL Zz JW XhUJdQiaduol SZFEOQWINEWL Lxx¥¥dooudua SXnFuwSaiorn YoioundeInOTw JnHLADESTSO AFL >rUIQUZXOXY (QQHWOQLLHWOO a no BURA EEE dda >Woed un LZHLEEDIOQuaelw (Jo> agawan HULpE=>ngquLOzak-s “Z0ng nove JT LO>unngEnna dE I TJLE0ESL IEA >T >U2enEz0zuUsd [U>EIXOOIXORT PEPE, SENCEET SRRELTEEIS:i LEseh=8804 = oa2EzsEsEifs LOXENLYOZUzw [Oozgxluwa>YxDd CER HNY JZEIF0OE EXJIEIOUWLN>C pIEaEL¥a iz vk iLB«>EanHzZy 00a k->05Zg MUWHUBHLOOEZ J VEXEZSZSJoulE |[FusunxzoUaxun HIFzZXEF-awWoUrF |[MWHAFWAESWA J US>MYOX>ONINW WVNAdEQQFEFT THe QLnN>AAXOIES NYO WFQ 0X ¥>HZOIHOxH¥e (FO-FQQUWEXZLZO YRLUzkzgxoUg |aJuggzligiaht CAX<NIAOLFH <TQ0UZWOO¥ IW % w ~ Oo 1 wv ~~ brig x aN Q wy or oy = Q mo oa od |! =F ~E asset 88 SSS SE B82 (BEET 05S SECs nasil E2582: 35%2 252388 0527 E523a3501 ESSE 5 8A [CRE VS&EZ EE yoy | ° Rd [ee i em £0 pd | SD ° 8 =~ | 24 £ PE3 (82805 A ESSE EE REL (3883 wa 23a ic EE |EEETREE 25¢E3RE E27 TET RES ESZSC28235_R (CREE VEX wv ° |g lg F, 13 5 se OU E £ y 28.2% £54 Fe Ele 2 $ ESRB E00 o 8S mod [= nl E32 a2 SL SA 232% - dgmgERd ERENE9sSEe TEECfgD o38Esss 25348200003 22855283 EQs3ges £2295C9QUe |EX22QR81F FT ESS EEF=2F22%% |ETFEERaz2i%2r03 E2E=qal22 4 S2£3 wo 3 _ © £ I) = ~~ 28,25 1 £58, SE VS SEE8X8 Bo 53 gw 3 em ggcdg@ La FER 7) g505%2537% TES-o¥Q ood% Ex20503%48 |£2228832 5238 ee = ¥= A= CE FTIR 2ARSX OCadsE AEE~M CERI EZaAQEZ=QA2A& [og © oN MLSIHOI>HQY (¥<ZUVJIZE IXY JI>x0ox¥E200x H>JdngIWd>Fg WWONLOXZCZO Wn sWni=nd CEYRZESCES BE EoO0Z CEBEN CEQA _JFEY Jw =E3 OIx¥S5ao4 XLoI=2Foz3E2 COF-Ioo xxx XO J Jax Zz x-3 ogZax>nn LFAWZO0eZ>T FnZXJvdaFa> swooLasJongd [EwOSILVawna ll Farts ns >NO>ITXULZ JL LOoOgougzdaow |[LOQWFAzJdIXEL MYOZ¥LUANBUNI [¥¥OSWZELO>0 LOQEizx>x Li0ZxEz>050 FugEQFE~FQ >> Rugixzrhuoa 2I3¥OTESULh 2d 9025882 S503 LS¥OU E> JWenoawa EHJIOLAC>UXY HIV IXOXX J F200zZ0NJdUZ3>L [F200Q0003>dF0 > “SZURS>S JAP Jdd> |JZ05300nx dx O00 ¥HOIEFO>20Z [¥HOLOWLLLOD 220 Z20lUorRE RzoarnEazZy EVE RESELERAY ZnO JH J £8 YHOO>UWE REIN CHOC WA SYNXY >dn0Luned>32 FAS UTXYLn>S ZoQUOUzASEE ZB0ENIGIanZY ZOE dFHFZ0 Z20uluiF0oabEZa HoOQUIF=EJI¥Y (HaG>JdJoUugxun CxOodeuL JSF [UXOn>zZz>F>uwa Jd 2dndzeeEYde ZJdnJIT WHIT I~E=4Y] SIRE JTF neaFEZTa 0x HI aU Jd>&x50-0 [HEi1oUgLixZzg2zO SZ Joes SghExFpoLan SEXNO>NEX >in [OX¥nagiuiay du 2ROSEESEES FEoisauizcad 8233 nxLz iw SFREE2ZIL ELE JJO0FH>d>FEL [Odo zz>uongd SZONFWOLO>wn (dZULOCOODJWSHAC TOJLHJEI>WUS>Y (TJdiLond>iz&ou USFzXhwhwda [@WdFozxhaohinz ci532E5gETE gESEEgEaEss gHE258528823 oa2bsd x LL cozzagolEa> [ORZoSFEzNSXOU EX I><TO I¥Q8 [EX IUTIChES0OYN ¥ JLLUFFWgLOa |(xdizdgz=z0z2>0 YUP Wage OWGFEDHEIHS pup HNe ISS FUS>Z Ix 20>202Z WHHL JTWASYYOWWHEZADZLEAFD Nd OZed0WN>ANIEFFWETITAO £3=298355strgsasEen Tae §JLbsJs08 En JLFSsgzdsaE <TIOZHNUF>SWA IC<TIQFWUOSHHFZN = = hd o gL. Ss $1 f.4 Lal ; La | = IPS ELE ¥6LEE2 ag» £EBR Qa w ao SY¥®X~-F 865 STEP RE AgEONO E 52 aga ss 22d BSE H2gd=EET = =<0° = X= FR LS ll N= aw LS N= | an 5 Ss 3 = E39 2 = &olg 2 5 S22 = © 5 aso 4 > Bw 2 > 2 3 2<5 8% z O= a az = . 2le ' oN — —_— Q ~ ose a = E sills fs 23EE3YY E082 2Y22EubL20U043 RUSE IE0 330552255 0F 3323320335 0y330EFSEESLS CIEE EPEERER ERY Rey QLOFLULLLUOU FLOR CO0O FC LCCL=L CUI EEEgE vou 2082005832 0E3E088=3328 250 ESOESERE QQOaVUUVOVURECT QOOFEUOOOU O=LOU RF =O ES USI OSS OEY LSS SOL EYP YL EIR uESEYS CPEB EIU PERE OYYEREGEESES LURES SVOYF=F~U FROOOUUVUFRFAL4VLOOUORFLLOUUFRUCULOOOUUULIULUIS GEC ZEEEGSUP EEE 2008522992580 8s CCU OYE ELE EOE OT 00US ol EEEEOESED 25530839 330353822322 25333350FEC OSE EEE EGS ESF Bde EeSRESEEEESESRES 295030 ERE3EE3 CUCU LCVUU EC EG=geSFEeE VOOEL<cOLLLULULVLQUIUFOULU < VOQLOFUEUFU Gi3seniiiserananirEeny FR8d8Lzbats ULL CULULLO OFLU VOFFFFOFD SCEREER COPE RE PEER EBBEREELYES Bo3ES GouYss GEEORS EESS23Ce3Y =338=563 REM EI BOE USEC EES S038 E 38S EJ00B8T333 EY Eh ER EEE MERE EAR ERIE EE hvh Ish oh UU ULLCcO0OF0 CUS EYEYESSEY QLUULUULUFLUOL E5222 22880532 euL200E0T28LES0234 EES330C38 0 ere2 Eyes hEeRIBroEnsEs C300 0U330BET0328388 8250060583 EESES ESE Ee OEE Ee Eg d22EES0g2Eu232ss SEOSbES2FEoPEbE3EGE035E3430kp33553s E523 EIesduicbiaraSuouukELoutS3ErTs =U GEE 0883P220F 0520 aYrPsES8b5ES UCOUFOOUOOFRFEFOOUUUREOUREFEOOREOOLUOOIIO0O S5goEEgEnt Bel zeinogeniiranidsay SRR REA EER Re Rs E2oG3ESLb2eE55 E02 8052058563355 88 EEIEPERYEE ou HEPES PE PREYS PY SESS EUO0EEES22 Eo 2 EE 0s bz 082223582 08E EZ QLUUOFOVLVULULOLUOFUVUFUVULOUVUFURELULOUCOOREUU 3383300 GuneE Riss Eaisussshrnizgis <2300EIGRL00I0R 3358322 RP35bE33302003 8 mn EFT 3 53- £2 £. 5582353 17) 3 wv) £270885% E IRE eYyeYS eye YYb Esher aE EgeD ICE So gg OEdd se upI30unegUEIERItt CIEE EPR ERY RRL Y QLOFLULLLUOU FLCOFC=CO0O FC LCLL=L CUI EEEgEL vou 2082005832 0E3E088=3328 250 ESOESERE QQOaUVOVURUT QOUFEVOOOU O=ELOU RF =O ES USI OSI OEY SS SL EYRE EYRE %EYS CPEB IO PURELY REGEESES LURES SVOYF=F~U FROOOULUFULCULLOULOFLLDUUFRFUCULOUUULIUUIS GEC ZEEEOSUReeElz22208802293e58028s SEBGaY EEE REE EER2T rat ERR iusEns B303L333FgE E38 IRpaI Iris sELEbrET SEE RR A SER 295030 ERE3EE3 CUCU CVUU ECC EG=geSFEeE VOOEL<cOLLLULULVLQULUIUFOULU 3 VOQLOFUFEUFU Ge3seniiiserananirEeny FR8d8Lzbats ULULCULULLOU-OFFAVVOFFFFOF0 SrEnrEr COPE EREPEERYBBERELYES Bo3ES GoYYss GEEORS EESS23Ce3Y =338=53 gSsgzaote BEoURICELEESsE Bg nE382zb3rRdrEsilet PSR G EI OEY I YESS ELSE NESSUS OESYY UU ULLcVOF0 CUS EYEYESSEY CLUULUULUFLUOL EERE oes Eee Eero EERE SEESEs E335 333E8E32 EE Eyor urs 92EErE3os E3335083088 33252380306 00E0ER0EEEsE CEE LEDER EoE SRE op dr desuagibE aD SEOSOESeFEg GEE bE035E 5285503385338 B3eg=Eear yds I0sRiburEsors0Eaniy <=0g GEE E0883P3250F0s3oEysdsoEg8L5ESS UCOQUFOOUOOFRREFOLOUUUREOUREFEOOUEREOOLUOOIIOOU SSEoEge tir asiyse ab etiseeaisiane CER E dae EEL seg BE dBase rset E2o03E50b2305 502 302053568 855385 Br IEPEPYEY ou HEP ESP EERE sp IEESY Ey SLEdEIuRE 30 eraser ochre idnsines G32 ues ons aaBLE OR oar LoRaBasEnt dus 2238300 8Er oe eiinsogzioetaetises SERRE HA HS SE EEE IS FHS SEI S$ oy v Ex & 8 sei- LE = E_£588%5550 a 8Q oa £5 29280850 CA 8=2LE82ELS 2 322g eYsyeeyLYbL SEs YS YYy ICE So gO dd sein I30sEozRrEoritE SOE eS EOE EUs ER EeE EGR gssEyse = §20058235E3 §g8=3¢8 < EGESE < oes 3330082 uraranga3ausE srorucEEy ES eS IO SIS Y LSS So EYL SELEIBRS CPEB ESE PY EE OYYBRELESES LLUILLLVOLILIIVOOU FROOOUVUFULCVLUOUOFLVOUUFRUREURUVUOORFROOUREOR GCC EEEEUSUReeElz22200550E 220320530 S3830GE Eng E REE ose er IbRcyoREas 33L333EeYg83383E 33303328 DEb xs SRI OR Le Ea EEBLb ERs RLERoE EREbERs 295030 ERE3EE3 CUCU CVUUEOCOULOULOEOEUR CPE aToE EE O00 0 EO UF TUR EEE Esgbbs sD SIRE ELIEEBELUUGEREY CORFU 532330433 COPE EREPEERYBBERELYES COLO JEEP REEY GEEORS EESS23Ce3Y Rh isi) 23305338 SEE RE EE FE ERE RR EERE EE ENE EAR EARLE ER EAE LE Ih] UEUFRULLCVOFRFOCRFLOUL0LU0LULCCUCOCUFOULOULDU ERE ooe CEE yr rio Bonn Exons GE33353335 0853220 Re 0Bbo2EdssEgel C330C3Ceg8Eas23808sc0 53233035083 UO 00O0UFLOUFRULOOOUUUOQCQU00OUVUUREUE OFOUO0 EULSEFOCO PEE EN EE EE SRS EES EYES SEOSbESeFEg ELE EbEgEs QUAUOFEOUELCT JU B3egsEear bedi as Iosiibrenitausate <=0g GEEE5883EseSFgssbgd GGGESSUI0LE UCOUFOOOOFRFEFOOUUUREOUREUOUREFOQUORUUEUOUR S5g0ESEgEnt Bein sei ogeidddsiiaaelt C3 SRS EEE t REEL BE bhabEREs Ee3CEsSLEes EE sEe Broo Rdzersiey Br IEPEPYEY OULU LUO0ULOUUCUCLOVVOUFRVUURERFD BO SOEgES Ease Ets aranonhessibdztr £2 QLUOFOVULULLVLOLOEFUVUFUVUOUFFFOLLLUOLVOOLVLU $3335 phuruzinssirsisye i sasiicey ERE EEE EEE PERE ES L @ 2 1 a | “ sl _1a& 5 = az ~E £2 ESB ELSTy 2< 3925805 EZ5=%8%3 3% CARESS ES = 232 2U2E0EdIU2eubzEs2 294304: Ey gE yg pers anny E3Y8EEoEaaniire leds ouroatey 208200 EE LE3E008=35-58552855888 QQOaUVUOVUREU QUORFUREFOOLLIVO yoy 3050520538520 88:5245220b322283558:0 < UUCLUUIUOVOUFRUUUCUFRCCFUSICIgEUCO0O0 FROOOULVFULCVULOUOFLLOUULEVUUUULOOEOUUL GEC EEEEOSUR ee 222250203254 SE3830EE En RgEREEa30=388E05E23358 B33L333EeYgRss8znskitpadsbatt DR REECE goer ane LBL os o00FcaeE 295G03CERE3EE3 222PSSbUTSESEES 2360 DC goEEReER Soa nae ans yBE Esha BSI ELSLIBFEBELYUGER 266 SSBESESE COPE E PEERY BE RELY RR ERGY BY GECTRaEE EEE EE Sob rans IingzDs BCogeREE Edessa 5-u8835352233520 MOREE IEEE ISI YSNLRULE IRIEL UEUFRULSLCOOFROCFLOU00L0L0OLLOUCOqLUIO OC EEE ool CE Er Pr yg E nore RRR MR EEE SR EE C380C3CEg8Eas seu gaoEEnasssEet USO O0OUFQOUFRUOUOU0UUOCO0 OFUREOQ EULSEFOLO CEPR oUrEe2EFE32s0ebaos SEOSbES2FEg Egg E5EgS BEREREESE B32gsEeaeygbros dein dr erly <= GEE E5883E32CF 0323388533858 UCOUFOOUOOFRRFFOLDUUUREOURFOULOOUVUOOORERFU S3EoEg Eirias usa ne yea CER eo Ee Ede L BEE BEESERsiis Ee3CEsSLLes EE sEasugrnsI8sEobIo sh ELIE ERes CLULLULOLLLOLLLLOLUCLO CERYRES SRI IR PREAH EZ POPES SSU0SELERESREEGIREES333G3EYE $3333 EhuruzEnasursiguasiyssiniss cP33CrIGRECC3CPE848855500508855RE83 wv : 3 §5l-.% 8 2 SOT LD Iridzslniis SEJEXSXREZE z VOLOUEUVULULCOFVOOURFLDVURLVLOUESOLOOUCY EFSOUU= §4¢ SCECgREaisn situa nr 8YREsEeasiniss L=OUEO QUES IUREOOL CEUE03EESE QFRFUIVUCOIO GGESS EOE Er aE 2 alah gs3ysEaE Es SIR LEPREEEEY LUI FCSOVFE<C- 229022 % OQ EERIE ORES USL 5E4ELS30RISBYUSES VOUUULUUOURFROLUVOULSCORUU GoSBRESYY = OSEEERE FLUE COUT 3E2UEReOEGE0R ZEEE T8383 072830 URFS0o8GERZRU3ES VOLO VY QRLUCO OU2885E08EE u 2% sce Wy 3g SERYMIUERYZEERYRES B3E330EEE Eee 385003550:93 3305 0gB0CE gE 22a0EEog23 0303533382008 SREY EEE VUFUL Eebzl% 2058%2 <Q ua MERE EP Et Rich GREER 22SS E000 aYZE3E0EO03EYE332R083GE00E380 BSIYYSY oou VUSFIUSFOUL 222702RE oo UU02382833043E35S80 U2GGEE33303053 CUUVULOOFLOOLUULUOLUOLULOOL 23 30388E FEUER C2P8828Y guPglEsErego83aagie ERE EE REE a hE FSOISFOV BEL 200BCEGE00ES 2 cok oo gzPoobekl2obel<Lsudid GGREXEESZRER YESS CEPR SEE 33023555305 SE SLEsbR Engel Eoinogasioszes LLVLOLOLVOOLCFOLOL 23YEGSEEEE8338ES Go E3C3g33roksiceshoezshiingns C2 gos R3B38C3E sR Inz srr IPRsr nar EISRbrE LE PEE EE RL EEE RPE PES VOLOLVOVOVLUOLEFEOELY BoBECERSE538 O53 o FUEU- 2080 LE3I022Y2P EEYEIEEY LEC 3ELE00<EEE52SS SLS0YEE0LL0SERE OOOO UURUFUVLOLOERFOUQUOUOUOLOU ERESEORIG OV LO SEQESSbhEESEE38Ey 22285268882 C288GE23383002853353862EIERE0R0E3 VOUFFEIUFUVUFOI0000 3 39 gECES EOL OE0ER E30 2P YER E430 3 38523333 CEOS eGo8S3835G8REEE8S8S3E ESSERE $2038 VULCO FICE FICCI AULCILCCOILIVUELT 220430 E3008 E<EE283073835858E3E0 USG0E334e UEOURFUOUOUUFRFFRFQUUFOLO0OO0 U8CuGIgneouboyd CUFEULCY VLE gU 2024 YC ouE3E RRsat ggEsugasryninsss VFLOULOLLVOLOLVOVOLODLOUV $U2S88 258080 eG 3 VLILLUFLOULLOLOL SPEr3c38d8odgecizgalszaichoeseigsd a wy oa | 0 [I wm Nl 28 8 BUF — ~~ e % pe = Z £30325, a 8280 B EZ 53X29 SZ ZEAE ¥Y oz oQ am a= =98 5 8% ou HH hs fh Zt o Jats U} zy 2esed Io Hi 39 Z 593% Sits La LL i i 288 ¥3 ggg i fi £3 G 358s cd S52 Seats J52¢ 2858 an 29 3 grat 29 Gn Zee a HE ZEEE G3 ° G 3 Se 3 285s GoSE EgZ i i hi Ea G i Q i Shi 5S 2 ogg gear oO GC © S3E gue 3% oe i sicee 52 2ooilt a idee vi Sats he 295¢ 9 g EG 2 gc 23gs a it 3 gEbD i gt Eh Io 9 sess Bon Hh ali fh 330 i i 3 Sr sages oo Gl 32 o 3 34538 o ¥ g 29 £3 89 3 cedse 5 Lo eh a Et a ges FE 23 satecs 3 HH: fo G ggg 20% Jaids 2 3 ges a 3 a Sa Oo E fa g a O ees 838 =F Q =< pe goes Ls zk a fie Co SS oie EET $353 Z = 3 3S s It] = Sait ae g a 3 ci 2250 Lo 30% 3 eu g 2 2 zs EH Sa g pe a E35 fe Ht 2 Sg $3 ix 5g ae 8G Joss oO Eq 28502 : = E 2§ves 5200 = a Oo EE = 9 © g Ga 53 9 O i 238 28 2S E ne g2gs = 20 ois g E288 i Sh Hi 3 9 i Co S800 CE SES 3 ges £3 ERE 5 i oes 3 oS SIE 29 » 3 | 5 a Tw ER. 12] 8X8 EQ Fsi45%8580 £25d390%¢s SagE "EEE = 9 = Q = ~5 E 5 Swed EEE 2<335R2 §Z35 HES OA EZaA 5 USE LO0LLLOULUILOECOULLULRULOLULCO ESE PY FOLQU SSEECENEBEanggRastayr IR Ered EERO OLILO UFOU< VOQUOOR gz OFOFUEUV 14 E OPRE3ds BEpdEoEReiadit ast Esdadiatusides SL IYSSELY CAV CI CY S3GGY oz I26E2380 OQ HEEL ISPS ESREI232008 EES S050 Sed ESO ECRESE REEL ELSES I0EE0EBE0UEERESES VOUS UCFOIOOUT FLO U C2CoE ZEYE3SY80EgRR 333032288323 ZEBYSEES i SE ZEGZOEERET Vo 0363s 2280638 JOUOL<O 5350 Su 2329032 2 B2E3esE0n3035538 003038 38258380350 oo O40 -FLO0O BRIBE IUROYEEEE3IES 23 8 UFEFFUERELDOROCUCULCEROLY CBEBEB00RG22 2 COLVLUCVOVFEUFURUCLOULCEEOLORFUL 523835C 2305s 8gbE Er Sr os EEF BErbEsPbEoly Veg c=0 <= VaR IO CLO 22385y COLUUCO 3553339 CE33538822343 343254 oO o YOUU REaO G 39F932es J3ERgsesdisdisastyansitiasarageey BYEoa5008225950050938 8008838250080 FREUSIFSOSLUUSHFUSH 2322P8 OEP R g2958ES CGZ3503034030E80E3S0LGE2YLLISYS8E0LEY UOUOLOUOUVURFUOUREE BoBUE3250SSUBSE0B00RS Eero sab aoEgEs ob oEnsE Soros VFLOOLULILOLVULO CI GEEE33353335030523R3% CEG3Z32 EZUZ33SEIE0EL0T=E SEE 2330 CE BRg E230 08 br pEr Erde i0farines EELSOLFOULS LLL LO 2GER 2203492 239 BEEN Ey a EE Ra inunry UEOUVOUVULOOFUOULVLO BES 8GE3295880 3 oEoEs FOCERFU aU PRSIERZEY 235064% LER ELGEIIEUEC0ES0L334550E25433320.238¢4 UU OOOUUOFEOOR USBESESULE ER O0EUEEES OLLI LO=V < ELEEERIP LEER 52252232049 Bus EEsEzanu8ianohagdiEseginzdses U3ZCEEZEoEZ0gY 238032 G £3 §99s 2 SOEZRIEsEiagigsesprssise ont GOSBECESEGEESCRESEEST 220600 g GESESE VOURLCULCOUICII IOUT == EEEGSUZErE022Ee 03 ELU8Ea3EdoBE Ce uRInEErEberor383srer GSO BRI IY=SES OUFOFSUFRFSFOLOO0LO0OU0Y Gores Eosr08srsnssdEgehlsssszrsiss VOUUQOEEFQUUFUVEFLOEFOLOO0OUVL ZOBESY Go PYEY VLLLOU LL CPEPG3385EBEFCYSo3TReaEE3F RY EsEEsE x rs a Tg | g2L- £28 5 3 cS nl cB & 8 e358 s=8% § QEREDe 0a 3< 3 WEL INENSZT ES E5022 EZ2dZ2Z=ECc=05Aw z DEE BY YS IOS rEBEsLEbYYY SER REE 23Eg a ogee Eos EUS SELOEZEEREEER 9 23 326 332% PY VUDU "DEO UgUFOFOUY Oo SEPes OOuU COD BOUL UO Oo LOLU00Q OFJQUOFQJFOQU EEE TDReRIL, MERE REA hhh hE Cog oUe a00CVLI0IIVIUFUFROFYUOUUFRUUZ FODURGUOLFFUS0UOULQUELOUOLIUOUOWOGY UP BURHPEO0U CEE REO EYREYIRShEYELSs AUREL OOLVLUOUCOVFUILLLIVOUREOFU = EEN SHE Yr YE AES RENE LOLLY URE R I=L DUET QC <Q @ E3330 ERLE Qu $ A OLLLLO EOE ORL oDURcsUFRJLOREQ BQO FLQOO00g0a0 EEE RUD COPS 0IrYeIoUSInI09IgrUsl dURRSLOEBOOFFLUUUUEULUIFIOFRULUCIUIRL UDR LUHEDORBUEFUFOIEUCO0OVLOLVLUVLVLVUOUFELO0OUY Ogu LUOURLUIUIUUIUFRFEOOFRFOO0UIUIFEFOL CURLURRABUOFLIITUULILLUIOULIUIILIULIVORFU CE Oru OY YY YEU YY BEEP EEsYe ENE Ys GEES EUECERabEEsaar ORE EEsSbEIubir ERO CRIOEE0B020 UZoudy 33 3G OQFOJUU FRO ODOVLFOOFISVOFRFUOQURFUSFSUREFEFQUELULCY UEP URRLO0FULSOURIIOIF0UULE0LLOEZC0GE COrFPRERmFOUOLUOUULRUULIIVOU000UFE00CL CELE OIBUOURARRUL ELSE UYSSEISInERGES BES OHDODOFEORELLULOQULOLURLOLUIUL ¥o3Ieee Vmod uUDd~F<~UOUVRQU0LOFOLULFFUFRFLULOQUOLILE UE REdRE0LOURIEQ QRUYERIGERIYYYS REEECEPEPEY 33 ERHE rE ES F335 GC Orme as oFJ0 LG OFQLOVLEY o FUPPOHPPPOFOORFEISISOS USkHFF SEIrty CP BEDE UBLUOREOFLULURURFUUgO0QILOY POI UE ormaeuaduescO0-0000LLLULOY BORIS YIEREES EOP UPEEOUCIe0E0IRIOFFULUCIUIUOIIIEL CUBR URDITTLIUIIL RIES RYE SESE eS ErPlr ou UROULQORIUUIQUUOFOJUOFUIQUOUOUFURUOO EE ECE b RIE EEE EL EOE gE IEEEY CERabCo80PEY20du duu 33302303350 VUES aoe VLU O00RESQOF Bebe Y QULUO ED Foro UeRc0ILII0caclB0g OOLOILIVOL-F OPP OP URODVOUUUOUUUSIUUVURFOOUUUFOLOUR CUE OE Ee Be EO E0LU EYP LYUEERgEYIgo Er VoRUURDOEVOFOFLOOUVVUELQUOUFULOFOCLUICOUE FE EES e EEC EE Es BE ELI roL BEER Osr ELSE 3ErE32EnaTbES UP OH TUT Oo = ov OIF E=O ov CEUCRERGBC3GRRERG ZX 0OGU302ER0%203EEE In — AR Lal g ¥8.,8.8% 3 & EE 2 SY ~=F 5 AGONY EL 2 25%238z5% EE 1IQAEEZAn 2 gy 20388 goes 23 a IY Q G3 953 Hn a © o oe £g2 Lo A ge get SSE gos SEER BYE gee we SREEC 53 5G VE Pac £558 £3 G E Q 29s bLk fei EP - C 93 LG © 298 Q EX 853 Go ignieE ES g 362 Ee 153%] Liar os 3 = C 3 < GEE $= F BE hen 8033 35 get SES J6 a g Se a 23 3 3330 HERE 9 gEES a < g33ieit 22 2 BYES Cine 5 ERD) EEE EGY GE SES 3 02 C 2% 23 OQ 288d 2 chon cess Br2 SY0SEE HH Oo gEESEE EZ53eE Th HE £23 Q 559 3iaccans nn a a 52 SSgEELs GEC g i bGEb S5cdsety 29 2838 3S EZ se =] EsEE gst 23 GEESE Q gg a 2g5iust Foi vs Si Hi zs ye gz goo Seossact Q 3 33sclEes in B9SiEE de he I] Ss SPE Segdsis 5S & ii 3 a CIEE 2xtoy © a SeEdEat 2325 he Sa Sue i Sect si 2gce: en Eg Si $ saiuss dps 533E 533 gs Eine Oo he 9 Ea sect 5 bees Sl gol a a i Ha Ta Eo SG 3553s Seis = ge ta gst Sh Z Ee 3 GEHL = gEZges 2 GEES 2 he 3 a 2 ine 58E aa ig a z= ok S3isRee BEL sg, n | = 3 ail i282 22% = = = o g £< Ns WE Z 2 - ol= 2528s 2 SEsdss < fe gs EE RB VOLO FVLOVOREU LOLOLVORFUV EgEroegdeny ECEites SEER $22530%0 SEREERERE 2383s LER Edens RIeCIiEs E3S3arEouTES FEiitiss EdrayoaEEds EIR uoOo OLUEOOg= EEC RgCe3uy ads 3ER30EES ESE SSEEACSYY SESEgs3f Ud UUUUOUUTg OULU Eagzagrenee pERgEosE 323 L<GOUURFCU OUUVUOURRFEO 053353550033 SEER 9 9 9 Oo g O<O Gi8385e283s8 $8335=ts GECIZEaasts ELERIEEs GEEEIESSE030 VELOUOOULCL SIC 3IY3ESYeYY MIISRIES B353305835E3 £308333Y CogsyestEles SEEEIRES VOOR USFLOLO o <= UEELI<USOORUY ULV OUUL- USSOOSCEENES | Z3BEUEDL UIUC SUFEU~ << Va—FO =o5bgSsk UO UOEUEOOU- OJ <OA=00U ES52530E328Y S MERELER3S cogsesiiicy @ SusEusedl CiCpissesssy | [RSZESLIEY JOOLUOULURFEOU © <OLVLEOUOLU PIIRITIIUUISY < RS03ISS50GY E20 LVUICVELOC OU <UL eYYss3 Ce ebRR Peele OU SIGSEESESSS GE3Ge38=389% | EIESRbRE3Es §2C33E3kEdey 3 F8334CRGEY < Zz < a < 28, £y822, os £2 22Bloa 2 £E8 PE S| 2ns 553 23855 = 3&8 ZA|A|ZC 3 < wn os > wo |A |e E2255 2EECRED EE2ES2EECEED Fipiidzsgtry Fpiig=zsgiry ESCEFEREEALS ESEEEEREZALE SGGUEIEYES SGGUEIEYES EE3g8lebeis F38302byls Q o (WH od pt dd Q oO Up fe oD fe COESEEGEYG3 COEQERGLYLS GIUI3SEGERIRS GICSSBEEEIES COUGLOUEEEEES [Q0L8Eo88EEES oo ou o ou ou o o o ESESSSobEdg: ESbgoSobEds: UUCOC~uuaIUC<g UUL<OC~uuUCUL<L EgdgsEonisss oydgsEonisss FREFURULROSOC EE URQURROSOT EASES SATE 202225222258 [2022092285 Y O<OU 233 gz 0 <OU 233 gz UEEYSE 83 = CEEZSE 83 = UVEQUUUULCHEEUC VELOUULUOLOULSHEEULUC BSPSUCURIILS BEES CYRIL CUFRUO0OUULUO AL oo OFFOCOQUOL oo GLSS03IUsIYEso GESS53I03IR0sEE C30UGOTESEeE ISSU8EOUESEeE 203836835508 1208336335530 CE2UREZEZ0RS [GE2UB3EEROES Eb2229358263 Eo2222358268 HoBIPE52259e [ELbeEpg2255e LE336E2383353 Lt S2SEEYS33ES FQUOLUUOUOFOULOC —FOLVOLWOUOFUOO0O E255E333U2558 2255E33303558 05985 S¢EEszr CE28h SeEsgEr CUSSSEESEE36S BY388EESEESES SEEPEEEC0R40s0 [S2EEEZESRES0 0S GG S<CEEEZE 356 S<BEEEsE BOEZU20092502 [BERL Y29029:G6e EoG3232U83E2T EIR EE ERR EES] SOEIUE2300R00 [BER E8RIS39RaS Ech ERP EIT POG32EI0ILEE 3 I = 2 BeE, ed gz ft ef? EQEZ E533 S82 5&8 lz Je 223g3yg SUES EEYYEYRY ESEZES EL3C3ue i3dscopsess E3fse BEPCEIL EPCEosERLEh 2IPESLE 0353 VLVLOLULOLVLOFEOFEU E gs EOQ 36S BoIIORBEIOSY 2 23 SUSL3IsE oO 35335 Ges <Q 53 UOOUIC9- UFO LAIUVOLI VOOU<O CUVUOUVUUU VOUUOLUUFUOOUY OE <OURU goibEy CRUZ RINIGEEES SIRE Y 8330508 BPgsdgicess RIZEicE £383353 ESESfEsidNdt Radish geZ3BE3 [sPIoEBROSrSY [3R30Esl SE3ECEE LULU LLLOICIVOY SESSEEE BROEI0E RgbggdslooEd RLOEUSE C3303 o U233E330S oo C2203 < 9330839 [SC0E30z323E EBEESS S3 o 3 O 2 53 Oo 3 C33§P33 BBolkcelcEss, RdNESE 223950 SILEL33INInLS oJ £30 } LLLUO0 ULL GUICLULO 33 LOU 33sfztE oR SSEUEReEeeh 3 ZESOE QILFEOU OU < SEER EIGY OC =O0 OFUCH = a hlcter du Lu Oo ¥3% AVEC SAY) <OQUOVOUVFOELQUU = < $IP3Cys SIGCEdEREIIEE H3EEfad SBosices [322030sgREBE BRYizeEy 20233350¢ VLU LUD GIFU < 255304 SERSRRUE [rEgogergsEbE EEFSERER 2<FSFCLG Eel EIssoise FS SECC uoLOoLOLO VEQOUELOURFROOLL ERE ELL 5353528 SEEEISREEERS R220 OY CI2Q30C8 ELIEPET3spes 3¥PciBas E3CRICEZ2 SCZSEC02203EGR ESGE CoE <LOVLUO CU VOUOLVLOFUROLCOU BPEL EY SUEEREOs [SEGPEbzbpeSs? QEEETECS Ee3peoos BESEILEEULERS EESESZES E3UDC32s |3EP3332F3258C SESLOSES HEUBHEEE BEOEIS0ZEDd3Y BERRLESY A 2 3 3 An o | 5 NZ c 3 | 283 B5t 2g §0 gE gE §2 Ed 2 E52 £2 20g TEA za EB 1:8 < LZ =a S22 £5: TN» CygeYEsYgYeY 23¥IESEesss S33mSbedgia. EIEIipEdsiis IEE OEUIEE45E QOV GECE23 BUBB Y223L86Y 2U0O8EEREYE SEE REEF REMAE SE3ez3en3nstE OFOgO LUOLI ou oouUUL OO VULUOOOUJUuU oO §3388EYsa site EEE Iie C22Y GEIYIYR 030333538588 5E2333E283ss 052355338930 33035053988k SESORESOREER0 RE eresiry CUO LOLLUULCIUG UO 1) ug UU Uo g 002552325083 SE3CIGEzoLy2 U<U << VoL 0U U=0O< QUURFORFG SE35EET2EEYS 530885=5858¢2 233835223338 CESESEESS ES u S3EEE23s0zEEh EOLOUV g3EGY 2 oJ Lou LULU C=O << <L < 0 UUUUOFUJUUOREUUUOO oULU 025383 = VULVA VOILL =U 232030 ieg2ds 2 FUOQOURERFRUREFOLOU 0 $3 LIL=<VO0 9 UgOOV0OLLVLLYURF <LOOCOVOCO-FF OQ UIGhRSsPEIZYR GEE3SuslEeiy © 238bES30oE0b PEZ233393838 IE |s Sobods 98320 UL —FO0UCUULO 0 0 Go2g3a220bsy US03200088rS oc 8 FLOLULO Q OUR PE NEE EES PY — < SVU OUFELOOUOULU = SELRINUPYELS Oo io EEEZE33S0GYEES SEEPOLSESE%E BG SusgePrgiiing g3ps3iioiid © SCEREEC<2Z03F02 3328 gio 33 3 2 FLOOULLOOUULUULUOUUOD FOLQURFO CEES? oJ 0 RECEP IPEEEEY Ss P3I235% COLE 9 f= fro KD fen Ad fee 4) fe fo KD fr fee VOQOEFFOQUgU 9 V $e3azhobhalED He gepgLozniy Gz [GC 2333007093890 RCIg3ecrEEnSE EF © §38E3353C3838 39EEGESGEREES PB 8 < < 58laod — =z 2 Z 2B, 284 EF ERY 582% % 528 s%g¥2 ES2Ed Ess i5|E83 IxvS 8g Z& a SalEca = = 2 |= wo | x = J gS a > 2 2 & ° g = © |< Oo I £ < = QO [= < gs RES BE. RELLE ge J%F ZElelsER2EE «| 0 |= < |Z (V(< 4 pe < w= = wn (= HQ CO v) b4 Zz sy RlsEEESE TE of iL 2|o clzlu@@ZEEwE2EE © < Sn SoD wEEEWzZL |B a 3 © ot ¢2 g S go 2 © £2 Zz 85 |22% £2 SESE ESS |g i . == el8Ex|28Ey glo SEa825%8 eS ss Dole lelelelelslelzlelzltle BF 2 <= ZE IR | RERERS|Rn sss = ~ | = > OD (<< w < Oo > | Ww (OO o ow Z|» a =) wl wn a U(x || =4 =f wn >| = | © w Od — — i Z (<< [a | [bw a. 4 0 — x |X x £4 < CQ QI- vival 2 - < — (Ua | wn 2 = id Q(X > [> OO 0 < ow Z (a |O (xT = T - waa laa 9 © © 5 lal £ |E|3 88. |5 ol ols of EEE Z J 218 glglzlz = So's 2's 22 2|2|1e (espe s Slee ee FE EPER ER FE EEE EEE EE EEE PEE IER E25ara ne nElS|E|EseE segs EEE |2| 288 85 ESSEX ELL RIRRLAE|E AE aes E El=|2| 88 Se 832E| 2535 S|ISIS|Ea<Ea<Ea<|Za LT 0 ERESIS : klzelelrlElRle lz 8 l& |nlslrlelslels = = |= |= sees = =~ =~ Ses N eee @ & 2 i < 0 wn) wu wo S@ - J >| S | = c ale 2 |Z (2 < < O |T QOL [|x |x | 22 2f BEEESE:| dE 26 nZGlaaldl= gn 3 a = = 9 3 ~ ls 252 |g |3 s 2% 2B E 2% |Elelglgl |8& |E& 885 ET |=E|E[E 5 |Z[E 252 21%|5(2| 2 / 2 / 85 = de 5 8E|<Z|F|8( 8220 / 8 = & C|E 8 5|a|=|S4|E|E|E|F|Z |§|2 eS ilo A = =|» Lin 2|a2|z|9 2 28 = [=] ]IR RR|RRZ|RIZZREREZ = = g-2 = £ So 2 So 2 gp gg Ea Ea I) g = = a 2 = = E lz = = £ £2 gz §3 ge 22 ze Ea £ a & a FLZIQULONIHORZO gExozuUaESH> XE¥¥LOW UHIZOWLZegUoZ ang Jn>Eguuz¥ahn dn>EFINY HEOoQuon>I153J0K = Frhgguri=zag THZE>F LxzaQFaafF5S2>00 CHa EI¥nen LHEZHW> ¥W> IOUHLENSOX SS ZuggpLEz2xy ZoIExzy “Qzduxuzvaloozg MOMMLOMUNXL > xo Sud Ferg BLEeLAb EES SEES PR2ULE nn <=0 “S>WwaOITFOZAa EENs QULi=kE=>FooxXx QUEL XOJOOIITXUUXHZEWN CFL ZHW>W>> LCEFLNWOH CW¥QOZZHH>ALALO>-O HZ SWI WJ SHIFZHWV eT OVNZHX JH Jd 3g ES CLUE Pxy Z2zo Wd EEOHYOPLO>TITL JUY JdE>LEFOF>0FX JEHOZOW LL IO >FEZ20SF0nA>0 >ZUngELOZ Jn >zwoadz duHEJUx>0gH>a ha WianuWUHS JX Lida gaok OY ZZULWOHO>FHEOUW wiaFzHns=2>0 wiaoza LLP 0d5LaxHAW JWQUWIF5S2Y Juagu OLOQE>>VUdIT>ULE-F0O a>>0zoWwioz [=A wou>0J50%08F 2-20 ¥RdgREFEIRY YHQnUpEW REECE nO3IoA 208% |rIsoaacslsod rEea2036 QOBEILELSSS CERES ZHSTRLESRREY ZU ae ES PEHJIYEgnofbaggos ZUWNRXEEL JOD ZUWwOndE LIVUOLZIFrnwalyYron HJdoUnhUpEUae>ael H1oU0Uzn=D Yo¥><uHaexiwazT VOI ZIXENnOhuL [VOIGT SEBO gnEE¥n 29> 30bvogzan 295358Y O>UU>HLELCWLAO> J SJWOJATIHEESAD |JJwoua> ZxHOL Ic 1W>0O¥ZY HIUnOdEodg do [HIQnd>n SnduudrEohEEWx g¥zogasgE ba IZ¥ECEAU ALZHauwWa JOH gx CW SILOEg¥on 2 [GZEg5gED COUS>ZJ0Jd>0x >In = JWFO>gUF¥YWn>d JWpEGd3Eau QQJI>2o0qUWUWEHQT QEFO>Q>Fa 20> QFEFOWVA UV ASE ZznoYa Jo THOT duets FS ECSU TARE WOoOHIZ2O0O>X>>XZZ2 [IXVNZLALS>SAOWAL OIXVENDTW >>0UMOSWUWITFWWETO |J¥USYOLiAWFVIYUSYS Jn JEdLEne>EEURHEIY EavOiFaQLual Za vOoligu HAIL Zz¥O WSHAOQ 20 (WE JZa0unJdeoxhis-dle Qo SESCZEHCESES8S2C BL iGEEELSSYZpotaGEsed SEXES RZ SzipT¥ SSE EINAESIS OTs B6230 SESYORELUDEESH>O oLHIZuUsWA x Hop guss EERE¥GEEEigndnhy ER20¥ LggnarER>2¥X0n LakExXxnoo E0LnUWUL XJZOUE>XOZHO XX JZ200UDOC JEXOJOELIN¥OQOZAFg |¥EHOUWXOUITIEFOI¥EHOUT Hay X¥000PJ03>uLg FEz0UXOEISXZZEEz00WES Ww>zonOduyzOLeL NFNOZWSALULWANATIFNOZaSy Cilgoegrakiavpegy |MgH XR SRUIMdHEIoRY XJQIF20LOI0aXFUOS NX JOHOOLLDa TNX JOEZA OW SxoHWOxuEs2oLddx Faoppurgaoguuibann QV OX>dJ00s¥dXuUzuwg [aze-bw §eezzlazgh a FLS>0U2a¥¥nvUZEE |«¥0a1Za5¥a50gE«c¥a1mdsSn = Qo 8 z z cS z g g = o < s = = §3 §3 g3 z 2 BE gg & a Ea Ea SUF gugLneLzxayn SWOYOooLELZNY Sue Ex 2za9 NEQGIELZAY PELELESTX¥0ad NEIL > Jong ¥OSKEITIXACH ¥O>0uw E>S>L ¥XO>=ZH 2>0 axOHLUgE>>>0 ax02a>xxLEl> ExOIxex 3% =x xu&l > EJ J0suocUUZz Ea EW OozZ SLad->0aluz SLEAZE oWOOE¥Y SWaikak EI¥g LioLxOoax¥s LI35E993Er38 kIGRUS SEC? [ITIESHEEEZ EripREfiEosr ErgEis grg¥ ESBS 03Y0Y F20xxlon>0Fx ESRECE Edad 2Z0LVOoOgn>0Fx 2ZO0>ET0VWBRZJn SZRHGE oe >EL SHOLOLFVRZdn SHOLE>FOoJdnY EHOWO no XzOUwWH>a>dunx XZOUETzZzHW>SZ>0 [¥zLago H2on FAOZaS¥SE>0 snggExzLSaY noo Za =>00 “HOJOZW>DO HOME WWEFOOZ —“HOQQoW Jxgda x 10saowloz XX 10 <0 Id |¥200=x E>Ev LOVNFEEFOUEIXJ AoukEVidFL > JF Rona nu gkFxQ ZU a> dbx ZZFLNUWUHUS> Jn |Z2F00T £258 EEPECGELERZY RISELEARSFRY SposD CEFR ZIL¥EEERECSES zibEgEolzsan Zinnnd LoWal (ZTIHEE>Fa>cL ZIHWOREETVWOHwL (ZTIHOZO [ya ea] HLH ZHWOOWOLWL HLHOQAOOREHSOAW HLHOOC suas PZungxxEge>oy VZuno Za 2500 [UZVOFQ JXOx¥n (Z¥XO¥EWWE500 z¥oogoW Je dao |z¥o0ud 5592p ESLEASPESER SOLE ABEEEFES 2808s2 ren EXESnIbEEES E<FUVNIXEXN> J EXEgEg AXLES ([GIJHIFZAXnSJ SJodIP098z0> ©J5%3 RE hsE JZ2oouw lo zZo> JZZUWNAIHNY>00UIZZOND CZHQ CJEHOZOX>000 QdJEunundEooouaaodXZnuw SIEOI _>zZzwytooguwon (I>ZOZUEZLoWgFWVI>ZONGD —>xzZzZ “Lda gogolehHy |JWJd00CYOWLWA EE JdW JOYE WwwwnT —“whaoza Lwao —-— LOU SON JWL OW Seoul |EJugguzs down EAUOUSSEFLO> JE IuOe- <0o=g [Wo>Q=£&Laof>d [Uo>nd>hb>¥¥zhjua>nx SS3SL o2EBaLaEZED REURSiogisEL tally ¥ JC = Ink ELE3LLSES SESS IFEUGENEE SEL EE S3ZH> [QUpUuSIgIviar QUEONAGA0ZHE OUR OXY UZ¥Oon FUWunJIEG0ZHO FUWOOnEFITFOIFWWOOY ELZnl [¥XJdQUZusJdIECI (X-40UVQITWAdSXZZIXJ0o0WW IXOOM (¥DIOO0L¥IS5¥ZZ ¥MOQOXEJnWLUGnI¥OIQUW E>2>>u FO>0OFQUWWWNT LRSM Ee ¥LU¥L> wIWOUuUESae>HWD JdwOxrgac<hozgaLOIo Lez MNTLWVI>NLCPAL ETL NITVRE=>ooUUnNIVVRELS IEEE WXEOSALASILU MEEoLXDOUSAZINEEOLE Cw>> FILO>g<qUsa>I [FILlQUxeQuUaEsdIEF-LQ0 QTd SHE AESES JRE GHEQEUSESEE ERE EE Chx 0 <-FFOOhRUaZIH FFO¥Y0NUZoD|<--OXE iy > = 5 5 5 £ £ £ g g g o o o 5 5 5 I= S o 2 * * c = £3 ss zt z% = a = a EE WE HEE z LaWOoUFQULWL> OxIguwusuudh aEOIdEEESXOY pes3gy SEEERERSED |ouzxggusuowy L298 X53E2HTEEEE XEShED IESE =w>Dg ZHOOa VL >2UZ ZLNd>>L0OLEL EE rboz XLOEXHOXEFT oF gglicuagoz Oo Exped >ZONOCFL OJ >UNEETIIHAOXFD FuL>dF% ZWUQUEabFIou ZIHLE>IXQLHS UHW> J» [WOW aVE JES 2 LUOHEUWHW>Y WW HnabFu> EaayrgobbHXz SlngxocxungUz JdFEJ0d WoZrgaHagd UQZOMUERDEZ oux>el |WIEJ-I0FRJIER WAST InoFaZau ELOLVL JOEL JWI SL S>no>Jd>Jny CLS3EY ALOE >0NE > AOC WZWU>>2>0 =500 [@uuod>wd>0Z WFHQWIFLSO%S dx do |O¥HZXODwuxg hud Saxo fF¥J1-0802 EESE>CY |2uH¥OA WAXY ¥ JOVI QWEIX J FElgF>r0 [QOu>IHANLA®N Dl >0adpE- Eau XEXnS>d EFghidVunaka E> 11000 ¥HEN Coazd> [Don Jdnona STL OZa [a EXE TapaaLgerzuzal AES hus d0 Eooowadiodg TEHLWL => oO i>Wwnx oi Slog nU>HLE>uLo>h wasnzUsu-nd > ¥OoULWo JIT Z=>0n0>0U>0 JOFOUDINMEH>AWL we Er Eo eg) TIO =z00atFnal SELoQO>Jgdez20nnedE SWOT FROoJxHA E> X¥ZooEdaxuu>aga SOW IIZESL EE L>bEgzXoUL ry >ulioxrs QUANUZELOF 0 <a xv JouxilunagEas JoU0UEW¥ ons = SYISUsT wl 2p FES YLOZEOoU SECEDE SNnOZHQ Qa I>JFEFS00 QOU>IHEFX¥LAAD E-ITIFECIIQUWFEQoUHLUEXE gA0%>Enaggos TWiIS¥ZZ|Q IC>ZdHIEZY (QOWOIHHHAOOLYE® SNWUWWNIIQUN AVX IUSXYXXYY |[OxXULguog<aoluazz CUASHUWJQOWUFRFWNIoAWN>A |[QdE>¥Y~aUHeeyY on gaa zc dQJVOWUNEIHZYN IQUWZ0Ja Una O> Jd PELOCUWOOAWOUWEVUQRWI ([OFEQJEXX=>OX ZV PEEP CE ELE TREE EE CELE saa 355<ug8aEs into SgUPGEZNSIASE QOUZXohFFLUOuEOLza0Y |(Fodwg sheng CLELZNONEULO ZA FSINCZW (NI¥YYY=>0NATE=EOT IVA NNOEnOhAJdFLAZE N>>F0 Hop reEe SESS>LNYZOUZWOJIOLOT (WLIS¥UoAZFLWET YXLEL>-aoBGLa>2g2T FXLWOOHEV AEDS SU0aUBZNJNOIUOLLIWZ [ML>¥ZLUNHRL 20 QUISEEZAFOGOTERAL PT REY IxdoYogdd QOU>>0nixCEPruczF] MaHEHO>IE>a>T SQTUIQEXIHERDOESZHD E320 ET a LLES LONXUSoL¥JrJdESx2&0oW 2nHOUSWUSSH> SVSOFEKF>STISZXINUULT [daHez hwoncdah > > B B E Eg Z £2 S 8 o © 5 1: oS oS 2 2 = = = cE = £ = £ hE: gz §3 gp gg ge Ea <a & a I> J dW HY J do JWOE Ya J > IWOEHYO J EFaugUraliu> EEaugphoii> HSE ESI ¥>UxIguwusuLh UxIguwauuh MIYwWSwhh AXOJEEE-SxaU aEIIEEESXOU aEIJEEEexey S20E08S0S0L |2ZHE00S0%EL RZhEdYs0sER XEREERRESEE XEEEPRRESEE “GEE ENREEEE ZHAVAVL>2OZ ZH nL >E0Z ZHXOaonL>20z ELOY HOXD FT ELIEXHOXDFO XLIg¥HOYXOFO EERXYS 29S >ZUNOL-A OIL >ZUMOLFAO JC ZzUOUZaFFInW zuoUZa-FIoW ZzULUZabFIoW ULOWaVOFJIZES> 2 WOW IZ>2 HLOWLOVFEJIES>2 ZS0QAUFEHFHXZ SSOYFEHEREXZ 2oQYFEHEEXZ gugo= caHLOW ues oo=HLOWn woz oaHLoOWV NE TEJUFIZX JE TEJUFIEX NJE TE JUFIXX SonHOLN IWS FLEES hgusy “pp ggndluse SALERRO ES>NE > ALEEOEES>NE > AL O¥E>0NE > Dounod>wd>0Zz Dunold>wib>0z Lnwnwol>wb>0oz CY HZX Dun huJd OxHZXOnY hud OXHZXODnEOW J JHYOoS Wax ¥ JHY¥OoS Wax Jn HYOAWoXY XY SEETECSEIEY BRRIILEIRY? [EziSSifil n @ n @ on 7] Fog 5EnaRhez ZEgv45Enanez ZhgLsEnaRes ZBLggrzuzHL 2BL5@rzLzHL 28LggrzuzHL oI J< TEHLE> oJ < TEHLE> oJ TEHIE> Wa>HLE>0WLO>n W>HLE>VLO>0 W>HLE->nWLo>n JI2zE>h0>U>0 JZ2E>h0>U>0 SITE >H0O>L>0 IE OOhUDa IZOD TIXZcOOThWOD SIZ ZZ0hneg SIXZZO0NnEQ EF SIXZZONhnEQ SEpizuiu>a<g SE JAxuw>a<o SE ixlurocn ULS>NS>WWOXY SZ ULS>NS>DWWOXY Z UL>VND>WWOXZ JouxionagEaH JdouxkiwunagEaoH JdouxkiunagEaoS poor >gsgn Wesaor<rocn Wsaeor<cpoxn asSaxI>JFIGQO asaxI>JFICQO asax>JFICO SUE QUHLUEXE SUE QOUNHLIUEXE SUEQUHLUEXE CS Ia>ZEEHIEZY (Qlq4>ZedHIEZY [QIC>ZXEHIEZXY CUVNINXEIUSYNYYD QUNINXEIUSYNYY QUNINXIUSXXYO QOUWUFWVLIAWV>A QOWUFWVMIAWL>A QOUWURFWVLIAWL>QA SII WUMS>HZY (@dodyold>HZY [@JdodUoWUd>HZON FoOoWOUWXUQEWI (goouWouWeLQkEWI [oouduxakEWT T2EAYiIgorgc SSEBgEIpsEis SosaPiigssd JO0B5%¥S¥C Ee dugB5E5XChsn <udB5ES¥CEsn FEOOuallLz=alfx FRLUOQualwzal0x FRUQualwzalx NgLOTAFRFENLCZU LOA FREShdzW gL OZAFRIHdZW Nonna JELLO ZE NOEL JdFLAZE WOEVVA JELLO ZH NZZOUZWOJIQOLOTI (W¥ZOUZUWOJIQLOT [W¥ZOZWOoJIQOLDT FAaoQUA>SSC2TI |FLoQUXASSC2TI Fao QUXAS>SSCET NJNOIUOLLLLZ JO IUOLLWLZ wJdn@iuollglz N>OYUIEFAUVS>T V>00UIEFOWVST WV>VO0UIEFGWVS>T nivel zwozFd Lx 0x0zwaozFd wWL¥OZUzwaozFd EY JLEFOEQSHDY (FX JXEFOEQOSHU EX JAZFOEQ3>HO GL¥IEoE¥Eol ph¥prJEExEol ohESEJEEEEQD <->052zZxniuIT [<-> Z¥nouT |KF>Jd>zZx¥<g<nunzT < oa N < =o S S S E E E % % % £ £ £ S S S o o © o — « «© © «© = = = cE = £ = £ hE: gz §3 gp gg ge Ea <a & a Hdd WO HY J HAWN J “Pp U>zZzXxI<nWT sftawoUraoilu> EEpugLhoLL2 ZEZ2E8EREed ¥>UxIguwusuLh MIZwWSWhh augOraLL> OXI IEEESxAU A¥IIESESXAU oxUxIxwouwund JHA XVM O SOF JHA ENYA SOF H2 2S ->2XOU xzzogoUgLZHL vzzdoUgUZHL XZIxzn¥a SURF JOInEHN Jz FE JAILER Jz nH EoUQoDZ HL ZHOU VL >Z0UZ zHUOVa WL >20=Z ZHELERS “== gLIEYHOXOFT YLIEXHOXDFO XLOGoune>20=z EES XYS~29-S >ZANXOLEA OIL Xz HAOXAFUO zWuzUZakFZIou zWzUZzab-FZIou ZWOXg<raga< UST WOOFJIZES> 2 WSIT WOOF Z>2 LOVE -FIZ VW ZEOPUFEHFHXZ EOSYFEHEREXZ ZOQLEYRIEZS gug= caHLOW ues oo=HLOWn woe EHREHXZ NIE JE JOR I2x NIE JE J0FI2x Nn IE Z-oaHaEH JppEssASEce IPRHogAcEib gpopd0raig Dounod>wd>0Zz Dunold>wib>0z Duh EISLSHES CY HZX Dun huJd OxHZXOnY hud OXHOL>WAES>TOZ JHY OE Wax XY JpHYOS WAX YY JnHZzXxOnxeHod ooun>IHaxuLan Qon>IHaxXLan QOon¥oa WL EN Y ZEFQuuUUnalQ ZEFQuuUUVnAkEQ ZFO>-IHAXLAWn Sd0Jddunana S00 Jddunana JN WLNA =o > 28L3@xzLzHL 2BL5@rzLzHL FLL Ya vas Sa< TEHLE> oJ < TEHLE> EERE Uo>HLE>nLo>rn LU>HLE>uLorn L>HY IT EHL E> $E253832U88 332538592188 |ZEEE5285E38 SIZ ZZ0hneg SIXZZO0NnEQ EF Sichuan SEpizuiu>a<g SE JAxuw>a<o SE IZ20nnal = SOL>N>WLOXYE FOL>N>WLOXYE SULAxWW >a <Q JouxionagEaH JdouxkiwunagEaoH JS UpULOXE poor >gsgn Wesaor<rocn molLxlbpeFaH SOFP8GRcGENE IBBFS55CCESE 3BrE2S3pSES CO Ia>ZELHIEZY (Qiq«>ZadHIEZY [ICCB RHLTUEYE CONTIN IUSXYYD [QUO INMIUSYYD [QUU>ZeeEHIEZXY QOUWUFWVLIAWVN>A QOUWUFVMIAWM>A QOUWINYIUSYNYUO Jo JUoUXS>ISHZY OJdodyoux>HZV OJaURFwIAWn>QA COQUOWXYQFWI |oQuoWeakFUI [00 dVolxd>HZ0n SXs0=FALSELY D3582384588Y [Tsp Tz Eas JO0B5%¥S¥C Ee |dugB5E5XChsn <uJB5SaESKEsEY FPRUOVNADWELOXY (FELWOVBRVW=EAOX EERIE ELDRD NgLOZAFRFENLCZU gL OaFRShdzw LOW Wa Oy Nonna JELLO ZE NOEVnAJdFLAZE WOEOZAFRZOLZW NZZOUZWOJIQOLOTI (W¥ZOUZUWOJIQLOT [W¥zOhodFLa XE FRoLQUXA >>I FAoLUXASS CET FAaQUZWOJIQULOT NINO JIUQLUCLZ JNO JVOLLWCUZ JO UxA>353g=T N>GUOUIEFAU>T >CO00IEFAV>T W>VU0J00LlgWZ L202 VzwaozFd WLx¥O0EUzwaozFd WLX¥XOUIEFQ UST EY JEEFOEQSHDY (FX JAERF0OEOSHU EX JOU 2WQZ=Jd oly JEEX&Xod [QLl¥UrJdEESx&0oW QL¥EEF a> <=> ZX CNUWT AF->Jd2>2Z¥XqNUWTIT C33 >Jd-EXxaw 9] 2 Jo © a 0 ° B ° E E E % % % = = = S S S o o © on =< wy «© Ed Ed £ s s g-8 g-8 gE °2 Sz ° 2 58 2] z 0 SE 2 5 Z 5 a Ea Ea HP Hd>ZXCNUWT (JJ JWOFHXO Jd [Jd JWOFHXo J EEgudrH¥ed EEgioQbeoiu> UoQFoLuL> E>>WUOU=RQLL > OINMWaWLD |Z M¥INWa>uWln abOxIxgwouuh REXJEZCox0U REXIEZZESXOU GOEPEESEAD QRIERESEEICE GETERERSEEEL X552OES08EL BGSE2HREIEE [S63 EPHIEEEE BLESSES AEE ZH2ZOo WL >2UZ |ZHZOLVWWL>ZUZ LOL >20z [FLIEXHOYXOFO [gLIdEgXHOXDOFT >ZOeEXxHAOXDFU >CZMMOLFAOIL >ZXXOCFA OI ZUoxXggaragds ZUQUZEalFIoW (ZUOUZakFFZIow LgQUEaFIOW |[UqOUEUFJIE>E [WOU ULFJIESZ E0QUAYEJIE>Z £32Y EHFHXZ Z32Y EHFHXZ guy EHFEHXZ woz QaHAgWV woz QaHAOWV 13n3EIGRSL [dpvngInonss [ApnHgInonsd SLEHOIN WALD |HdLEFOEE>NES |JULEFOXE>0NE > LOVEOYFSVES [Luuwod>wb>5z Wunol>wih>oz CYHOW>WA>TZ |OXHZXDuYhLd |[O¥HZXbuynhod JnHZXONXYHLD JNHYOL WAXY [JuHYOL woody Qon¥oLuUaexY QOV>XIHAXYLAIU [QoOu>IHaX¥Lan ZFO>IHaAXLAWn PERCE Ee EER ynstie SJ00nUWUna =o SJ J Juno no —- J JdJunano Joldadonans 2BLggrzuzHL FBC go>zL=zHD OI ZIgeI LEH Sa< IHL E> [O2< TeEHLIE> UW>HYITIEHLE> WaHLE>nLOrn WaHLES>SLTrn FEEE52085038 25853832088 32853890138 glx OoConUWOn QIZs OldxZxOnuned go JzZzxOnnegt l= QoJdJocduu>o go SEs sulL Ase goLszuurag QULS>UNS>WWONXYE QUL>V>WWOXS Ze2YpHlo¥E JoluxbunagEad JouxiunagEad wolxionarEaH Wooor<>ogn Wooo >on SOPE23SPI%S (8BR&F5coZY [BRFSS AT ERE CIC ONHLUENYE |[@1<>ZedHIEZX[O 1a>ZEEHTIREZY CON>ZELHIEZX QUO INE IUSKYYUQUUINEIUSKYD QOUWINYIUSYYUOQOWUFNILLN>AQOWUFNIAWn>A SIQUFVICLUV>E|IOI0JV0UE>HZVNEIQdUOWUY>HZY COO JIVOUX>HZVOoAWOWEURFUIIOoQWOWeUQrRWT SECC ER CERES SEAR Ea E std SECA EE Nea aE SES CRaESECHST CELE EERLOGUE ELEY Vw200xFFRLOVADW=00x na On W2a0¥unquizaFrshgzlnauO2arshazl NOEUZAFZTNCZUNOEVnNA IFLA ZFIMOEVNVA FLA Z- NEZZUHO JFLO EWE ZOZWOJIQOLOIWEZOUZWOJIOLDT FROUZUWOJIQULOIFAQLUXASSCIIFAaQUXAS>SSC2T NJNOOUEASSCZIVNINOIVOLLUCUZNINO VOL WILWZ N>00IUOLLUIUZN>VQUIEFAaU>TM>U0UIEFQUV>T iE SOTERa > TNL ZOE0 awa gr JInLEBEl sual EY JOO 2WAZF Jd JXEFOEAOSHUIEX JAZ FOEOSHO ol¥asErF a>HO LY JEEXXoULl¥0OrdES¥ZaoW <->0>aF=Exaodl<-> ZULU IKF>I5Zv nin E 8 E 5 S S Eg E E % @ Z = = = S S 3 o o o ° be oo «© © «© = = = cE = £ = £ hE: gz §3 gp gg ge Ea <a & a Hdd WO HY J HAWN J SP EJEEo>xXOUV EbawgUrouu> EEpugLhoLL2 HN ttn ¥>UxIguwusuLh MIZwWSWhh xZQoUQ0Z =u a¥ZzJdEZEZ-oxaU 1-1 OXZLEHRGCEJdE = JHZ2n¥a SUE JHZxh¥a SUE IHX0aunL>20=2 xzZzoLoUgLZHL ¥zZzxoUgUZdL XZzuUgx¥xHAOYAFO Jndu =H JE JAaJokEH JE JNM XOLFO OJ ZHITOa LL >E0=Z ZHIUo nL >20= ZHXUEa FZ ow FLEX HOXOFT YLEEXHOXDFO LUO URIE>2 FEUXYS 291% >ZUNOLFA OIL >ZOUFEHFHXZ ZWuTUZzao-FRInW ZuWTuzoEFRIOW ZWHZFOOHLQOW UL JWOD JIES> 2 UL JWOD JIZE>2 Wg dd Ud ZS0QUFEHFHXZ SSoYFEHEREXZ ZSZ2EQIngusY EuoZroaHagy wgZFosHagd ough F>0=3 NIE JE JOR I2x NIE JE J0FI2x J L>wh>oz donHgIAJULY JQuHgIAJUIY JonzxOn¥hod ALEC =>nE > ALEEOEES>NE > JL OOo woo Dounod>wd>0Zz Dunold>wib>0z Lnn>IHox¥won CY HZX Dun huJd OxHZXOnY hud OX HOLU®nL FL» JHY OR Lax x¥¥ JHY OA Lax x¥X JnHJdJUnawna > ooun>IHaxuLan Sown>IHAaX¥LA® Qoungg>zLzHL ZEFQuuUUnalQ ZEFQuuUUVnAkEQ ZEON TELL => Sd dduWnane SdUddWnano — dO LL >nLo wv ZBLggrzuzHL 2BL5@rzLzHL FoLE2RlzE22 Sa< TEHLE> oJ TEHIE> I< OThuE Uo>HLE>nLo>rn LU>HLE>uLorn L>HZ20nne dT2E>00>0>0 dT 2E>0H0>0>0 JTzaxUu>o<O ITXELOTONWOO TEXELOQOVWOO TEZ>ND>WWOES SIZ ZZ0hneg SIXZZO0NnEQ EF SixuxLunoEoH el rr oo JoxxWuW>a go SEEEEFESP RES ULS>NS>WWOXY SZ ULS>NS>DWWOXY Z QULLI>JIFCOO JouxionagEaH JdouxkiwunagEaoH Jo QUuHLUEXE poor >gsgn Wesaor<rocn Wa>zgedHIEZXY asazI>JFL0Q0 Qa I> JIFS00 Q>JdNYITUDSNYD QUEQUuHLUEXE QUEQUHLUEXE QUEFUFwuIAQAWn >a CIa>ZEEHIEZY (@iq4>ZedRIEZY [IC IQOLUY>HZN CONTIN IUSXYYD [QUIN IUSYYD [QuuduaedruT SOUOFVISLN>E |GIWOFVICLL>E |FoWwnlOIwWlaoxan SIV WUM>HZY (@dodyoWd>HZY [@JoUz¥o¥>wa Jd COQUOWXYQFWI |oQuoWea-UI [00QQuE>>LH00n SEEOSTACSHSY (S350 A000SY [S558 LEREAS2E JO0B5%¥S¥C Ee dugB5E5¥Cchsn <uJRAE CFLS FREUOWALWRLONY |FRUOWVWALDWRAONY |FRWQZWOJIQWLOT NgLOZAFRFENCZU gL OaFRsShdzw gL OOxa>> = nIEnhaJFLAZE OEwnadFLAZE WOEOIUOLUQWZ NZZOUZWOJIQOLOTI (W¥ZOZUWOJIQLOT [W¥ZOQUIERQ UST FLOOOxES5<2I FooQUXAESS CEI FAo0E0zwWazZFd JNO IUCLLUCLZ JdnOIUQLULLZ WJIdNESFOESSHO N>OOUIEFAWV>T VN>U0OUIEFAUVST WVN>U0>JdEEsxxxow lOO zwazFd wLixOxOzwozFd WwLxd5Zzx<nloT EY JEEFOEQSHDY (FX JAESFOEOSHU EX J JWOREHXA J ong JEESX&od [QLl¥UrJdESExX&oW oLl¥>Wollaliu> <-> Z¥nlLI |«F>35Z¥niuT KF>08¥IWSuud I= = 5 £ @ = © o z 5 5 = = = cE = £ = £ hE: gz §3 gp gg ge Ea <a & a - dW OH Od = JW HMO J 1 dd HMO J sftawoUroilu> EEgugLhoLL2 sEauggnoke> ¥>UxIgusulLh MIZWSWLh UdIgwauwuh AXOJEEE-SxaU LEO IESESXaU OXOJESESXoU S20E08S0S0L [REE 80o0%0L R208 Ys0sEn XEREENTEEEE YEREERTEEEE “HENRY EEE ZHOU VL>ZUZ ZHLVWOLVWL>Z2UZ zZHLOanWL>=2U=Z ELOY HOXD FT YLOUEXYHOXDFO xLOUE¥YHOXOFO EEEXYS ais >ZUOg-Aa Odd >ZUNXOLFA OIC ZUQUZEza-FZIou ZWoUZEzak-FZIou ZWOUZaFFIoW ULOWaVOFJIZES> 2 ULOWaVOFJIZE>2 HLOLOVEFEJIES>2 ZS0QAUFEHFHXZ SOOYFEHERXZ 2oQYFEHEEXZ gugo=z caHLOW ues ooa=LOWn woz oaHLoOWV NDE d= JU dX X NDE J JU dX X NDE J JU XX SonHOLN IWS FLEES Agus SonHOLN IWS SEE OXE>0NES ALEEOEES>NE > AL == OXE2>0NE > Dounod>wid>0Zz Dunold>wb>02z Lnwnwol>wb>oz CY HZX Dun Jd OxHZXODunY hud OEHZXODNEOW J JHY OE Lax XY JHYOA Wax YX JnHYOAWo xX SPLLECOErEY |ECSCECREEEY EESGECREREY wn wn wn wn wv) wn 28L3@xzLzHL FBLggrzuzHl 20LIGXZLZEEE Sa< TEHLE> oJ < TEHLE> oJ < THIE> LUo>HLE>nLo>rn Ue>HLE>uLorn L>HLE->nuLg-in SIZE >0n0>WU>0 ST 2ZE>0n0>W>0 SIZE >00O>W>0 ITXELOTONWOO ITEELOQOVUWOO TXEXLOQO0nWOD SIZ 0hneEg SIXZZO0NnECE SIXZZO0NhneEd SEpizuiu>o<o CE Lixziusago SE ixlurocn CULS>SVNS>WWOX Z QUL>VNS>DWWOXZ QULS>VS>DWWOXZE JouxionagpaH JdouxkilwunagEaoH JdoWwxkiunaEaos WpooIr< >on Wear ocn WaaeoI<cpoxn QpraI>JFI0C apa >JF-F<0O Qo I> JIFIS0 QUEQUWHLUEXE QUEQUuHLUEXE QUEQUuHLUEXE CIa>ZELHIEZY (@Qlq4>ZeLadHIEZY [QIC>ZXEHIEZXY CUVNANXEIUSYNYYD QUNINXEIUSYNYY QUNINXIUSXXYO QOUWUFWVWIAWM>A QOUWUFWVWIAWMn>AL QOUWURFWLIAWL>QA Jo JUQUXSISHZY OJdoJdYQUXS>HZY OJdodUouWX>HZOV CoOQUOWEYQFEWI |oQuoWeldFUI [oQugweyarFuT SoEfYiigorgo ZSEBgEIpsEEs SospPEiigsssd {0085 %¥5¥C Ee |dug85%$5XChsn <uJE5ES¥CEsn CELsyphipuzasy LRrsSgavu=ax FEUZTualwza0x NEULYZOFSNCZU LLY IOFSHCZU gL DO2arsha2iy NOEHOAJFLAZE WOEHOAJIFLAZE WOEIVAJFLA ZH NEZLZWOJIQOLOT W¥ZXZUWOJIQLOT [W¥ZLZWOoJIQOLDOT FoLOXOxES55<2T Food UXESS CEI FAOI0OXASS CET NANT JUL LW wz NANT JOUOW LW wz NNT JOUOWW wuz N>OLUITEFAV>T N>ULUIEFAUVS>T WV>UOUIEFQWUS>T NL2oE0zwaozFd MLx¥OEUzwaozFD WL¥OZUzwaozFd EY JEEFOEQSHDY (FX JAERF0OEOSHU EX JZEFOEQ>HO [gr JEEXEod [Ll¥OrJdEsEx&oWd [ol ¥ JE=sx¥®aoWd <-> Z¥n0UI |«F>35Z¥niux (<-> Zxdniazx 2 2 3 g Z : : % % % = = = S S S o o © 3 5 5 a Q Q «© «© © = = = cE cB wu .B hE: gz §3 gp gg 8g Ea <a Ea SESoodraEls |SRs2EFFAYEI SES2Z¥ShveS ESoueiSuta ECSI8FE Es |BSdnadFatts AEQIEE-oxOU AXOXIRUSWLD [XOX IZuwWaouLd SEEE2ZRSEEE DRS RELSEEU og giisiEd XEREENTEEEE XEOEQE50200L BA0238S02E0 ZHOU NL >E0= ZHALFHEEJEE [ZHOLEHEE JE ELOY HOXD FT LOU nL>20z Luann >202z EEEXYS ais >Z0xx¥HAOXORFO >2Z0gxHaxDFO ZUQUZEza-FZIou ZWUoxXggeragds |ZUOxggaragdg ULOWaVOFJIZES> 2 UgOUVUEoFIVNW WLOLVEA FIT VW SEO0NVUEHFHXZ ES24BY “=> ESQ9By “Z232 BuoZFonHagy WOUFEHEREXZ WOUFEHEEXZ NIE JE JOR I2x NW JIEZ-0oHAOy WMJIEZ-goaHLon SPEESSASEIE BRand0rggE DPRARIRNIEE wv —- wn HH wv Dounod>wid>0Zz Fuh ESSLS ASS EnhEISLshss CY HZX Dun Jd OXHUWL>WES>TZ (OXHOUL>WBE>OZ JNHY OR Lax ¥¥ JnHzxOnxhod JuHzxOunxHod ooun>IHaxuLan SONNY OAUWAXYNYY [QON¥OS WANS ZEFQuuUUnalQ ZFO>IHAaxXLAY ZFO>IHAXWLaWn Sd0Jddunanc SJd0nuwlunakEa SJd0nuUUna ka Sa< THIEF > QS ISIE ZEN SILO >ZL ZH LUo>HLE>nLo>rn US ITRELES> Lege ITEHLE> SEzied8aisl JEEESoBloss JEEESBless SIZ 0hneEg ole<Ogohudn (gJLgoqohwdo SEpizuiu>o<o FE IZ¥0WnEoE (QA JIZX00nedE SOL>N>WLOXE gOLoZll>a90 |OULAXLILAOA gD JouxionagEoa JEU ULOYE JEU ULOXE HeeorgpoEy DolxlbgaeFaH Dougie rEaH S8e5222028E 5BE38sipesh SBEiBsleeys SI IC>ZLHIEZY (OQ ICONHIUEYE [OQ 1<0BHTUERE CONTIN IUSXYYD |QUU>ZedHIEZXQUA>ZXEHIEZX SOUOFVNTIELN>E [GOW ANY IUSHYYUIOOW IBY IUSYYD oJodUQUX>SHZY OJdoUFwnIAWn>AOIQURFVNTIAWN>A COQUOWEYQFWI [000 JWolX>HZUICOQIYOWUNXIHZY SXsEEALSELY B35, TzEgabsaiisndzigatksn 20TS5%5S¥2 Hen OBES aS ESN4agBEgagsEsY FEUTuaOL=za Ox ERugugz >LH QhEuRgusE >LHQWV NLULOZAFSOHCZW gL Zn wW2aO¥ungl 20 w=2o0yv OETA JdFLA EE VWOEIZAFRENCZWNgEIZARZTLZ2W WEZOZWOJIQLOT W¥ZBOHo FLO ZE-nEZ00hoa JLo EH LaozCea>><2T LEOZzZUOIoLOIINAnzZLUDJoLTT NIJNIIVUOLWCLZ JDO >3g2zITInbUxa>5g=T N>VUOIEFQY>T >U0JUOLUCWZn>U0IUolucWZ L200 zwazFYd MLXOUIEFa UW >TMLYOUIEFRQU>T EX JESEFR0OEOSHDO |FxJdgelzuozFdlExdagbzwozld AULXUO>rJESXxXxOW Blx = Q>HOLXUZEF Q>HO <->352ZxniWIT [<-> AF ENEZoUC->I>0FEZEad Q a od Oo a < Z : Z % % B = = = S S S o o o 5 5 5 a Q a «© «© © = = = cE = £ = £ hE: gz §3 gp gg ge Ea <a & a JHY Oo WAXY JnHYOo WAX YN IN HX OO WA NY Soown>IHaAxYLan Doun>IHaxXLan Doun>IHAXLA®n SEFO0nUUVnAkEFQ SFQ0ULUVnAkFQ SFOoVWUnAFQ > Ja0dddunana Ja0dJddwnana J20Jzupsnas 2BLIexzL2H JBLZg>zuzH FOLIO xzZhzH ISX IIEHEE > Od IT LHL > OIE IT LHL E> LegiEzuiaeis TegLEsuLel EEN] “I2E>0N0O>W>0 SI2E>0N0>SW>0 “IT XE>0NO>W>0 TXxqoQonuoo Tro Qonuoo Tr ogoounuoa QlxZXOnned = oJxZXxOnunxa = odxZXxOnwnxa = SEgjLxzuuraaa<o COLSN>WWOX SZ QUL>N>WWOX SZ QULS>VN>WWOXZ SJouxbloarcH JgouxlunarEaoH JouxlunarEaos Wao oT L >On Waar >on war >On >a I>LdFFI0C a>aIXI>JFL00 a>aI>JFFI00 UFO UFEYZE WERT UEYFE UE UEYFE CAL >ZxHIFZX Qld >ZdEHIFZX Qdd>ZddHIFZX CON INMTIUSHYYY [QU INAMIUSHYYD [QUUIRYIUSHYU SOUWOFVNILSLU>E |QOUWOFUICLVn>E |QOWOFLNICLN>A IQ IVOLX>HZY (GJ lUOLXRHZY [10 lUOLX>HZOY CooUWOWEUREWT |ocuWduWeUdr-WT [ooudweydruT EXT nOTWEOXLy ([d¥Ln0TWoXLh (dX 00TWoax<<n so09R Scag y |ca00aESYcagy (cnJ2aE552E 50 SEHCAROLLEE EY FEES AEOLEEEC BEEZ QE0L5EEY NEULAZIAFENCZU MLLAZAFENCZW NEL JZaFEsNgZW NOEJhodFLO ZTE WOEJhAJdFLAZE WOEIAJFLA ZH NZ ZSZWOJIQLTOT W¥2Z3ZWOJIQLOT (WEzEXzWoIgoLoxT FaOS0xd>5<4=T Fook 0xda>S I FoaowWwioxa>3 I NN dJUOW IW wz Nd Nd JOO wz NNT JVUOLW wz NT CESEE EE URT Mr C¥OTEESYpeT M>0LHOTIERR IT NLT zwozF] wLleOxbzwozlFd WLYODzwgzlFd EX JE Q2HULU |FxJa gk 2H |FxXJxEF a=H0 ol¥>SSJFESv&od L¥UFXJFEsS¥&¥old Qi¥>FJFE=Es¥&od AF2O0>ZzxqNUWI |KF2d>Z2XxAnUWI KF20>Zx<nUWT wn Jd Jw Hao J wn ¢JWwo HMO J wn Jw Hxo J IsfbawoUtollu> |TEE>wWouUlolu> |TELawoUtolu> S¥>U¥IZwouLd SZ>08IYwduldh SE¥>0O8I¥woswLdh CoO JdEsFox0oU [Dax0 JESS 0oU [DAaXOJEEES¥AU EJHOZO¥a SOF EJHOZOX¥a SURF EJHOZn¥aSURF SSEEESoo0Eal S2EBEEROUSCL <BEEfossion 3 LERRGEAES EEE EZRAGERESE6E SLR GE AES SEE SELOEZXHAOYXOFD >ELUEXHOXBFDO >XLOEXHAOXEFD J>zO0MO«FROIT |JI>Z0MOCFROIL |JI>2Zz0NMOaFa OI LZzUQUZEa-FIW [LZWQUEa-FIvuW [LzWQUEar-FIou JUCOWoY-JIE>2 |JUCOWOgFJIE32 |JUCQUWOY-JIE332 HECQUFEHFEHYZ HECQUFEHEHYZ HECQUEEHEHRYZ HELOZFOAHAOY HEWQZFJAHOOY HEWOZEFOAHASOH Un dE J JU d2Y [UnJdE J JURJd¥Y [UOnJdE J JU JI2X COCPE8Sls ES [2OCLE8SlsnES OEP ESSls uss Sanh IELBLES Sarno L305 SonhboEL3lE2 ZEOXHZYOn OUI EOX¥HZXOVWEOhEI EoxHZx¥Owuxhod of 7] & 4 E ° B ° E E E % % % = = = S S S o o © Ed = =3 8 Q a «© Ed «© = = = cE = £ = £ hE: gz §3 gp gg ge Ea <a & a JyHY Oo WAXY JnHYOo WAX YN In HX OO WA NY Soown>IHaAxYLon ooun>IHaxXLan Soun>IHAxXLA®n SEFO0nUUVnAkEF. SEFQ0ULUVnAkFQ ESFOoVWUnAFQ > Ja0dddunana Ja0dJddwnana J20Jzupsnas 2o53gEslfnC gaissifisnc gaizgsglifnd EsSEEzasty ESSfEsRLstn TsSEESEISt] “IZE>0V0>W>0 SI2E>00>W>0 “ITE >NO>W>0 TXxqoQonuoo TxxCoQonuoo Tr ogoounuoa QJxZXxOnuned = odxZXxOnunxa = oJxZXxOnwnxa = SEgjsxzuu>a<ga SEfLxuuw>aaSN>WWOX SZ QUL>N>WWOX SZ QUL>SVN>WWOX ZS SJouxiloarcH JgouxlunarEaoH JouxlunarEas Wao oT << >en, Waar >on war >On a>aIXI>dFI0C araI>JFI00 a>aI>AFFI00 UEQORHLUEYE WEOWHLUEYE WEQUHLUEYE CAL >ZxdHIFZX Qld >ZdEHIFZX Qdd>ZCdXdHIFZX CON INMTIUSHYYY [QU INAMIUSHYYD [QOUIRYIUSHYU SOUWOFUVNILSLU>E |QOUWOFUICLV>E |QOWOFLNICLN>A Io IVUOLX>HZY (Gao lUOLXRHZY [10 lUOLX>HZOY CooUWOWEUBEWTI |QocuWdWeUdrEWT [dooudweydruT IxLo0TUWEOXLy ([E¥Ln0TWoXLn (den TWoax<n so025ES5C Gy |cu0gaESYcagy (c2dgaEsSEcEG0 SEYZNECuLEEEL SHER NECLEEES STEYR NEOLER EL NEL IZAFEZNCZU MILO AFENCZW MELO ZaFEnNgZW noEIha JFL ZE WOFFA JIFLAZE WOFVLA IFLA ZH ae LE EE] PEER UISTE FS NEE RUEIT = FooWOxa>> I Foo Qoxa>>S I FaoQOxa>3 I NJNIT JVUOLWELZ NJ JVOLWALZ Nn JVoLwaLZ NrCEEEEnEYRT Mr CSTE EsYpeT M>0R0IERR PT NLD TzwozF] wLYgxbzwozFd WLYQGEDzwozlFd Ex Ja ZF 2H |FXxJXEF 2H |FxXxJxEF az=H0 Ll¥OUSJESY&oW L¥>FJFES¥¥od Qi¥>FJFEs¥&od CFE2d>ZX¥INUWUT |(F20>ZXIqnUWUT <F20>ZqnUuWT wn J JW Hao J wn Jw Ho J wn 4 Jw Hxo J IEE>wuo0tolu> IEfFcuwgoUlolu> ZTEFauwgoUlolu> S¥>0O¢IZwouldh SZ>UMIYwoWLh SE¥>O8IYwswWLh CoO JEsFox0oU [DaxIJESEFSx0oU DAaXOJEERFS¥AU EdHOZXA>UFE |EdHOXWNXA SURE |EdHOXWNXA >OF- SoZ SEEDPOZnE SCFIEPOOOERE RUSRiUSSESE = LERRGEAEES6E k3LG55ERESS6E K20RGEREES6E SELOEZXHAOYXOFD >ELOEXHOXBFDO [>¥LIEXHAOXEFD S>Z0ONMOLFAOdS | I>Z0OXOLFR Odd | JI>ZANIIFL Od LZUOUEa-FIvw |[LzWOUEar-FIvyw RzWzUSaFFIoW JUCOWOY-JIE>2 |JWCOUWOU-JESE [JUST UOURJIESE HECQUFEHFEHYZ HECQUFEHFEHYZ HECOOURFEHEHRYZ HELOZFOOHAOY HEWQOZFTAHOOY HEWOZEoaHASH Un dE J JU d2y [OnJdE J JURJd¥Y [UNJdE J JU JI2X COCPE8Sls ES [2OCLE8S Ss nES [2OCPESSls uss SonhGIELBLES Sarno L305 SonhboEL3lE2 EOXHZYOn OUI EOX¥HZXYOVWEOEI EoxHZ¥OwuxhoI 3 g 2 > Z : : % % % = = = S S S o o © _ o eo = “ “ «© oo «© = < = £ = £.= e= °2 Lz °2 gp ge 8g Ea Ea Ea JNHYOOWAXYY [JuHYOo Wo ax JHY Oo WA XY Soown>IHAXYLoy Qowu>IHaxXLan Soon>IHaAXYLEn SEFO0nUUVnAkEF. EFO0nUWUvnakFQ SEFQunUUVnAFQ Ja0dddunana Ja0JdJddunana Ja0dddunana So53FESIgNC ZanZgEignc aizsizlind EsSEEzasty ESSEEZhst as ESSEEZRIsty SI2E>NOSWS>0 JIZE>0N0>W>0UL JI ZE>0N0>W>0 TXXOQONWUOL (TXE<OQ0OVWLOQI Txxdogoonuoo ol CununedlE QJXZX0nunedlEI |OJxXZ¥0nnediE- SEigjtxuurago OEJSxuW>aado QULS>VNS>UWWONXYE QULSVSWWOXETIT QULS>VWS>UWWOXET SJouxiloarcH JouxloyerFaHa Jouxlilvnaro Ha Wao oT << >en, WrooITL >a T Waar >JdFIUO o5aI>JIFITOT aSaI>IFIUOT UFEoheUFE2ZFE UFEShaLUEYED LEon=LEZED CAL >ZX HIF ZX OIC >ZXEEHIFZXY (QdC>ZdHIFEZX CON INMTIUSHYYUIQUDUN IAYIUSHYU QRUIVNYIUSYYY SOULOFUNICLN>EOOUWUFVNICLL>E |GOWOFUNIELB>a Clo IVOLUXY>HZUGIQIVALUX>HZY (@JolUal¥>HZ0 CoOOWOWEUDFWICOQWOWEURFWT |oouoWeUDr-WT IXLnOTWEOXINEIXLNOTUIOXLY (EXLnOTWTOxXIh soO0RES ian <a TgassSSaagy [<aguassSEansy SEERA E OLE GREER REOLzRTY SEERA OLEEEY NLULO BAF ZNCZUNCLOAFETNCZW LOA EZhhaZW WOE Iho JFL ZORA dFLAZE OE hAa JFL Z~ NEZRZUWOJIQLIIVNEZOZWOIQLDT EzLZWOJIQLOT FooxOxda>> IF oQ0xa>3<=T (Faoooxa>> 3 NJNIT JUOLWCUZNINOIVOLWALCLWZ Jn JUOLWugLZ Nr COE EE nap Tar 08 0TEEa dT M>0R0IERRY>T NL OT zwgzZzFIlnliegebzwogkFl] wie gebzwozFd EY JE Q2HUEFX JX EF 2H |FXJZEF Q=2HO Lol¥>SSJFESv&odol¥>SJFES¥¥aol i ¥>>JFEs¥&od CFOS ZXINULUITCF2O>ZYCNULT LF2LU>Z2XCNUWT wn J Jw Hao JwnJd Jw Ho J wn Jw HMO J IsbawouUtolu>IEtawgUt-ollu> |TEbawoUl-olu> SE¥S>UYIYWoUWLOSE>UNIYWILWLD SE>UIYWSIWLD CoO J EsFoxoU0a20JEE-oxaV CaO JEERS20OU EJHOZN¥aSUFRFE JHU SURE EJHOZ0¥a SURE EE HEE HEHE EE cH LEN RGE AES E63 ARSE REE SEE EZRA GERESSE6E SELOEZXHOYOFO>ELUEXHOXDFY >XLUEXHAOXEFO J>zOMOFROIII>Z0NOCFROIE |I>Z0M8OCFR OI LZUOUEa FFI nWLzW GUE -FInW RZWOUESa-FZInW JUCOWOY-JIE>2JUCOUOU-JIE3>2 |JUSOUOURJIESE HECQUFEZHFEFHXZHEOQUFEHERHYZ HEQQUFEHEHYZ HELOZFOOHAOUWHELOZFTA HAO HEWQZEFOAHADY Un dE J JUFJdS¥UONJE J J0F JY UnJdE d= J0R dex NA ONHLENIWLONAONHOLENIWLYD VION HOEN JWI ERLE Ona EZ BLO n20ES EpLLEo¥E20ES WnnlLW>Wwo>0ZzDWuLW>WD>0Z WnnunLuw>uwo>ozZ EOXHZYOnOUIEo¥HZXbux hid |EoxHZXDuxho3 % > % = y Z : Z % @ B = = = S S S o o o z lz 5 a “ = «© «© «© £ s s g-8 g-8 gE °2 Sz ° 2 58 2] z 0 SE 2 5 Z 5 a Ea Ea M¥MLIQOZF>>CEI XL JOB >>CBI XS JQBF>>C2T XSoSECuRsSEs “SnSECuRsEs “SnSECIRSES LUonarREFaZ>T WUwNaREFAZST WUnnaRkEAZ>T EQUua dang FUQuadloungd EUwnadlongd CZOITWOLUWSHT SERZUT w>Ha SERTUE wa ¥LOuhegaHTIaWw CouhxaHIZoW Couhea-HITZauW ¥FOOWUOWNUDNI ¥FOuUOWKUNI ¥FOunvuowhinz LFAZIEF>Y0E RFAZIEF2YAE RFOZIEF>¥LE SwOOOzwa>>> Fwolzwd>>> Fwiidzwd>>> SNOFAEE>WLn >VOFAEE>WLdh SwnOFAaEs>WiLh LOQUIFEESXOU [LUQUIEESXOU [LOUOQUIEESXUOU ¥2352335587 g282753508y piddngsstin Fogis? Jd |FUEEQE pari Fogfs? 43> IgE EDE 2d¢ EU2E0Z |23g7SEupEDE E>0n>s-uorFy E>0b>zpWdrFg E>00>zELAFG XO JUB¥oagdg [KH JUVUAN¥OLOJD [KEHJUA¥OA OID F2ANQURFEING F2RENQUREFING [F2RNgUREFING JZUXESOX I> |JZUXES>OXI>2 |JZUXES>OXI>2 YXHOHEOIn>0 (XHUOHSOLZU>OE (XHOHLOIwn>OE oz0cdnuoHFRFZy R20xnWoHFZY Rz0xnWoHFRZO EVE EgSrEgxEX EERE ER ZT IXX EREXER TAX §oSEEScogrt BHBEESeogrt BAREESEssrt zaB2ERSEYER ZaBEEEEEYae |ZaB2EE5E%ar ZxO¥EIIX50d (Z20OXETIARS5S0d (ZOE TOX¥S0d HoOUxJOaay¥ [HaGUxJOooxaey [HoOUxldooxaew UXOWX CNY > EupuUes re > LP ERs rr zZJnQuwegkraka> ZJdouwekaka> (ZJn0ueFaka> JTFZx>wWanacd |[JIFZX¥>wonad (JIFZx>wancd HLJaJdoQuizdl HLaJOQuLzdl [HLaJdgQuuzdil SZFHOQUWINFL |EZFEUQWIXFL (EZFEOUQW IXFL SEupUESIozsY O¥uEESsEose GxnEussigze SnHLUADESWSO [dJuHLADXSWLS>O |JuHLADESWSO QOHWOLLWOO COHWYOILLWOO |VOHWOCLLUWOO JfunyiFylogdn [dduxirWociy [Hux aFlocgda JJo> agowa_|[ado> agoawa_|[aJdo> agawa Jzong nO¥xJzaZz0ng wOx¥xJzlazng wO¥x Jz I JLEOSE IEC >IT L005 CIE >IT ILE IER>T Err Esp Rr Ew PC TO Fat SES EEIC EIU on EEE TREES ass oPEEEsEeEIb Ears EEE a SEES: CozZgXluwa>Y¥xUOLZaxlwua>Ex¥loazcdiwa>exy EY IIEIOULWXEAEY IIE TIOULMSEEY IIE TOULOYAE ¥ IIa >0A>HZNXJLAC>Ea>HZOE Ja g>aAa>HZ® YUWHWHEAO OFZ JX UUHAHLO OFZ AN LUHWHEa OFZ J FUSWneoUAXWOFUSWneoUSXUNFL>UneoUAXWn Pe et EE aT ee a et » TSHQOnWn TEHQWW TIEHQ® nYy<aoCu- EEL ESREE E820 gaEELE £82 FOFQUUWSESXZLZOFOFRFQUWEXZLZOFOR>QUWUESXZIZ sluggzighanrieJusgziigianfeJudgzilglaht <TQUZUOVUOY JW>CTOVZUWOOX JU><KTIQUZUOOX Jw —_ ~ 5 5 E Eg Z g < ° o o 5 Bg lg on 15) a © «© «© £ s s g-8 g-8 gE °2 Sz ° 2 58 2] z 0 SE 2 5 Z 5 a Ea Ea XL IZWOONX JW > MRdEESEELY XL IQBF>W>W pr ugErFo SE —>w=aa a> —>W2aUNnWOoa wlan LWLUYWZ Wunnakawnal Lunnaradan EQUOeHEFAZ>T (EQUuna Juz Jl FYUnaddawo SEQUe ICSD] |SEQIUSISEL SEQTUOOXZI gLozuoLosHg LOhgaio>n LOhegaliEa> ¥FOWheE HIZO ¥EQugoauze ¥E229o1%38 LFAnUonnlUnI R-uzZzIELHWED L-NZIEW<On SWOZIEF>¥0SE Ew000zaxaqn ZL0O0Tza Zs >nOLLUIWa>>> DuoFAZLA WO FUSES ELTS LogboEE2uLh [LEU icG¥ed LOoQUIEaS¥YXY ¥280gLEsE00 [z28205-0Ez pEdsogbdnss Fue 283 Z>0L Fogfslogs Fogfs2igbs] 23359E 302 |gsg7Es2¥r 2IpSEVUSXER => EU>20Z E>50u>s«<I<r- =>0n>zE>ua Jd EHIIS>SFWOFO [EH J0ANADEYY [EHJOAXI>HOWV F>aUaNdoagdQ F2EREOgUYLN>E (F>angUE2a0Xx “ZOU QUHFEIWNGS [HZUXESAS>SHZVN (JZUXES>XZLZO ¥XHOHES Sox d23E [XxHOHLSOAORZl [XEHOHAZOOoLo®n Ee) LZOxnUWOLANXWY BRZUVNWOX JW ZnoxnuwaoHFZY) ZnoxdEguwad (Zn0x <32S33 SORGEErasFE E000 sa88 FRpomgoazats ZoUWELOEEN ZOUEFEXZLZO |Z200&FEnongd ZxO¥FE>a>W ZgOxcIolahl Zgox¥bIgueHg Ho OURITI¥5S0d (HaGUxJOo¥ Ju Ho OUxJOT&ou cEouxdDoEey WXOUXINZLIT WLOUXINBUDNS ZJOUEINY > (ZJOUWEFUXIZ ZJ00uWel->¥aE JIFZWgRoREa> |OXIRZ¥>WaZ>T OJIFZ¥>wid>>> HLad¥>wWanod HLJaJoQwongd [HLadgQualuldn EZFEQLOUVLZ IL EZFFUQUWWSHAS EZFEUQUW2>¥U0 SEVELoUETL O¥uEugIEEayY GxuEuse5oxd JunHLOWSA LO» [duHLADXOWUONI |JuHLADXDZ>W QOHWALUESWS>Y QOHWOOUSXAZE QOHWOQOUEJd> AdNX¥XOoCLNWOO dda >FWwo>>> |[dJdnx¥XaFu>2UZ “JdO>o raion (JJO> AS>WLy ([AJO> awnrY FZ0gbgagaun 220g wSx0U [Jzng neo TdL= NOME IIIT ILEOZEL>UXN TJLEOZA-TY CEES eS PREPS RETR Era SL EEE S nga ouEEEsySs02 [GUBEESLERES SUBLESCASCREZOUEECSYREAYE QUEEE3XEREY SEzgzpuLIgbzoszgxlycong O82 lud>Fg EX IIL ua>SYYOEYIZI-TORI® EX IIE ITOEOJ Y¥hEEesPYlnsoieibaarandarZ ibaa iool XUUHe>ooaHZuUURHABLN SOF IxhuHuBLR2 Sod FUSWOHLADEZdFWSWneoOHFZy (FUS>uwuneod xe NWHANXOUOXLNOWWHAFWUNEI IXY (WUHOFWAX>NN Po ESEEPE wo dndEaYERJd>F0 dE QEFQ EQ > NE IOYE EISNER a gquEn Ss MP oS cua nd FOFQOUWE LUX I-FORaYWEgaW FOFQUWIUWLZ JL a JuWgQuUEXEIZ0onJuogziX¥sod R2WBQZEINEL <TIO0SZUCKLAWF|CIOQZULWVAEEY [KIQQUZLWOLO>n 2 2 8 5 £ £ s g © o £ s s g-8 g-8 gE °2 Sz ° 2 58 2] z 0 SE 2 5 Z 5 a Ea Ea XLJQ2F>WDW “Ihe ELZuER XL JQ2F->W>W JruEELLLSS SnuEsubuoa S>Lza0hwod wunnarkadin Wunnarkagadn Lunnaradan EQUuna Jawa EQOwa dawn FYUnaddawo <EZO0TLWOOXE J SEQTUOOMZY SET UOOXEd LO iEa> Longa lE-a> LOhegaliEa> ¥FOwOooIxol ¥E229o7%g8 ¥E229o1%38 LFAZIELLOS LFAZIEWLLOQ LFAZIFEL<LOL Swoobza zy swOO0zaZx SwoObza Zz IUSEEELTS >nOFAXAIL FUSES ELTS LOQuUJdFa>Y¥y LUOUJIEASMYXY [LUOUJIEAS>XXU E302 2885020 [E193 4305020 [2052435025 Fogisiiers] FogEsZacrz] Fogfs2igbs] Z3gaA0EYexEEa ZI FUSER I2JpdaEUSxUn E>0n>zsE3uad E>0h>skF3uad E>0un>zEsuWad EHJUAX TIT >rHQOY [EHJVUAXTI>rHQUV |[EHJUAXT>HQOWV F>a0ngUE200x (F220 0VWQUE220x (F>2a0VQUE2a0OX “ZUMZESOXZLZC |JZUXESDNZLZO (JZUXESOXZLZO ¥xHOHEhOLan ¥XHOHE holon ¥XHOHE holon Sedofesoly EdEadsecd Casfadesol: oZEESUEICE EBLESSrSis cBpitigei:s Z2oUWEgrFrgnongsl Z00EFENCNT] (Z00&F-Enohal ZOE IOWSHST Z20O¥ETITOWSHT (ZO ETOWSHI Ha OUxJOI¥ouw ([HoOUxdUzZ¥aou |HaOUxJOzouw CEOUXLANUNI |[YEOUXINAUNT WEOUxIABUNT ZJONUUWER>¥0E (ZJ0UWEEF>¥0E (ZJ00uWel->¥aE dTFZ¥>Wa>>5> |OIRZ¥>wid>>> [OJIFZ¥>wid>>> HL Job unaWln HL 2JoQualulin Hiadobualuldh SZFHOQUWSNOU [EZ2FEUQWSNOU [EZFELQUWSXOU SRULUES SUEY OYuEESIgUED GXuEuse5Ixd JdunHLa 00250 JuHLaDOX0Z50L Dural 0Z50L QOHWOOLUEJdJd> QOHWOQOUEJA> |0QHWOOUEJd> JEN¥EFL>20Z [Dd Fu>202 (OdduxdFu>202 pe awry (JO owekryY (Jo awnrY JzZzng nag |Jzung nagoJdg |Jzung nag TILEQCEAFTIVNG TJLEOEAETITVNG TJLEOELS=T WN Wr ETSs 2 WS>IXOOoX 1233 Era SLEEESLUPEY [ouESEESyArgd [GUEEESSLRES SHZECSXETEY QUEECSHENEY (GUEEESXEDEY CRLZgXlWwISFDS [OLZgxlwid>Fo |[OaZgxlwd>kFa EX IIEIOEO EY IIEIOEO EX IIE ITOEOJ ¥jEegrso2d ¥Ztagreozd CESS nESSY MUWHUWHLY5O0d NUWHOHLYSOd MUWHUHLYSOJ FUSWOWXOLEEY (FUSWOWXOLEEY (FU>WUneol xed AaEaLERErdy MARECEPErLY APEC ERERLY nc aoguaone Jd nucaogcuaonad nycaoocuana J FOFQUUWSLZ JL (FOoFQUWILZ JIL |(FOF>QuUSLZ JW SJWAgENJxEL aduegziidxEl a dudgzlidxEL <IQUZUOLO>n [KIQQZUWOLT>wn [KIQDZUWOLT>wn a oo 3 3 £ £ = se < ° oo o - 3 5 5 0 0 © = = cs £ = £ = a .= £3 53 §2 zg z¢ Zz «= a = a = a EMMY LONDOR EY X¥LOWD>VR EEX XLOU>UFa Jn>EFINVBRZ an dn>FEFINCAZ an JV>FIN0BZ an IHEE>FO3Jnx ITHESE>FOS>JuX ITHIE>FOSJ0X LHEZHW>5Z2>0 LHEZHW>3>Z2>O LHEZHW>>2>0 Zu3Ee=Lsags ZugExEusay ZugEe=ussy © Oo CEEFD8E x CEEFYTE xo ELMFURE LAs SEI QALaEGEEId LALO IE QUEUCFL>TFY QUEUcFL>TFX QLEFVCFL>JFX IEINLLHLE IG fEgnuunLdn IEInLLUHE EIR HT Z=HW0no wl > == ZHWVO wo> HT ZHW0nO w> Zo OWI JIQ J ZAPWIFFFJIQ J ZOO WUJIFFJIOJ JEHOZOWY > XL dJEHOZQUXY SEL dJEHOZQWE > L SZWOLEFTnhun Szuw@adzunhu SZWOBEZTnhuL Lia gaokEH>awun wWiagaokEH>awn LWiogookEH>awn ULa Zap <ESald wEZazap<=5a0 wfazap<=>a0 Sw w “Sd T=] w Sd Sw wl “dQ L>QZLEER>ED C>SQEdESE>CD L>0ZxESE > XHQOUEWgkF >a XHOOWUEWakE>-Q XHOOUEWOF>ZQ suEO833EE 05S |, oR0UsgEE0ss ROBE EEEDse CHE na 20S FR OZUE LAE TOUS RL ZUEDRE ESSER ZuWnudEbooouwadZzubnnd-oaouwat ZuwWou-E-oaowo HdgUznslaolernHloWznslaodern HJoUWzunsLaode CIOL oLWa-JURIO00aNoLWa-d VOI00g on Wa ZO>UFQUFJIEOXWNZO>QFQURJIZEOXY |(ZO0>QFQUF XOX JJWOUASEFLAG> Jd IWOUASFLIAg>d JJLOUASEFLAO> HIVUNJ>PNE2XYZOHIUNI>OESXYZY HIUNI>OE>XXZ EYEQEAU>DE SIZE UEOFAU>DESZx ExEgEaU ESE DEON gIoa Xue ILOSgsdakxus SOLOS gada xxl ZEFRZEEO0 guard pGaEalBgnar ZEEE DCs OEFOVNAUNUZHY>AEFONA UNE ZHY BERGEN GZHg JgUOUUEEITEOIISUOOANEESTIEDST JgLUOOREEIIED I8NEACTWISYZZ AVE AQTIWASYZZ IVE NQTWI>NXZ S¥UOUSYS JUWWWONIJI¥OOUNYS JnWWWnI “OU S JnWWwWn ToxOoiguopnudEZovduligua Hud FTovdoliguo Hu UEdde eho dz a<hoze Wzixe a<lhao = SL aGESREOSESEBT IER 0SE5: SL aBELRE0SES ZysSPeEBBE SEE TLS GEIL T2s SgsZsEdirsaz oLEQsuUseaIH>OLLOZUSaaEIH> OLE Usoa ETH EF20¥¥00nUZ¥obEF>08¥00n02Z¥ah ER>I¥¥00nUZ¥a ¥JdZOLOOLELZOO¥ JIZ0LOOIELZNY XX JZILVOOLELZY ¥EDQOISOryoAMERRILIox¥he dl ¥EHOLEZIOT ln FEZOUWSrEESS>LIFZZzO0UWSrEESS>0L FZZIUWSEE>S > NFNOZaoXXUSYLSNFNOZaSYxL¥l> wFNaZooxyxLxl NIHQDOEUREUUZNIHOIOENEaUUE MIHI JEU Ea0Y PESREEERgoEEaAT aREoReaERE AE dSEEaREES ESP CESRRE LES RLGEER3ET2 azRFGE CGT Wa AX ILOSLONNUELCZa moSLonhx <¥amd5r0nx0 5 5 EP 2. Sa EC om oC 5 5 3 < x <3 ° © £ = = = c= = oc 2 Sg cs 2 2 22 z2 & a & a Ea x x > > EFEXMYLOVNS>UFX ‘-SvionsUra ¢-Svionso FuREIRg8z229 FUSEXngez2y ZUSEEPRE2 ITHEE>FOSJ0X IH SEOSdnk IH >Fo>d LHEZHW>>2>0 LHLUZFRW>5S2>D LHLZHW>5>2 ZUIEzEL>0Ep ZRLEzELEEP ZuExxsuSD x EEE-UEE Sos EE-LEZ NE SEREEFUE nL g<=0 Ixd NANI C=O Ixd NONI L=0 I QUEUVickFL>TFN QuUAUiaFL>TdFX QUT VaFWL>T SEInLUHD Pp JIR SEHnUUHD EIR EHuULUHLE SHT ZHW0no w> HW ZHW0no w> = Huw ZHWnOo ZOU IFFJIO J Z2OQWIFFJIOJ ZW dE Jd JEHOZQUWe SEL JE OZQouWaSal JE OToWa> S>Zwytaosnununh >zZzaUubosnununL >ZQUBaF0nn LWiaogaookEH>awn LWiogaokEH>awn LiogookEH wiaoza E500 urgazao E500 wuigzo = wo Io) “dQ 0 w “Sd wl wl x A>0ZXESE>EY A> 1x E¥SE>F0 A> 13d ES > XHQWUEWAakErQ XHWOhUEWaOkF2>-Q XHWOHhUEWAOkR LEEO23858252 LRA 0355255 hTzhsosnas o EHEC HEP SSsRR UZ HERE PISERR 0 ZHERARETSS OL ZWwuwunundEgoaguwad zuuwund-—oaoguwaa Zuw@udE=oo dd] vw HJloUzunslaoWerwnEJdoU0znsloder~n [HJdoGzunsiad 4 00LC0g¥auwaF Jung ¥auuwar-d VOID on VV (ZO>U QUE JIXOXWNZO>VFQUEIZEONYN (ZO0>0FOURJX = (HAJ WOUVASEFLAD>JJJLOUAaSELAO>d JJWwUAa>-0o VV HIVNIPNESXXZNEIVOIPOE>2XXZY HIQQI>0he>X X |IZEXEOSFEUS>HESEX=YEIOSAU>hESZX ZLXOFEUSDE SO GHEE 5IS aX LUOOIEONgua xo OHE0Ngoay C EEEEZEe00 guar dupred2aDotnar AUFEAE200g OFEFOWVAOVNUZHO>CEF>WVAUVNLZHY QAE=->naongz I 2gugeuEEEICOTIgubuyEELTIEOT JgulbouerLT Z A8VNENOTIWASHYZZ INV INCTIWUISNZZ AN INOTW> IT Jd¥USYS JnWWUNI|J¥YULANYS JunwwwnT “OA N¥S Jun J EexCGouguasnudFacoduguasnud |FaxoHiguc > < WEdJx aha qUE IF o<baozqd WE Fc a<h S ISEuBELEsSSRsirabEtaefasil SrabEErssd > = =z = a = = Svs 2EEINE SZ2ESusE5E30Y <= SUSEGEIRY Z |oLbEgupanzgH>oibkeusaasgn> Ohb¥gusan hn EF>IdY0O0nO0Z¥ahER>UYYOOUZ¥Yah EF2Ud¥¥0nUZ U IX JZITVUVOOLELZNUX IZYUOOCELZNY 1 Z2¥0UOO0LEL NW ¥EHULLFOTIYXNANMEHYULSsoTIXY Nan MEEXLOFOoTY L IFEZIVUWSEESS>LIEXZXUWSrEESS>L FXZXQWSEE> 2 FOE ZaSxxLEL>nFNoZa>xxL&l> WFVOZa Sx xl g NJHEDJPEHEE YUEN IHEEIEHRUEE [UZHEZ2F9EHRS EEE RE EE EEE EEE el EC EECE SRE 2TE SBP LESREET 2 ESRPGESERE «Xo JUOS5L0nXOEI¥a JLESL0nx0 <¥a LESTE on ea) = = = mo = 5 g 3 En £ £ = = = sa 3 Ss oA © < = cE og gE «= a « wn Ed e |g e |e :|2 2 |Z 2 |Z 2 [8% £ |E i oz £ [5 4% £|& 5 [53 2 |Z gE |e 5 |8 Ji 1.2 2 f 8 8] a |g5 EE 5558 z [ZEzd £222 3 £8|E & A3IAS z EL a8. AQ Q o ££ 573 £15 25 SE [52 EE 25 [2 lz 2 RF I x BIB [EE |= E = = = = = gig |x [8 = = 8 sg zg EB aoe E £ £ £ £ E 5 B ele Ss Ss Ss Ss 3S = |E $8 [x18 | 8 | |g [8 | |B 23 |e E £ £ £ £ 3 5 s& |B 5 3 3 3 8 ® |Z Erle | OE IE OE OIE ORE cE Eze EE EE IE Fo — £22 Te |= = = = = = EA 2 |B) = |E £ E E E £ e |= < |g |= Ss S So S S S Zz |Z Z |B5 |B SE & «= «= «= «= & MM > Bis 1s 1s 1s Is Is Is 2222 12 12 12 12 | |= |= = |= 2 <> = = = = = Fy o EIS 8 E18 8 8 |S 2 | og [3 - 3 = -l -] = = e 5 |B oO oD oO DS oS D oD 8 5 SEER EE IEE FF BE E5518 | IE | I 18 15 [33 Mm < |= ° = ° = = = = © © [=2v] Qo = Ola |= £2 Bz [Eg [BZ [3.ESzE 2 SE EL. IEE BE [B3EEZEE Q [=49] Q 1 2E€-gE |X& £2 £8 gd + fil En 255228 |B = 3 E 5 / 0 > OE oXla vb s Ye B55 E505 E aid 4 2 zz Bes RIate sop tEaas 4 2 = oo £2 D3az SEB =< |< 5 |x Z o ged 2m xox EE 22ZZ 2 ox >Eo3|8 ox9 EEE [BigiedssgoiccnziEyss 2 EIS [8 |03zcA0nicrzra iL GEERZRES a Soglz la |= [3 [2 18 |= |g |g 8 @aZ|= [= [= —- - — — —_ — —_ |= 2 |e |e |e |e |& |g < Zz |z2 (2 |2 |2 |2 |E E |E |E |E |E |[E |¥ EREEEEE |B © < en fe | | (@ |w |B = = = = s = 5 85 18 18 | 8 |& s c s = c c XL 5 |B [5 |8 [8 [5 |2 BIER BEE EEEEEEEE EE 222 ZR SE Z| Z| aSaSadasad|a Sz = Is : [Jz SEE EEE 2s [3 zz IS SEEEEE SIEBER E |G <= meme eT = MOM (EME (d(¢ = |= 2 2 2 |= [2 |2 | = |2|2 a a a a oo a. a aaa zz |z |z |& |& |z 522 = = = = = = = = = = = sls = sles 5 [8 |5 |8 |8§ |8 [5 / 8 |5|8(5 |B / 8§ [5 / 55 / 88 |5 / &8 FERRE IZIZZZZE ZZ 2222 252 SER IEERRERERIERIBE BERR |3EE SIS | 8 8 IS |ISC|I8ISIC [SS [SIS|8|lS |S|S|S8 ol = > a 5 g 5 5 5 2 £ K Fg @ => a @ g ™ = a Z 2 3 IE = © 2 |, g Q CIEE Exlz |Z Z |Z S |=2 |x|zBEZE| 52 EXE 2 1c BE IBS Llels 125 EERE LEE 0 S615 22 EIE BE CEs EIE|5E 282 12 2 | |? EEE 42 (2584858248 gels IE Eg |z gE [532 [3REEEB|EZE iF) > a 22 Elz BS ECZSEaE S35 |= |B © |B x >|5|& =| ZE|S|EB < — «oN on = wy © > |S |= en = ||| xX |S a > a kal a = a | 2 |e oS ole Ql —= — — — pet — — —_ == NN oN NNN NNN £8 i= £ E12 g |5 2 Z 2s T al 5 53 2 ge [$2 R °*2 ad 8 - Ec 5 of |S od “ 20 BES ] < £2 28] = 555 / 5l55 / s [g / s / 8 / 5 / s [5 (5 [5]5|5 | |g |5lgs 222222 222s |g 2 EERIE 2 IEEE slB|e|8le|e|e |B|8|BBle |B |e |B |°8 |& |° S [B=] QRIL|LL|CC QR |L|C o o © © © © © QC —- = [=i 0 wv = £ Se g 3 2 SEE g 22 bl = z < 4[E|% 8 |2 SZ 2 EEE ZEEE sz EEE glalz zs 5 Ex 2 lz l= lz |g BE 2 BEE SPL ESE BESS RE EB EE ¢ BEE s:ElERRE SIBEIEIS SB IZ IIB §I-RE 2 [2 |» [2 |= EE uEBEelE-z=FEE 2 2 2 2 5 | |B 5 —| Nea | [OD X(N =| on << wy 0 © 0 aN Oo |= (en zlelelzlelels lzlzleglg Is lls le lh lg 8 Rls NNN NNN (NN oN (a (a a} ~ oN ~ oe z= |T |E2 E T= |g = E Ae [8 |<q 25 |Z g = 5 < ch (2 |S 2» 2 |e [28 Cx cm |= [22 3S sR |& |8 iz £40 r es I=3 - Mo |B 22 (858 2 RZ dg |B|&3 wv oN ° - mo = oN 5 on © s . 2 So [2% 9] rw . LS —— gt Slwvren F TQ as |S % = 5N [TA=4 |5|g2 << I 5 a2= g Ze 12 SPN ER 3S 5 3 28. 2B = 3S alse d 2 >0 [20x &P|er s |s |sls [5 |s sls 5 / 5l5|s|s 212 22 22 |22 EEE EE SS I18E 1818 [38 3 / 3 / 8(3|3 ao |8 g ¥ : z 8 glofof¥ 2 212121] i glo |3 Elz S88 ZEEE EE EE 35er a > = o Ef 5€ Bz [23 22228 SEED 52 34 z|z|2|35 = 5|8|& 5 s| sls BREREED 2 = o| © 2232 : : 55 BE 1hpbil EEEEEEE 222 2h5] 5 / 5 | poannna i: : BREED 2 =3[z / 35 / 5]3 : SEE s [88 : Np 8|3|8|8 : ) a, gl [¥ J Ig 2 : o « = gg 2 gl 2 = 25ES 2 3 Ze : 72) Q = > IE 22s : : 2138 23122 ESRER z mi ln > > £28 = oak 5 3 shui ZzReit a wv | wn & g seit : ah E —_ JeEEsEcl: i. MEHEER 622 CL g [] RRRRIZE 3 Z |3 |85 / 2 / 8(8= Z58|8% [2 aa if a ln) ¥ = = = = 2 2 3 ‘3 £ £ £ £ ° Q Q Q a & 8 3 = = = = = = = = 3 5 3 3 8 3 8 3 = gs = = 8 g 8 8 £2 | |2 2 =~ = = = £ £ £ £ E |& |& & 8 g g £ g £ E £ £ 8 3 13 |Z z gE 2 2 BIB Fax n= Zz |= T|% |222y% EEEagzd Bs ES 3 o Sealy SEgzZS” ZC [BQ 2 & ag BBLS Q OZ a Ew = @A ET OO gg 2 nn £ Sais £EESgE 5 _z9g525 = 3 3|ZS2%5 |Sxzro¥3. BEssseese 2 = ZEpii BETcinesoapEitats 2 g5le=%ER SsZEEER SEEe gee zEE ZQ[E QR & i 28 Zz ZEGRELY 2 ERIE E2552035: FE5EEICEEE RE Fag g : |REjiElEgszioEiFzpEbEREiivis wo |x © - = oss = 2 2 % < «a oN oN o a} «oN ~N oN aN g g § 5 3 8 3 8 3S 3 3 3S 8 E 8 £ 1 - - o & 2 8 2 5 5 5 5 > = 2 = a B a a 5 5 5 5 © < < < = g = “ = 2 2 oof 2 Z z = = e = = = = — == ‘3 ‘5 3 g § g 3 to fo [TR 2 E 5 |B |B |B |E £ EEEEEE & 8 1&8 1&8 18 |& ] EEE EE £ £ £ £ £ £ £ SIS|S|S|S|S 3 3 3 2 3 8 3 elelel el gle = = gs = = = = olole| eS ec 8 8 g 8 8 g g E|E|E|E|E|E 2 2 £2 £2 2 = = glg|o|g|elw = = =~ =~ =~ = = o| 000] 2D >l=zlzlzl.z].2 £ £ E £ £ £ £ EEE EEE =] ° o k= o k= ° VN NV VOD D £ £ & 2 & £ £ alalalalala [a Te Ta we g EIE|E|E|E E BBE : E|E|E|E|E IFRECRE 5 i g g = Ze [5s £E § 4 a0 gg i . a 2 gE8ss z5keze 5 Eg BZ ZEEZS 8528: 2 EY Ox [Zh z Eszh3 : g 12% 22 EQ 5% EEsEs S555 : Js = zg 88 e zo TEE ggog ofo(2 [aE ab SE Sg. Ee £558 Z £58 Bx olaE Sa S52 Li = EES mdi] 53 EizgoiRE EE feiiaiesst Eig efit cElagcEes 3 a 5 gis z2352 <|n & £9 OQ EE 2U85Eg 382 = in £28259 5 0 2 EE 2 13 |8 g £lelelelelEe|le|lE|l.E E|E £|lE|lE|E 2 SIE|5|5|5|5 EEE [55 E|E|E|E|lele > S5|5(6|5|5|5|5|5|6 |5|6|5|6|6|5| EE =| — ff f= [= | |] 0 enlen |e |wn]|n|S|C 3 AE EE EER EE A = Lele EEE Lie ele|ls|lE| gs SIE] all elel el elo] =| «| BEE EEE EEE |B EE EEE] E Z1312 gg 5 5 5 | gle gle <= = =< =< <= (<= <|=<|<]<|2 2 5 / 5 / 5 / 8 / 8|8|3|8|8|8|8 8|c|e|c|elc|elelele |=|eglelele|ele 2(2|2(5|5|5|5|5|5| E|5| 5 EEE (EEE |2| gg |£|EE|E|E|E|E|E ee EEE EE HEHEHE EE ERE HEHEHE O00 [Be [Ro | | Be |B |B — — — E|E|5|5|E|5|5|5|5|5|5|E|55|5|5|E|55|5|5 |E|5|E|5|5|5|5|8 E|E|E|E|E|E|E|E|E|E|E|E|E|E|E|E|E|E|E| EE |&|E E|E|E|E|E|E EE EE EE EE EE EE EEE EE EE EERE EE EE EEE zzlzlzlzlzlzl2zlzl2lzl2zl2zl2l2z2l2z2l2|2]|2]|.2]|.2 zz zlzl=zl=z]2]2 El EIEIEIE[EIS| BIE EI EIEIEIEBIE[EIEIEIE|E]E EE EIEIEIEIRE GIEIEIEI BIB E(E|&| B55 EIR |5(E|E|EIEI5(E |&|5|E|E|IEIE|5E EEE EEEEEEEE EEE EE EEE ERE EE EE EEE elelslclele|le]lelelelc|c|le|e|le|lslcs|c|e|elE cl|le|lelele|lel|le|le BEERS RRR SERRE EE ‘BE ‘EE EI'EI'E['EI'E]'E 0 sn| snl sof sn| sO cbf 20 S| anf SH) 20) sof Snf cof S0| 0 S0| 20 8H nl an onl sof sof sof Sof 20 HEE EEE EERE EE EEE EEE EEREEE EEE EE E|E|E|E|2|E|2|E|E|B|E|E|5|E|E|5|E|2|E|E|2 |E|E E|E|E|E|E|E 2 2 = © wv = of 8 g = 253 sll lelglelslels 222 Is ges [ELS EB EEEZEE Zk 28 / 8 gis & > gl2a(2|2 SIE] z 225 EEE SE EECEEE FEE LE 22s ZzzE Le BElziger z EERE: OE ZIEIeIC|Z 85 8322 2 Oo (22 = SEHEEEEESEEEEEEEE 2232 5551228 REE C= |52 YE 2 2 FEZ EZ RES % EE S|0| S| a OI |@|=|N|(n(F|@|L DR DO|—= [Nea nO (0 NO |= | en = Kal a[S|z|e|e|S eles == == === [== =alala|d|a NNN nanan nn|nfafen|en|onlon nnn |n|n|on(en S| £ ‘Bd E55 me em] em em ee ee Blo|- =lalalalalalalalelalalEIE EEE IEE ZIE2lZ Old] & CIS ISS IS EE EE IEEE EE EE EEE EE EE —- SEES ESS 55585555555 5S a zmlelgles(ls| EEE (EEE EEE [SSIS] |S]S 8 a] |= E88 8a aaa sala alee alae alelalalal EE sls Sie EEE EE Rai aE fae =lele|8|8|2|e|5 / 5 / 5 / 5 / 55 5 / 55 / 55 5 5 5 555 5 5 6 E85 EE HHEEE HE EEE EE EEEEEEEEEEEEEEL HEE EE EE EEE EEE EEE EEE EEE EEE EEE —- ZP@@E|C|O|C|O OIC IVICLIC|O|C|IV|L|RV|CLC|C|C|C|C|C HER EHEBHEEEEHEBEEHEEHEHEEEEHE E|E|E|E|E|L|E|E|E|E|E|E|E|E|E|E|E|E|8|E|E|E|E\E|E|E|E|E|E|E "gow (vv (BEB |B (BB (BBB (HB |TB |B (BB (BIB |B|B |B (2B (BR [(B(B|T HEHE HHH HEHEHE EHH HEHEHE HEHEHE EERE zZizlzlzlzlzlzlzlz.2|.zlzl.z.zl.z|.zl.z2|.z2|.2z|.2z|.2|.2|.z|.z2|.2.2|.2|.Z2|2]|.2 El EI EEE BIE EI EIEIEIE| EI EBIGIEIEIGIRIGIEIEIRIEIEIRIEBIGIEIER 5I5|5| 5555555555555 5 5555555555555 EE EEE EE EE EEE EEE EEE EEE EE EE EEE 88 BR § EIEIEIEIE BIE SS | 2 28a Ee a|2 2 =| = |B EE = FPP 2 2 2 Rass ccea2aa Eas ssE dds E|E|E(E|E|E|E|T|3 (3333 3235533 R|3 5 | E| EET o a 2 ol IE 2 E > SO g 32 «fF. E g (58 SCIMEE = 21212180 H o|2|=|o 2 BER g fEEE IZ - S|3|& 15) 819 ZEEE Ieee [BIER Els Blelalez SRE 2 Al EEE EEE EE Ee EEE EEE EE EE 9|< | | Oa A | CE < aed | |S (> EM HEF EF EEE EE EEE SEER EE EEE EEE nv |a|o|=(ans(n|O |S |=(Aea|g(vn|los|0 (|S |= |x| alana afmiaiaialalt s(t St S(T (FS (FTO | |n|n|n qggig|f|a|a|2|2|2R RR REE 3223322 22 8a 55 )4 clole |ololclolalglala|e 221% 14515 IE1E IE EEE SEIZIEIZZIElE ZEEE Ez EEE lm zlzizi22lz|ge zziz2i2|2|2z / z|,, wla|22(2|«|E |n|a S22 [E|F BRT (RRB BRT B LE 2l=2zlzzaly BE a ala al of af af a a a a al a al af af a RBBB |R(B|R|= 55555 5 5 2 2 5 £55555]3 £|€ 55 / 5 / 6855 5|5 HEBER RAR EAR D oD oD Qo oO oD Qo ofS EEEEEEEEREEEEEEEEEIRHHEEEEREE FER EIEER (|3EEER RE EEE 28285 EE (58 LILILUL|L|C|IC QUILT IONC[N0[0] I | | BB [Re [= fe E|E|E|E|E|E|E|E |E|EIEIE|EIGIEIEIE|IE (E|EIE|EIEIEIE (BIE E|E|E|E|E|EIE|E |E|E|E|E|E|EIEIE|EIE (E|E|E|EIEIEIE |E|E "DIY |B (BV (DB (VW [BBV (BV (BD (B|TB |B cw v(B (BT oT 23333323 |33 / 33 / / 3 / 3,3 / 3!3 33 / 3333 [3B Zlzlzlzlzl.zl.z].2 2Zlzlzlzlzlzlzl2.2].2 zZlzlzlzl.z].2].2 2Zlz EIE|E[E[E[E|E|E EI'E|I'E[E[EIE|I'E[E|E|E S|I'EI'E|E[E[E|E EE 5|E5|5|5|5|55|8 |5|5|5|5|5(5|5|5|5|5 55 55555 |5|E 818 |8|8|8|18|& |&|&|&|&|&|&|&|8|8|18 |a|&|&|&|&|818 |&|] = = en — 3 $3 F cles clels|le elelelele|e|elele 3 3| ‘EI'E| A'El'E[E|'E ‘EI'EI'E[EIEI'E|'EI'E|E | Mid -|'E LEEELEE ERE EEL EEE ERE ERE EE EEE E|E|E|3|E|E|E|E |E|E|E|E|E|E|E|E|E|8 [E|8|5|3|8|3|E |Z a «| [=] |a e % a < Oo js) Z 8 gE IEE 3 5 2 <a 2 < z 2 = 72 2&5 (22 g > x |Z SOE &5 wl IZZIE 20 a 21816 Slum 32 [2 s g = 220 212122 on 2 =] = 2 ECIZLEEIZIZ 1812s BIES 5% 20% |g SIEIZ|12 O|%|a Zlo|%|8|5|3 / 18 / 3|2|2 g ZE|5 Z 3FIg8 BIRBEESBI8I5IE Z|] |2 EE 2|ela SHEE ERE EEE EE EEE EE 515522185 |8 4EI2|% (252354 = ELE 22888 E52 wo || oD |= mig n|e|h | o|—|N gzlelesleR |= PA EA EA = EC EE Re = EE I I SY SS SN EE) 2lalals|alzjeE (BR 22222 NRE |BREEEES (2 EAP HEHE Z| 2 aegis EEE SE 8 3 o |< Hearne od: - Jegeac See 5 lilo Jeera 22a Hi als HE nn Eo E|E|E|E = Y5y E55 & 3 Tr E- Ei a Hla =(2|2 E|E|E 5 Ize nin jj IRE 3330 5 71919|3 BIE|E|E FREE Hh HE EEE Ize EIEIE|2 HEE 22g cel E|E & HE £25333 in mi Hm, = EE £ aE £ & E282 in i £8 |. z FEET Jone 5522 Fidei bs RI] BBERaant [=] HEE habe Q BREEEET @ BEoREGE oO FEEDERS BRREIEE > gle gg)2)2 5 E|E 21822 BRIERE! g BEEEAGE EI E|E Z|E|E|2 o BREREET SIZ| BEERIEEE 2s Eg BREE & 3|E 25353: 2 2 £1g)£)8)2 z |= Zia 2222 ° gz E|¥ EEC 2 — = E|E| & wn S252 Lola > 8 / 2 322 @ 2lzlz HE] 2 SERGE 2g 28% EE EEE £ ggg 2 [5 i Sle ° Sig g fies 22s > a 82 g|818|3 AM % EZ] 3E5 ggg @ @ g|< g 3 2188 30% 20 28 > 3138 / 8 oI eis: SEE Ee 8g3|g8 HEHE EEE 2EEEZE EEE ES > £2 FER |» 812138 52 gag] 285) 83 81%(8(2 3B(8(% B38 822 = <| oN = A a ala Ala A ae Sel=2lgela =2512|85|815|2 EZ EEE IEE = <=) |S IES giggle = ESSE EI EE le 5 z|z|z|z|z|§|z|s|5|%|2 =| 55 =]5]= =| & S252 2 E222] 222] 22] 22 ]= Q £|€|2]55 8 / 5 [53333323333 2333 2 gle|=|2 2 |2=s|s|s|e|s||elele|ele gel El] 5] EE 31552 5|8|5|E|E|E| 8 |E|E|E|E|E|E|E|E|E|E|E|E EE |E|E|E 8 £|E| EE |& 518 85|2| 2255 / 58 |E|E|E 5|5|5|5 5 555 EEG EE ES = ER|CIOIO|HE|&|E |= Ef == = === [== |= = === [== © —_ $E TTI EU A IEA SHEE EEEEHEE Z22 525 28 L2 08 228822 s|.E[E|B|B|8|2|3 (333 5|3|'8|3|8| E|E| E|E|E|'B E|E|E|E|E|E E _E 2153 / 8]. |5 BIE 2319232 >|ag x 22 J lolol 1B5 EEERIEGIRIRE EZR EER 2 [ZZ] SE EIRIBIEEIE SIZE 1252S Z|&2 slo El5E| [22 [EEZEE ER Ec aca: Sl=glZ| |B 2(>[&|5|2(2|12|7|8|12 SEE SEER EERE EEE EEE EE Z|213|2 O|E|=|& i=l == == tt EZ 212518 52 EZ 32z ERE IEELE 1] Q 7 = S213 2.235253 Zlg2ls 2 g=|3 ANjen | |n|O| (0 O|—|a NTN (OI ND [=(en || nO (0NS —_ ===] == |= |= aaa aaaaaaaeafoafme ia ajax lm|os | TT TT TTT TFT TF FT| TT TT lala EI81818I8] dslzlclelzlzlzlE gl ele lglg REE gl2l2|3|8|3|3|6 BI13|8|0|3|0|8|3|8|8 (688 Elica QIKR|<|<=2|<|<|< SISSIES ISIS IES IES IESE] ]Q(S|S JEEEEEES RRR EERE BREE zI==e|8 8 188 IEEE EE Eee] S|E|3|E ARR [AR=|T Sala RRaRalRaRRR(=|a == —_ === === == ley |eyfev|en een |ey|ey|enfen|en eye aN ae BB 33332] sl|g|(z |g zB 23K sles £lslele|e|e|s|ele |=|lele|e|e|ele|e|e|| elses |le|e|s E|E|E|E|E|E|E|E|E |E|E|E|E|E|E|E|E|E|E|E|E|E|EE |E|E|E|E EI5|5|5 / 5 / 55|55 (5 / 5 55 55555555558 5555 pd [rd fod [od | [od fod | od | pd | rd [ot fod | | ed fd | od | ed | ed fd | ed | ed | ed | ed id | | ed [ed es es = elelelele|ele|le|e|lelelelele elelele EE EE EEE EEE EE EE EEE EE EE EE ERE EEE Figg ggg ge (gg ee gg ggg egg (gees E|3|3|8|2|S|5|E|S |E|E|E|E|E|E|E|E|E|E|E|E|E|E 2 |E|E|E|¢ g a 5 = & £ > oO z = OOH Z| [=|>|=|S 20 zl B52 Zk Zep EEaE0E 285 [220 4|8|6 NEE] i= == zlZlz Z 5185 gl [ZE2| 2 Z|z|< Sg Slee |¥ < o SI2ER =2 rE g 25121813822 |5 Zz - <|&|& Siz ol¥|glS Clg |S 3 ze 2 alg Zz E = 2iz2ERE EE 22225 E2E EEE 22 BER 2>2 25155 ag S12 EIS gl= 313 SolEBl2E MME EEE EEE HERE EE REECE EE — Neng |n]| Oe O|=|Nfen|t || O(N (R[ON|S|=—|61|en | wos S| STITT ST nnn nv in| vn |[vn|n [OY |C|0 0 Oo |0|e TTT TT TTT TF FTF TTT TT |S TT =o [28EEEEES8E 1. Islslailelslsld Isle sal B2BE EEE REE EE [22 E8 GE (32 1852122222182 2 2 ele 225 5|RI5 EE 2g gE (22ElE]2E El glee bEIRIRIRI RRS Sig “4 2RZEBLEREEREEEE5E I= BRIE 3EE B38 3 3| 233332233332 |B [3B ITE 3 c|glz|e|ele|z|e|le| ele elses |e |=|lss|e|e|E|e|e Ele E|E|E|E|E|E|E|E|E|E|E|E|E|E|E |E |E|EE|EE|E|E|E E|E 515|5(55 / 5 / 5 / 5 / 5 5 / 5 5 / 555 |5 |5 555 5558§ 5|& = [= = = = = = === =| = —- = == [=== — |= £lelelele|lele|lele e|lele|le gle £ Ele glelgle|lelE|lE E|E E|E|E|E|E|E|E|E|E|E|E|E|E|E|E |g |E|E|E|E|E|E|E|E|E |E|E a g 2 z 213 E z 7) wn |B a = 2 g 255 = Hlo0lc MM [> BeizenBieca de 2 [sflEcRe: of E|Z|E|2 gig Bl1Z141222 [2 |F SI22|32|E|2 = S|8|= BZI2CZ 225% |= BE glaE4%|5 2 Gz EER HEHE EE 72% 25 E5EE | z|Z|S ZEEE 2 2 =z Q 218|3 JB|ZISI5E EIS I2 55 ZEEE SE 222151212 28 =z = = SSEiERETTEEeel b FEnace: Kk g EEE BRERA ERE EERE RE EERE QS (=N|n|F Vn (OIRO | =| [en = no S| RD |= |en = |v FS I IN SN SI NS IN BE SN EI EEE © © [00 (0 x |X aa] aa ST TT TT TT TT ~~ qT TTF TTT TT <= 2232 elzlelzle|elslzglg Qn —| =~ ~~ 3 £2 scl EE 8 EEcs EEE gee ZEEE sashes 3 Eg 3 Jafg[aieges aden 2532 2235 58 Z=lSlelel le ISS |B|E 1 HEeiEEs Esa aEE TTT: 3 ZEEE Iz EEE EEE EEE FE HEE EERE : if 5 15% E|E|E|E|E|E|E|E|E|E|E|E 1 Yai 5 : EIEIEIE|E|E 2 2 EEE EEE EE EE £ fle £ EEE EERE EEE EE E|E|E|E | EE|E[E|E|E|E| EEE 8 EEE JERE f BEE g 515 5 / 5\5\5(5(5 / 5515 515 51505155 5 |5(5315 (5 55550553 3 i [od fd | - 3 c|lelelele g ££ EEE E|E|E|E|E EE BEE EEE HRRE EEE clelgle|ele |e Sede age tea ns ans 25932 ££ g5l% £ E|Q|.E|E Dogg: 2 |E|2E|2 / 812 / 9)5|2|5|2 E|E|E|E|E|E |E |E = Zz Zz y J lsle 5|52s2E 5812 E = E25) [2 2|]e al=(glo[z lls 5g 2 Z 2E|1Z€|2 5 z Zz 2E(5(3 ZEEE 2Eg EE SESE EEE = E E g| g 2 / 81213[8|2 < ZZ) == Z| ale 22: : g S <|@ a2 4212828 2 areeritiin in SiEEcaiaz: SEE gr Sask % 5 o¥|< 8 ¥ EE] £ sg & S2B|IE|2E YAS ® Nfs BIB 1213121315512 22125 3 3188 8 8 82 |B 22538555 geg33lz 18 838 lala lalallala als = SERIES EERE EE 3 Slo|o|alald|alalalal 4 2g wv || nn Ser SLLIZEEEIEEEE IR Glalalelala aE slalalalala 2lelelwlElelelele| ells] [RIRIRZIRISEE|E] 72887] SRR TEE EE EEE SElEg2Ealys Leelee] EERE EE EERE EERE SEE ERE EEEEEE Elsl=l=lalzl==slele Ole ElElelE == == E|E|.E|.E|E|E|E E|E|E|E|E[E|E|E|E|E|E|E|2|E|E[E|E|E|E|E|E|E| |E|E|E|E[E|E|E B|5|5|5|5|5|5|5|5|5|5|5|2|5|5|5|5 5|5|&| 55 |55 555 55 | [fom [om od | | [om [om [om [om | om | [om [om [oR om | | | | = td | rd [od fd [od | ed [ed az = clelelelelelelelelelelelele|B|BlelelelelelelelelBlelelelele Bl EIEBIEBIEIE EI EI EI EI RIEEBIEl A HEGRE GI EIRIE EEE IEIE onl sol sof Sof S0| S| oo] S0| SH GO| SH &0| SO S0| = |= | BO SH| &0| &0f SO So SH soem | cb Go| Sn Sof SN gle elg|e|e|e|e|e| eel ele elm e)e| eel le|e|elS|e|e|ele|e E|E|E|E|E|E|E|E|E|E|E|E|E|E|3|3|E|E|E|E|E|E|E|E|3|E|E|E|E|E FEE EH «| 2 | ao] s =(EE|2(S SESSREZEEEE EF RlspElE H%zlEE 2iEEEEEe fe 2S22501z SEEhik =|d|< <A A 2 i <IAlZ] |= |[ZC|= 55 EERE EEE EEE BEE EEE EEE SEERREIZZE 32 ERE EE EE SEER EEE EE 2 E &|2|3 5 z g SIR12I1<|Z2 z S8|%I2E|E|5 22 |2|2| 5 12 1812 A125 18|5 51218 5S 2 8 8 | & FT n|O IN| |S|(=|N|a| nC RDS [=| |n|O(S|0| [S| alafaa|aa|manfmnmlmimninlnlon(nldg ox (F(t || |0 (0 [A0 SERRE IIB I2|2 522222185 F|2 FFE IR 5 38 8|2)4|2 2 2 [2 [2 |e 2 2 2 |2 |Z g E [EE |E |B gE 8B § 8 |& EY 0 0 =n 0 £ |E |g |E |E o oo = < ~~ 2 EB |B IE 0 0 = = = 2. BEBE 25 |BSlEs|g dias = 0 = ClzZ o| 2 |= © 8S |AS|AS|AS|AS 2 z2 |2 EE Z |E 3g EEE |2 lz £5 |B g HE ls 12 13 IE |e ge |& |g |E |B |Z 2181812151822 52 == ' | | + |B REE RRIEIERE “a Sn = |= la | o TaeleeeefgiEE KE BEB IB |e IZ lzl= 22 EI EIEE EL 12 |= 18 5 | dE i=l El =El=] Een & & « « 5 clelelelelelelelelelele|le E|E|E|E|E|E|E(E EE EEE IS 12 |= |2 |B 515|55 / 5 / 5 5 / 5 5 / 5 55&§5 III IE | a|a|afS]_]=]afa]=| =a] S|=|alE Ea |B |& E ge le le lg ls |s 3 5 [5 I I |B clelelclelelele|le(elcs|le|le|e|® Qo oO BESTE )EI EE EBIRIE EEE EIS = = = £ s anf ol eb| ah| oh| &b| sb| ch] eb| ah &h| zh| oh sb © eS e e 2 ge gg glee egg gees |5 |&8 |B |B |B E|E|E|E|E|E|E|E|E|E|E|E|ElEE [EE |E |B IE Muna S30 5 J |e EERE = a z| | 2 5 EE EEess Bula B = |x| 218 |g |2 [2 |525E8 2IES IEEE 258 > 2 3 [EE 83 5 3 2 | = | 2 SEE: 282 xl x 22 Z 2 g§ & |&5 2g | nA = > = EZ £8 £25852 ZEEE £2 > |Z¥%oz SceeEiEsziseceEs £2 2 Zacct oD = @ EI 2x 2 g2(<|3 5525 S«|& SHE z £ SEE z g SESE RIEE ESR ERs SHEE E 5 2 525k Sno] |S |(=(|m]s nO |b f=) > — oN © Vn |V|V|O[(O[(O LY |L|L|VY[O 0 ~~ & & Ba nlE|a ane e282 2 5 =E | z 2 © © 5 5 5 8 2 z € |E |§ 8 |B 2 § | |§ |§ |& 5 EIE|E 82 | a o a a a 2 E |E |& |& |E &£ EE IE E EB BE EB |B IE |B B 2 [2 [2 |2 [2 > S555 |S £ 2 EE EE & £ E £ £ E = EEE IEE |B 2 |g [8 |g |2 2 2 |g 128 |g |g 2 5 |5 [8 8 |&5 |B Ra = = Ra =~ = 8 E E 8 E E E £ E £ E E E 15 / 5 818 |8 (5 / 8 / 8818 [8 |3 = g = = ge = £ = ce £ £ = = s |g |g |g |g S Ss |g |g |g |e |g |e 2 [5 |& & |8 5 £ 2 [& |& |B |& |8 = = = = [+3 [= [+3 [= = = [+3 = [+3 la < 2g mm |g =@ 2 |a|a TE CEIREEEEEEE z E¢Eg Bg 2 8 8 18 |& BE |& & | g 4 2 2055155 18 |g =k Ep 2gze 2 2 2 | > |= g SEESlEECBEiEEl 2 ZL CZ gg 5222852E2000.08 5 8 2 5 24 FE E5S2¥28 EE |X 8 = = @ SESEZEZERCED © 12 PE | |E ORs H SIEB8aSg x > |= |=xo [© | SOE ZOE ZAHER C= a | |aalbElx [X= |X EEE EEE EE FE FE EE ZOE SESEREZ<EBERAnAnAaL ERE = wv Oo = Fd Fa = — oN oy =< wv 0 = =~ = = = = * © © © 00 0 0 PE DS DS 1 5 BREE R 0 8 8 3 = £ £ lglg |g |g |& 8 [88 |B 8 |= o oD o Qo = £ gE £ i= ‘g eg [gle |g |g [8 £ |Bl2 |B |& |§ |R5E (2 (5 |Z £ 8 lala TIE|E|E ZEEE =| 5 8 & 3 TTT la sls ls = | ow ow = MW 2 mE (@ a ¥ & SEE 1 Zz SE 8 gg Z lz g zl | |@» 2 @n £2 SEEE Cd 9 oF E = = oO O|3 FESS [0 SE, gees ZEEE Byes EE 5|12 / 8I8 5 zz 1g 7 Ig EEE SRS FA [R83 gz = |5] =| (Z|E El gl 99 9 Y| | 8 Z| ZE EE |E = lel2] IZlalele =a [F]2|2 =| Eg gle |==lzle 222 [S| = 5 9EE2121212 121212 12I8E 2 2 |Z|222E|EE EEE |EIE|E 2 1s = [®||=|E|E|E|E|lE |E|E|lE |E|5|= F Sl lal? 5 |5 / 5 / 8 / 888% 833 |3|%|s “lalxl2|8]8|8 RE EHEEHEREEEREHE 28 212|glE|5 qe 3 |3EE|1E|E|EE EEE |£|2|B =e E2135] E88 CO ICICIEIEIEIERE [EERE [EES 2853S |Q|Q|C|E ala § |5|E|5|E|5|5|E |5|5|E |5|E|5 2 8 81212121212 55) & |E|E|E|E|E|E|E |E|EIE |E|E|E £18]2|33]9|8 / 8| 3122 CRE EEE EERE EER HEHE RE EE EE EEE EE £EEIEE EEE Ede [tele Eee REE 2 (BIRI&I&IZI&1R [&&|1& |&I&I&|Z|Z|R|&|S|3|3(3]3]5]5|3(5 = = = B=1R-] = a El |B IE EE g & 5 5 | 8 [58 5 p e |elBlelel|E] 2 |2|R]le |e|e|B|e|els|lelele]e]e]e]elele 5 |§|=|§|8|=|8l= |=|=|§ |8|%=|55 85 EE GE GE EEE & |53(552052 13218 (5 / 83 / 5855 552555555 2 [2322822 TEE |2|E|3|2 222 2|2|E|2 2 ||| 2] 2 = © ¢ EE, Ep IB £ 3 & xz Q g £18 Eo g <Q = [= [SX olZs Eln|E Blol%lz |%| |B EEE = 2 E42. BEER 2 ERE BEE EEE za |oE |& 9 lie MEE Oo 22s 22 EF BE El 2[S ZB o ds Eeia 2ESdE Jaze ee ESEElE 2 E E288 (3 / 8 S% AEE EEE EES 208 |= |2|&| Es g|Z|E 2122285222255 55 OOR|O|% > |a|<|> gx |<|> »|¥| |= | @|<|<|2|0|>|2|0|x [=] enn QS |= nn | O00 NO |= en ||| OO] 0 < ge == — |= === == aaa aaa a o OOO [OOOO Oo [Wo [© C(O |0|v |v (vv (v(o|e|w|v|(v|v|v |= 2222 E12E|E|E|E ElE[5[5[5(5 5|5|5|5 EHHHHE zlzlz|z |Z | al al al al al al a z|z|z|2]3] 2] 2|el2|2l2léle w= = [555s Ele|e|E|lE|E|E 5|'5|5|5|5|5|& $5585 8 & =lEl=|ls sss o|e|z|e|e|ele 3|5|2|4|8| 8 / 8 ZEEE [EEE olelojo|lololo 7 a a 3 T|v|v § 88g sles [5 |EBEH |B E|E|EIEIE|EIE ololololelole|sle |B [REE 2 5 / '5|5|5|5|5|8 2|a|alalalalglale |g [Egg |E BEER EE aa |@|@|a|a|a|ale |& [T&T § |2 Z| 2|2|2|2|2| 2 wow 5 FB id : Ee x eL2k : - iit i ! LA 8 |x £1Z He it LR 8 Q 2 Farge : : + Re 8 $25 i hs = g 3 HH om “ g 2 : i i © x = 2 & 12:82 - = 0 > [ 3s - i : |E £2 3lels : : > 2 S123 g SEE a x 2 z : : ie | a ; zI2l3 Es . 22 / 8 : | zg - “>= ) - in 218|8 2|3[8|3|3 NEE o = Eg s 3 ° z £ = $ Eg S i EE : % 28 E BE: £8 2 |= £IE|E 25 3 [2 [358 [E32 E HEIR Zo ® [5 |5|5|8 32 < |g BIB 22 sg [2 |EER £2 £lEl2 [5 |slslelsl EIT 2212 |2 2E|2E |BIE z Z8lg|8 Ss 1815 / 88 |g z (22212 |Z 2828-85 2° |eo|2|ls|lE [2 212|12|8|2|3| 5 = |=|E[E|E |E |E|E|E|E|8|z|S glelel€ |e |glglg|g|e|=B £ |E|E|=8 £ |£|E|E|E|E|. § |§ g El5|E 2 |glelel§ |e |=|eg|g|g|§|8)2 2 |2ElelE |e |&lelelEl x gl® = REE ~~ SEE 58]5| 2 RHE EEE ERE EE EEE 2 |B|E|EIEE|E |E|E|EIE|3|E(E 5 |E|2|8|85|2 |2|8|3|8|%|5|E 2lglg 2 =|=|E|E|E & 22333 E oe HEHE : $2888 § £15 5525 z £ E |E 2 2 elele = 2 § (5 / 58 | |E|EE|5|ElEE § 5 al = ~~ © 2 |R|2|2E |E [EIE2|3|222 2 E © a Top = © 7% Z Is sEgnfyEs 22 g 2 SOEEOREE ZX £2 Z ez, |g E23EifoafE 2 5 2 22 |fgBEEESiiEiE: = & IE Zea £ ge o|Z|E ceBal 2 £2 E 2 2 | £28 EXOH SERRE 2 SE, BEEEEEEzca ae 3,50 Z zz |E HF EI GE = Exec EE %|% = g i 3 3 SEICRt EEiiEaEnci: AEz)5 E53 g glz| Is Of w= ~ 2 12lzlgla lz lzlelnizlalzlz a 3 Elg% I [8|8|8|8 8 |8|8|8|8|8|8[8 © S| |e |e Definitions

[00186] As used herein, a “cytokine polypeptide sequence” refers to a polypeptide sequence (which may be part of a larger sequence, e.g., a fusion polypeptide) with significant sequence identity to a wild-type cytokine and which can bind and activate a cytokine receptor when separated from an inhibitory polypeptide sequence. In some embodiments, a cytokine polypeptide sequence has at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of a wild-type cytokine, e.g., a wild-type human cytokine. In some embodiments, a cytokine polypeptide sequence has no more than one, two, three, four, five, six, seven, eight, nine, or ten amino acid differences from a wild-type cytokine, e.g., a wild-type human cytokine. Cytokines include but are not limited to chemokines. Exemplary cytokine polypeptide sequences are provided in Table 1. This definition applies to IL-2 polypeptide sequences with substitution of “IL-2” for “cytokine.”

[00187] As used herein, an “inhibitory polypeptide sequence” is a sequence in a cytokine prodrug that inhibits the activity of the cytokine polypeptide sequence in the prodrug. The inhibitory polypeptide sequence binds the cytokine polypeptide sequence, and such binding is reduced or eliminated by action of an appropriate protease on the protease- cleavable polypeptide sequence. Exemplary inhibitory polypeptide sequences are provided in Table 1.

[00188] As used herein, a “protease-cleavable polypeptide sequence” is a sequence that is a substrate for cleavage by a protease. The protease-cleavable polypeptide sequence is located in a cytokine prodrug such that its cleavage reduces or eliminates binding of the inhibitory polypeptide sequence to the cytokine polypeptide sequence.

[00189] As used herein, a protease-cleavable polypeptide sequence “is recognized by” a given protease or class thereof if exposing a polypeptide comprising the protease-cleavable polypeptide sequence to the protease under conditions permissive for cleavage by the protease results in a significantly greater amount of cleavage than is seen for a control polypeptide having an unrelated sequence, and / or if the protease-cleavable polypeptide sequence corresponds to a known recognition sequence for the protease (e.g., as described elsewhere herein for various exemplary proteases).

[00190] As used herein, a “pharmacokinetic modulator” is a moiety that extends the in vivo half-life of a cytokine prodrug. The pharmacokinetic modulator may be a fused domain in a cytokine prodrug or may be a chemical entity attached post-translationally. The attachment may be, but is not necessarily, covalent. Exemplary pharmacokinetic modulator polypeptide sequences are provided in Table 1. Exemplary non-polypeptide pharmacokinetic modulators are described elsewhere herein.

[00191] As used herein, a “targeting sequence” is a sequence that results in a greater fraction of a cytokine prodrug localizing to an area of interest, e.g., a tumor microenvironment. The targeting sequence may bind an extracellular matrix component or other entity found in the area of interest, e.g., an integrin or syndecan. Exemplary targeting sequences are provided in Table 2.

[00192] As used herein, an “extracellular matrix component” refers to an extracellular protein or polysaccharide found in vivo. Integral and peripheral membrane proteins on a cell, including fibronectins, cadherins, integrins, and syndecans, are not considered extracellular matrix components.

[00193] As used herein, an “immunoglobulin constant domain” refers to a domain that occurs in or has significant sequence identity to a domain of a constant region of an immunoglobulin, such as an IgG. Exemplary constant domains are Cu2 and Cu3 domains. Unless indicated otherwise, a polypeptide or prodrug comprising an immunoglobulin constant domain may comprise more than one immunoglobulin constant domain. In some embodiments, an immunoglobulin constant domain has at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of a wild-type immunoglobulin constant domain, e.g., a wild- type human immunoglobulin constant domain. In some embodiments, an immunoglobulin constant domain has no more than one, two, three, four, five, six, seven, eight, nine, or ten amino acid differences from a wild-type immunoglobulin constant domain, e.g., a wild-type human immunoglobulin constant domain. In some embodiments, immunoglobulin constant domain has an identical sequence to a wild-type immunoglobulin constant domain, e.g., a wild-type human immunoglobulin constant domain. Exemplary immunoglobulin constant domains are contained within sequences provided in Table 1. This definition applies to Cu2 and Cu3 domains, respectively, with substitution of “Cu2” or “Cu3” for “immunoglobulin constant,” with the qualification that a Cu2 domain sequence does not have greater percent identity to a non-Cu2 immunoglobulin constant domain wild-type sequence than to a Cu2 domain wild-type sequence, and a Cu3 domain sequence does not have greater percent identity to a non-Cu3 immunoglobulin constant domain wild-type sequence than to a Cu3 domain wild-type sequence. These definitions also include domains having minor truncations relative to wild-type sequences, to the extent that the truncation does not abrogate substantially normal folding of the domain.

[00194] As used herein, a “immunoglobulin Fc region” refers to a region of an immunoglobulin heavy chain comprising a Cu2 and a Cu3 domain, as defined above. The Fc region does not include a variable domain or a Cul domain.

[00195] As used herein, a given component is “between” a first component and a second component if the first component is on one side of the given component and the second component is on the other component, e.g., in the primary sequence of a polypeptide. This term does not require immediate adjacency. Thus, in the structure 1-2-3-4, 2 is between 1 and 4, and is also between 1 and 3.

[00196] As used herein, a “domain” may refer, depending on the context, to a structural domain of a polypeptide or to a functional assembly of at least one domain (but possibly a plurality of structural domains). For example, a Cu2 domain refers to a part of a sequence that qualifies as such. An immunoglobulin cytokine-binding domain may comprise VH and VL structural domains.

[00197] As used herein, “denatured collagen” encompasses gelatin and cleavage products resulting from action of an MMP on collagen, and more generally refers to a form of collagen or fragments thereof that does not exist in the native structure of full-length collagen.

[00198] As used herein, “configured to bind ... in a pH-sensitive manner” means that a polypeptide sequence (e.g., a targeting sequence) shows differential binding affinity for its binding partner depending on pH. For example, the polypeptide sequence may have a higher affinity at a relatively acidic pH than at normal physiological pH (about 7.4). The higher affinity may occur at a pH below 7, e.g., in the range of pH 5.5-7, 6-7, or 5.5-6.5, or below pH 6.

[00199] As used herein, a “cytokine-binding domain of a cytokine receptor” refers to an extracellular portion of a cytokine receptor, or a fragment or truncation thereof that can bind a cytokine polypeptide sequence. In some embodiments, the sequence of a cytokine binding domain of a cytokine receptor has at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of a cytokine binding domain of wild-type cytokine receptor, e.g., a cytokine binding domain of a wild-type human cytokine receptor. Exemplary sequences of a cytokine binding domain of a cytokine receptor are provided in Table 1. This definition applies to IL-2-binding domains of an IL-2 receptor with substitution of “IL-2” for “cytokine.”

[00200] As used herein, a “cytokine-binding immunoglobulin domain” refers to one or more immunoglobulin variable domains (e.g., a VH and a VL domain) that can bind a cytokine polypeptide sequence. Exemplary sequences of a cytokine-binding immunoglobulin domain are provided in Table 1. This definition applies to IL-2-binding immunoglobulin domains with substitution of “IL-2” for “cytokine.”

[00201] As used herein, “substantially” and other grammatical forms thereof mean sufficient to work for the intended purpose. The term “substantially” thus allows for minor, insignificant variations from an absolute or perfect state, dimension, measurement, result, or the like such as would be expected by a person of ordinary skill in the field but that do not appreciably affect overall performance. When used with respect to numerical values or parameters or characteristics that can be expressed as numerical values, “substantially” means within ten percent.

[00202] As used herein, the term “plurality” canbe 2, 3, 4, 5, 6, 7, 8, 9, 10, or more.

[00203] As used herein, a first sequence is considered to “comprise a sequence with at least X% identity to” a second sequence if an alignment of the first sequence to the second sequence shows that X% or more of the positions of the second sequence in its entirety are matched by the first sequence. For example, the sequence QLYV comprises a sequence with 100% identity to the sequence QLY because an alignment would give 100% identity in that there are matches to all three positions of the second sequence. Exemplary alignment algorithms are the Smith-Waterman and Needleman-Wunsch algorithms, which are well- known in the art. One skilled in the art will understand what choice of algorithm and parameter settings are appropriate for a given pair of sequences to be aligned; for sequences of generally similar length and expected identity >50% for amino acids or >75% for nucleotides, the Needleman-Wunsch algorithm with default settings of the Needleman- Wunsch algorithm interface provided by the EBI at the www.ebi.ac.uk web server is generally appropriate.

[00204] As used herein, a “subject” refers to any member of the animal kingdom. In some embodiments, “subject” refers to humans. In some embodiments, “subject” refers to non-human animals. In some embodiments, “subject” refers to primates. In some embodiments, subjects include, but are not limited to, mammals, birds, reptiles, amphibians, fish, insects, and / or worms. In certain embodiments, the non-human subject is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, and / or a pig). In some embodiments, a subject may be a transgenic animal, genetically- engineered animal, and / or a clone. In certain embodiments of the present invention the subject is an adult, an adolescent or an infant. In some embodiments, the terms “individual” or “patient” are used and are intended to be interchangeable with “subject”. Cytokine polypeptide sequence

[00205] The cytokine polypeptide sequence may be a wild-type cytokine polypeptide sequence or a sequence with one or more differences from the wild-type cytokine polypeptide sequence. In some embodiments, the cytokine polypeptide sequence is a human cytokine polypeptide sequence (which may be wild-type or may have one or more differences). In some embodiments, the cytokine comprises a modification to prevent disulfide bond formation, and optionally otherwise comprises wild-type sequence. In some embodiments, the cytokine polypeptide sequence has at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of a wild-type cytokine polypeptide sequence or to a cytokine polypeptide sequence in Table 1. In some embodiments, the cytokine is a dimeric cytokine, e.g., a heterodimeric cytokine. In some embodiments, the cytokine is a homodimeric cytokine. The monomers may be linked as a fusion protein, e.g., with a linker, or by a covalent bond (e.g, disulfide bond), or by a noncovalent interaction. In some embodiments, the cytokine polypeptide sequence is an interleukin polypeptide sequence. In some embodiments, the cytokine polypeptide sequence is capable of binding a receptor comprising CD132. In some embodiments, the cytokine polypeptide sequence is capable of binding a receptor comprising CD122. In some embodiments, the cytokine polypeptide sequence is capable of binding a receptor comprising CD25. IL-2

[00206] In some embodiments, the cytokine polypeptide sequence is an IL-2 polypeptide sequence. The IL-2 polypeptide sequence may be a wild-type IL-2 polypeptide sequence or a sequence with one or more differences from the wild-type IL-2 polypeptide sequence. In some embodiments, the IL-2 polypeptide sequence is a human IL-2 polypeptide sequence (which may be wild-type or may have one or more differences). In some embodiments, the IL-2 comprises a modification to prevent disulfide bond formation (e.g., the sequence of aldesleukin (marketed as Proleukin®), and optionally otherwise comprises wild-type sequence. In some embodiments, the IL-2 polypeptide sequence has at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of a wild-type IL-2 polypeptide sequence or to a IL-2 polypeptide sequence in Table 1. Inhibitory polypeptide sequence

[00207] Various types of inhibitory polypeptide sequences may be used in a cytokine prodrug according to the disclosure. In some embodiments, the inhibitory polypeptide sequence comprises a cytokine-binding domain.

[00208] The cytokine-binding domain may be the cytokine-binding domain of a cytokine receptor. The cytokine-binding domain of a cytokine receptor may be provided as an extracellular portion of the cytokine receptor or a portion thereof sufficient to bind the cytokine polypeptide sequence of the cytokine prodrug. In some embodiments, the cytokine- binding domain of a cytokine receptor has at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of a wild-type cytokine-binding domain of a cytokine receptor, e.g., a wild-type cytokine-binding domain of a human cytokine receptor.

[00209] The cytokine-binding domain may be a fibronectin cytokine-binding domain. In some embodiments, the fibronectin cytokine-binding domain has at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of a wild-type fibronectin cytokine-binding domain of a cytokine receptor, e.g., a wild-type human fibronectin cytokine-binding domain.

[00210] The cytokine-binding domain may be an immunoglobulin cytokine-binding domain. The immunoglobulin cytokine-binding domain may be an Fv, scFv, Fab, VHH, or other immunoglobulin sequence having antigen-binding activity for the cytokine polypeptide sequence. A VHH antibody (or nanobody) is an antigen binding fragment of a heavy chain only antibody.

[00211] Additional examples of inhibitory polypeptide sequences that may be provided to inhibit the cytokine polypeptide sequence of the cytokine prodrug are anticalins, affilins, affibody molecules, affimers, affitins, alphabodies, avimers, DARPins, fynomers, kunitz domain peptides, monobodies, and binding domains based on other engineered scaffolds such as SpA, GroEL, lipocallin and CTLA4 scaffolds. IL-2 inhibitory polypeptide sequence

[00212] In cytokine prodrugs comprising an IL-2 polypeptide sequence, the inhibitory polypeptide sequence may be an IL-2 inhibitory polypeptide sequence of any of the types described above. In some embodiments, the IL-2 inhibitory polypeptide sequence is an immunoglobulin IL-2 inhibitory polypeptide sequence. In some embodiments, the IL-2 inhibitory polypeptide sequence comprises an anti-IL-2 antibody or a functional fragment thereof. In some embodiments, the immunoglobulin IL-2 inhibitory polypeptide sequence comprises a set of six anti-IL2 hypervariable regions (HVRs) set forth in Table 1 (e.g., SEQ ID NOs: 34-39 or 750-755). In some embodiments, the IL-2 inhibitory polypeptide sequence comprises a set of anti-IL2 VH and VL sequences having at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of a set of anti-IL2 VH and VL sequences set forth in Table 1, either as individual sequences or as part of an scFv. In some embodiments, the IL-2 inhibitory polypeptide sequence comprises a set of anti-IL2 VH and VL sequences having the sequence of a set of anti-IL2 VH and VL sequences set forth in Table 1, either as individual sequences or as part of an scFv. Exemplary IL-2 inhibitory polypeptide sequences include SEQ ID NOS: 10-31, 40-51, and 747, and a combination of SEQ ID NOs 32 and 33 or a combination of SEQ ID NOs 748 and 749. Protease-cleavable sequence

[00213] The protease-cleavable sequence may be selected from sequences cleavable by various types of proteases, e.g., a metalloprotease, a serine protease, a cysteine protease, an aspartate protease, a threonine protease, a glutamate protease, a gelatinase, an asparagine peptide lyase, a cathepsin, a kallikrein, a plasmin, a collagenase, a hKl, a hK10, a hK15, a stromelysin, a Factor Xa, a chymotrypsin-like protease, a trypsin-like protease, a elastase-like protease, a subtilisin-like protease, an actinidain, a bromelain, a calpain, a caspase, a Mir 1- CP, a papain, a HIV-1 protease, a HSV protease, a CMV protease, a chymosin, a renin, a pepsin, a matriptase, a legumain, a plasmepsin, a nepenthesin, a metalloexopeptidase, a metalloendopeptidase, an ADAM 10, an ADAM17, an ADAM 12, an urokinase plasminogen activator (uPA), an enterokinase, a prostate-specific target (PSA, hK3), an interleukin-1b converting enzyme, a thrombin, a FAP (FAP-a), a dipeptidyl peptidase, or dipeptidyl peptidase IV (DPPIV / CD26), a type II transmembrane serine protease (TTSP), a neutrophil elastase, a proteinase 3, a mast cell chymase, a mast cell tryptase, or a dipeptidyl peptidase. In some embodiments, the protease-cleavable sequence comprises the sequence of any one of those in Table 1 (e.g., SEQ ID NOs: 80-90 or 700-741), or a variant having one or two mismatches relative to the sequence of any one of those in Table 1 (e.g., SEQ ID NOs: 80-90 or 700-741). Proteases generally do not require an exact copy of the recognition sequence, and as such, the exemplary sequences may be varied at a portion of their amino acid positions. In some embodiments, the protease-cleavable sequence comprises a sequence that matches an MMP consensus sequence, such as any one of SEQ ID NOs: 91-94. One skilled in the art will be familiar with additional sequences recognized by these types of proteases. Matrix metalloprotease-cleavable sequence

[00214] In some embodiments, the protease-cleavable sequence is a matrix metalloprotease (MMP)-cleavable sequence. Exemplary MMP-cleavable sequences are provided in Table 1. In some embodiments, the MMP-cleavable sequence is cleavable by a plurality of MMPs and / or one or more of MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, MMP-13, and / or MMP-14. Table 1, e.g., SEQ ID NOs: 80-90, provides exemplary MMP-cleavable sequences. Targeting sequence

[00215] In some embodiments, the targeting sequence facilitates localization, accumulation, and / or retention of the cytokine prodrug and / or the cytokine polypeptide sequence (e.g., after proteolysis of the protease-cleavable sequence) in an area of interest, e.g., a tumor microenvironment (TME). The targeting sequence may be a sequence that binds an extracellular matrix component. Exemplary extracellular matrix components are a collagen or denatured collagen (in either case, the collagen may be collagen I, IL, III, or IV), poly(I), von Willebrand factor, IgB (CD79b), heparin, a sulfated glycoprotein, or hyaluronic acid.

[00216] In other embodiments, the targeting sequence binds a target other than an extracellular matrix component. In some embodiments, the targeting sequence binds IgB (CD79b), a fibronectin, an integrin, a cadherin, a heparan sulfate proteoglycan, or a syndecan. In some embodiments, the targeting sequence binds at least one integrin, such as one or more of a1B1 integrin, a2f1 integrin, a3p1 integrin, a4f1 integrin, a5B1 integrin, a6f1 integrin, a7B1 integrin, a9B1 integrin, 04p7 integrin, avp3 integrin, avpS integrin, allbB3 integrin, alIIbf3 integrin, «MP2 integrin, or allbB3 integrin. In some embodiments, the targeting sequence binds at least one syndecan, such as one of more of syndecan-1, syndecan-4, and syndecan-2(w). Cytokine prodrugs comprising such targeting sequences may also comprise an MMP-cleavable linker as set forth elsewhere herein, such as an MMP-cleavable linker comprising any one of SEQ ID NOs: 80-90, or a variant having one or two mismatches relative to the sequence of any one of SEQ ID NOs: 80-90.

[00217] In some embodiments, the targeting sequence comprises a sequence set forth in Table 2 (e.g., any one of SEQ ID NOs: 180-640), or a variant having one or two mismatches relative to such a sequence. pH-sensitive targeting sequences

[00218] In some embodiments, the targeting sequence is configured to bind its target in a pH-sensitive manner. In some embodiments, the targeting sequence has a higher affinity for its target at a relatively acidic pH than at normal physiological pH (about 7.4). The higher affinity may occur at a pH below 7, e.g., in the range of pH 5.5-7, 6-7, or 5.5-6.5, or below pH 6. The presence of histidines in the targeting sequence can confer pH-sensitive binding. Without wishing to be bound by any particular theory, histidines are considered more likely to be protonated at lower pH and can render binding a negatively-charged target more energetically favorable. Accordingly, in some embodiments, a targeting sequence comprises one or more histidines, e.g., 1,2, 3,4, 5,6, 7, 8,9, or 10 histidines. Including a pH-sensitive targeting sequence can enhance discrimination between tumor versus normal tissue by the cytokine prodrug, such that the cytokine prodrug is more preferentially retained in the tumor microenvironment compared to normal extracellular matrix. Thus, a pH-sensitive targeting element can further facilitate tumor specific delivery of the cytokine prodrug and thereby further reduce or eliminate toxicity that may result from cytokine activity in normal extracellular matrix.

[00219] Binding a target in a pH-sensitive manner can be useful where it is desired to localize or retain a cytokine prodrug or the cytokine polypeptide sequence thereof in an area with a pH different from normal physiological pH. For example, the tumor microenvironment may be more acidic than the blood and / or healthy tissue. As such, binding to a target in a pH- sensitive manner may improve the retention of the cytokine prodrug or the cytokine polypeptide sequence thereof in the area of interest, which can facilitate lower doses than would otherwise be needed and / or reduce systemic exposure and / or adverse effects.

[00220] In some embodiments, the targeting sequence is configured to bind any target described herein in a pH-sensitive manner. In particular embodiments, the target is an extracellular matrix component such as a hyaluronic acid, heparin, heparan sulfate, or a sulfated glycoprotein. In another particular embodiment, the target is a fibronectin.

[00221] Exemplary targeting sequences for conferring target binding in a pH-sensitive manner are provided in Table 2 (e.g., SEQ ID NOs: 641-662). In some embodiments, the targeting sequence comprises the sequence of any one of SEQ ID NOs: 641-662, or a variant having one or two mismatches relative to the sequence of any one of SEQ ID NOs: 641-662. Pharmacokinetic modulators

[00222] In some embodiments, the cytokine prodrug comprises a pharmacokinetic modulator. The pharmacokinetic modulator may be covalently or noncovalently associated with the cytokine prodrug. The pharmacokinetic modulator can extend the half-life of the cytokine prodrug and optionally the cytokine polypeptide sequence, e.g., so that fewer doses are necessary and less of the prodrug needs to be administered over time to achieve a desired result. Various forms of pharmacokinetic modulator are known in the art and may be used in cytokine prodrugs of this disclosure. In some embodiments, the pharmacokinetic modulator comprises a polypeptide (see examples below). In some embodiments, the pharmacokinetic modulator comprises a non-polypeptide moiety (e.g., polyethylene glycol, a polysaccharide, or hyaluronic acid). A non-polypeptide moiety can be associated with the prodrug using known approaches, e.g., conjugation to the prodrug; for example, a reactive amino acid residue can be used or added to the prodrug to facilitate conjugation.

[00223] In some embodiments, the pharmacokinetic modulator alters the size, shape, and / or charge of the prodrug, e.g., in a manner that reduces clearance. For example, a pharmacokinetic modulator with a negative charge may inhibit renal clearance. In some embodiments, the pharmacokinetic modulator increases the hydrodynamic volume of the prodrug. In some embodiments, the pharmacokinetic modulator reduces renal clearance, e.g., by increasing the hydrodynamic volume of the prodrug.

[00224] In some embodiments, the cytokine prodrug comprising the pharmacokinetic modulator (e.g., any of the pharmacokinetic modulators described herein) has a molecular weight of at least 70 kDa, e.g., at least 75 or 80 kDa.

[00225] For further discussion of various approaches for providing a pharmacokinetic modulator, see, e.g., Strohl, BioDrugs 29:215-19 (2015) and Podust et al., J. Controlled Release 240:52-66 (2016). Polypeptide pharmacokinetic modulators

[00226] In some embodiments, the pharmacokinetic modulator comprises a polypeptide, e.g., an immunoglobulin sequence (see exemplary embodiments below), an albumin, a CTP (a negatively-charged carboxy-terminal peptide of the chorionic gonadotropin B-chain that undergoes sialylation in vivo and in appropriate host cells), an inert polypeptide (e.g., an unstructured polypeptide such as an XTEN, a polypeptide comprising the residues Ala, Glu, Gly, Pro, Ser, and Thr), a transferrin, a homo-amino-acid polypeptide, or an elastin-like polypeptide.

[00227] Exemplary polypeptide sequences suitable for use as a pharmacokinetic modulator are provided in Table 1 (e.g., any one of SEQ ID NOs: 70-74). In some embodiments, the pharmacokinetic modulator has at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of a pharmacokinetic modulator in Table 1 (e.g., any one of SEQ ID NOs: 70-74).

[00228] In any embodiment where the pharmacokinetic modulator comprises a polypeptide sequence from an organism, the polypeptide sequence may be a human polypeptide sequence. Immunoglobulin pharmacokinetic modulators

[00229] In some embodiments, the pharmacokinetic modulator comprises an immunoglobulin sequence, e.g., one or more immunoglobulin constant domains. In some embodiments, the pharmacokinetic modulator comprises an Fc region. The immunoglobulin sequence (e.g., one or more immunoglobulin constant domains or Fc region) may be a human immunoglobulin sequence. The immunoglobulin sequence (e.g., one or more immunoglobulin constant domains or Fc region) may have has at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of a wild-type immunoglobulin sequence (e.g., one or more immunoglobulin constant domains or Fc region), such as a wild-type human immunoglobulin sequence. In any of such embodiments, the immunoglobulin sequence may be an IgG sequence (e.g., IgG1, IgG2, IgG3, or IgG4). Exemplary immunoglobulin pharmacokinetic modulator sequences include SEQ ID NOS: 70-74 and the combination of SEQ ID NOs 756 and 757. Arrangement of components

[00230] The recitation of components of a cytokine prodrug herein does not imply any particular order beyond what is explicitly stated (for example, it may be explicitly stated that a protease-cleavable sequence is between the cytokine polypeptide sequence and the inhibitory polypeptide sequence). The components of the cytokine prodrug may be arranged in various ways to provide properties suitable for a particular use. The components of the cytokine prodrug may be all in one polypeptide chain or they may be in a plurality of polypeptide chains bridged by covalent bonds, such as disulfide bonds. For example, where a pharmacokinetic modulator comprises an Fc, one or more components may be bound to one chain while one or more other components may be bound to the other chain. The Fc may be a heterodimeric Fc, such as a knob-into-hole Fc (in which one chain of the Fc comprises knob mutations and the other chain of the Fc comprises hole mutations). For an exemplary general discussion of knob and hole mutations, see, e.g., Xu et al., mAbs 7:1, 231-242 (2015). Exemplary knob mutations (e.g., for a human IgG1 Fc) are K360E / K409W. Exemplary hole mutations (e.g., for a human IgG1 Fc) are Q347R / D399V / F405T. See SEQ ID NOs: 756 and 757.

[00231] For example, a pharmacokinetic modulator can be present on the same side of the protease-cleavable sequence as the cytokine polypeptide sequence, meaning that cleavage of the protease-cleavable sequence does not separate the pharmacokinetic modulator from the cytokine polypeptide sequence. Examples of such structures include CY-PM-CL-IN, IN-CL- CY-PM, and any other permutation (or variation in which additional elements are included between, before, or after the listed components) in which CL is not between CY and PM, where CY is the cytokine polypeptide sequence, PM is the pharmacokinetic modulator, CL is the protease-cleavable sequence, and IN is the inhibitory polypeptide sequence. In such embodiments, the pharmacokentic modulator will modulate the pharmacokinetics of both the prodrug and the active cytokine polypeptide sequence. In some embodiments, the pharmacokinetic modulator is an Fc, in which case the components preceding and following PM in the exemplary structures above may be bound to the same or different chains of the Fc, as discussed above.

[00232] In some embodiments, a pharmacokinetic modulator is present on the same side of the protease-cleavable sequence as the inhibitory polypeptide sequence, meaning that cleavage of the protease-cleavable sequence does separate the pharmacokinetic modulator from the cytokine polypeptide sequence. Such embodiments can be useful to provide a longer half-life for the prodrug than for the active form.

[00233] In some embodiments, a targeting sequence can be present on the same side of the protease-cleavable sequence as the cytokine polypeptide sequence, meaning that cleavage of the protease-cleavable sequence does not separate the targeting sequence from the cytokine polypeptide sequence. Such embodiments can be useful to facilitate localizing or retaining both the prodrug and the active form in an area of interest, e.g., a tumor microenvironment. Where a pharmacokinetic modulator is used, it can be on the same side of the protease- cleavable linker as the targeting sequence (e.g., to facilitate lower and / or less frequent dosing) or on the other side (e.g., to avoid long-duration immune stimulation), depending on the desired effects.

[00234] In some embodiments, a targeting sequence is present on the same side of the protease-cleavable sequence as the inhibitory polypeptide sequence, meaning that cleavage of the protease-cleavable sequence does separate the targeting sequence from the cytokine polypeptide sequence. Such embodiments can be useful to provide a gradient of cytokine emanating from an area of interest, or to provide such a gradient more rapidly than would occur if the targeting sequence were on the same side of the protease-cleavable sequence. Where a pharmacokinetic modulator is used, it can be on the same side of the protease- cleavable linker as the targeting sequence (e.g., to minimize systemic exposure to the active form of the cytokine and / or avoid long-duration immune stimulation) or on the other side (e.g., to facilitate lower and / or less frequent dosing), depending on the desired effects.

[00235] A number of exemplary arrangements are illustrated in Figs. 9 and 10A-E. In some embodiments, the cytokine prodrug comprises components arranged according to any of the examples in Figs. 9 and 10A-E, ordered from N- to C-terminus or from C- to N- terminus, optionally with additional components inserted between any of the illustrated components. Exemplary prodrugs IL-2

[00236] The following table shows exemplary combinations of components according to certain embodiments of the disclosed cytokine prodrugs. The numbers indicate SEQ ID NOs for a given component. CY is the cytokine polypeptide sequence, CL is the protease- cleavable sequence, and IN is the inhibitory polypeptide sequence, and, where present, PM is the pharmacokinetic modulator. Where a range is given, any one of the listed SEQ ID NOs may be selected. Where two SEQ ID NOs are recited conjunctively (using “and”), both SEQ ID NOs are present and can function together (they may or may not be fused to each other, optionally with an intervening linker, or bridged, e.g., by a covalent bond). For example, SEQ ID NOs 32 and 33 are VL and VH domains that can function together to form a cytokine- binding immunoglobulin domain, as are SEQ ID NOs 748 and 749. SEQ ID NOs 256 and 257 are Fc polypeptide chains for forming a heterodimeric knob-into-hole Fc that can serve as a pharmacokinetic modulator. The components may be arranged in any manner consistent with the disclosure, e.g., as indicated elsewhere herein. In some embodiments, a cytokine prodrug comprises a combination of sequences as set forth in Table 3A. an an an 756 and 757 70 71 12 73 74 756 and 757 70 71 73 73 74 756 and 757 70 71 7 73 74 756 and 757 70 71 7 13 74 756 and 757 70 71 12 73 74 756 and 757 70 71 73 73 74 756 and 757 70 71 7 73 74 756 and 757 70 71 7 13 74 756 and 757 70 71 12 73 74 756 and 757 70 71 73 73 74 756 and 757 70 71 7 73 74 756 and 757 70 71 7 13 74 756 and 757 70 71 12 73 74 756 and 757 70 71 73 73 74 756 and 757 70 71 7 73 74 756 and 757 70 71 7 13 74 756 and 757 70 71 12 73 74 756 and 757 70 71 73 73 74 756 and 757 70 71 7 73 74 756 and 757 70 71 7 13 74 756 and 757 70 71 12 73 74 756 and 757 70 71 73 73 74 756 and 757 70 71 7 73 74 756 and 757 70 71 7 13 74 756 and 757 70 71 12 73 74 756 and 757 70 71 73 73 74 756 and 757 70 71 7 73 74 756 and 757 70 71 7 13 74 756 and 757 70 71 12 73 74 756 and 757 70 71 73 73 74 756 and 757 70 71 7 73 74 756 and 757 70 71 7 13 74 an an 70 71 72 73 74 756 and 757 70 71 70 73 74 756 and 757 70 71 12 73 74 756 and 757 70 71 12 73 74 756 and 757 70 71 72 73 74 756 and 757 70 71 70 73 74 756 and 757 70 71 12 73 74 756 and 757 70 71 12 73 74 756 and 757 70 71 72 73 74 756 and 757 70 71 70 73 74 756 and 757 70 71 12 73 74 756 and 757 70 71 12 73 74 756 and 757 70 71 72 73 74 756 and 757 70 71 70 73 74 756 and 757 70 71 12 73 74 756 and 757 70 71 12 73 74 756 and 757 70 71 72 73 74 756 and 757 70 71 70 73 74 756 and 757 70 71 12 73 74 756 and 757 70 71 12 73 74 756 and 757 70 71 72 73 74 756 and 757 70 71 70 73 74 756 and 757 70 71 12 73 74 756 and 757 70 71 12 73 74 756 and 757 70 71 72 73 74 756 and 757 70 71 70 73 74 756 and 757 70 71 12 73 74 756 and 757 70 71 12 73 74 756 and 757 70 71 72 73 74 756 and 757 70 71 70 73 74 756 and 757 70 Tn Tz TB Tm 756 and 757 To Tn Tz BEER Ta 756 and 757 To Tn I IB Tr 756 and 757 To Tm Tz IB TE 2 80-90 or 201- | 748 and 749 756 and 757 242

[00237] Additionally, any cytokine prodrug described herein, in Table 3A or elsewhere, may further comprise a targeting sequence, such as any of the targeting sequences described herein. In some embodiments, the targeting sequence is any one of SEQ ID NOs: 180-662.

[00238] Additionally, any one of the cytokine prodrugs described in Table 3A may comprise a consensus sequence according to any one of SEQ ID NOs: 91-94 in place of the listed protease-cleavable sequences.

[00239] Also encompassed by this disclosure are cytokine prodrugs comprising a sequence with at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of any one of the cytokine prodrugs described above.

[00240] In some embodiments, the cytokine prodrug comprises a sequence with at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of any one of SEQ ID NOs: 100-111. In some embodiments, the cytokine prodrug comprises the sequence of any one of SEQ ID NOs: 100-111. In some embodiments, the cytokine prodrug comprises the sequence of any one of SEQ ID NOs: 803-852. Combinations of a protease-cleavable sequence and a targeting sequence

[00241] Any compatible embodiment of a cytokine prodrug described herein, in Table 3A or elsewhere, may comprise a combination of a protease-cleavable sequence and a targeting sequence set forth in Table 4. Where a range is given, any one of the listed SEQ ID NOs may be selected. The components may be arranged in any manner consistent with the disclosure, e.g., as indicated elsewhere herein (e.g., Figs. 9 and 10A-E and the section regarding Arrangement of components). Table 4. Exemplary combinations of protease-cleavable sequence and targeting sequence Targeting sequence 80 180-662 81 180-662 82 180-662 83 180-662 84 180-662 85 180-662 86 180-662 87 180-662 88 180-662 89 180-662 90 180-662 91 180-662 92 180-662 93 180-662 94 180-662

[00242] Also encompassed by this disclosure are cytokine prodrugs comprising a sequence with at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of any one of the cytokine prodrugs described above. Pharmaceutical formulations

[00243] Pharmaceutical formulations of a cytokine prodrug as described herein may be prepared by mixing such cytokine prodrug having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and / or non-ionic surfactants such as polyethylene glycol (PEG).

[00244] The formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes. Uses

[00245] In some embodiments, any one or more of the cytokine prodrugs, compositions, or pharmaceutical formulations described herein is for use in preparing a medicament for treating or preventing a disease or disorder in a subject. In some embodiments, any one or more of the cytokine prodrugs, compositions, or pharmaceutical formulations described herein is for use in a method of creating a cytokine gradient in a subject, comprising administering the protease-activated pro-cytokine or pharmaceutical composition to a subject, wherein the subject comprises a site having an abnormally high level of a protease that cleaves the protease-cleavable polypeptide sequence, optionally wherein the site comprises a cancer. In some embodiments, the abnormally high level is higher than the level of the protease in a healthy tissue of the same type as the site with the abnormally high level (e.g., in the subject being treated or in a healthy subject). In some embodiments, the abnormally high level is higher than the average level of the protease in soft tissue.

[00246] In some embodiments, a method of treating or preventing a disease or disorder in subject is provided, comprising administering to a subject any of the cytokine prodrugs or pharmaceutical compositions described herein. In some embodiments, the disease or disorder is a cancer, e.g., a solid tumor. In some embodiments, the cancer is a melanoma, a colorectal cancer, a breast cancer, a pancreatic cancer, a lung cancer, a prostate cancer, an ovarian cancer, a cervical cancer, a gastric or gastrointestinal cancer, a lymphoma, a colon or colorectal cancer, an endometrial cancer, a thyroid cancer, or a bladder cancer. The cancer (e.g., any of the foregoing cancers) may have one or more of the following features: being PD-L1-positive; being metastatic; being unresectable; being mismatch repair defective (MMRJ); and / or being microsatellite-instability high (MSI-H).

[00247] In some embodiments, a method of boosting T regulatory cells and / or reducing inflammation or autoimmune activity is provided comprising administering a cytokine prodrug to an area of interest, e.g., an area of inflammation. The cytokine prodrug for use in such methods may comprise an IL-2 polypeptide sequence. In some embodiments, a method of treating an autoimmune and / or inflammatory disease is provided, comprising administering a cytokine prodrug to an area of interest, e.g., an area of inflammation or autoimmune activity. The cytokine prodrug for use in such methods may comprise an IL-2 polypeptide sequence. These methods take advantage of the ability of certain cytokines at relatively low levels to stimulate T regulatory cells, which can exert anti-inflammatory effects and reduce or suppress autoimmune activity.

[00248] The cytokine prodrugs in any of the foregoing methods and uses may be delivered to a subject using any suitable route of administration. In some embodiments, the cytokine prodrug is delivered parenterally. In some embodiments, the cytokine prodrug is delivered intravenously.

[00249] A cytokine prodrug provided herein can be used either alone or in combination with other agents in a therapy. For instance, a cytokine prodrug provided herein may be co- administered with at least one additional therapeutic agent.

[00250] Such combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate formulations), and separate administration, in which case, administration of the cytokine prodrug provided herein can occur prior to, simultaneously, and / or following, administration of the additional therapeutic agent and / or adjuvant.

[00251] Cytokine prodrugs would be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The cytokine prodrug need not be, but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of cytokine prodrug present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically / clinically determined to be appropriate.

[00252] For the prevention or treatment of disease, the appropriate dosage of an cytokine prodrug (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the type of cytokine prodrug, the severity and course of the disease, whether the cytokine prodrug is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody or immunoconjugate, and the discretion of the attending physician. The cytokine prodrug is suitably administered to the patient at one time or over a series of treatments. Nucleic acids, host cells, and production methods

[00253] Cytokine prodrugs or precursors thereof may be produced using recombinant methods and compositions. In some embodiments, isolated nucleic acid encoding a cytokine prodrug described herein is provided. Such nucleic acid may encode an amino acid sequence comprising the cytokine polypeptide sequence, the linker, and the inhibitory polypeptide sequence, and any other polypeptide components of the cytokine prodrug that may be present. Exemplary nucleic acid sequences are provided in Table 1. In a further embodiment, one or more vectors (e.g., expression vectors) comprising such nucleic acid are provided. In a further embodiment, a host cell comprising such nucleic acid is provided. In some such embodiments, a host cell comprises (e.g., has been transformed with) a vector comprising a nucleic acid that encodes a cytokine prodrug according to the disclosure. In some embodiments, the host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., YO, NSO, Sp20 cell). In some embodiments, a method of making a cytokine prodrug disclosed herein is provided, wherein the method comprises culturing a host cell comprising a nucleic acid encoding the cytokine prodrug, as provided above, under conditions suitable for expression of the cytokine prodrug, and optionally recovering the antibody from the host cell (or host cell culture medium).

[00254] For recombinant production of a cytokine prodrug, nucleic acid encoding the cytokine prodrug, e.g., as described above, is prepared and / or isolated (e.g., following construction using synthetic and / or molecular cloning techniques) and inserted into one or more vectors for further cloning and / or expression in a host cell. Such nucleic acid may be readily prepared and / or isolated using known techniques.

[00255] Suitable host cells for cloning or expression of cytokine prodrug-encoding vectors include prokaryotic or eukaryotic cells described herein. For example, a cytokine prodrug may be produced in bacteria, in particular when glycosylation is not needed. For expression of polypeptides in bacteria, see, e.g., U.S. Patent Nos. 5,648,237, 5,789,199, and 5,840,523. After expression, the cytokine prodrug may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.

[00256] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for cytokine prodrug-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized,” resulting in the production of polypeptides with a partially or fully human glycosylation pattern. See Gerngross, Nat. Biotech. 22:1409-1414 (2004), and Li et al., Nat. Biotech. 24:210-215 (2006).

[00257] Suitable host cells for the expression of cytokine prodrugs are also derived from multicellular organisms (plants, invertebrates, and vertebrates). Examples of invertebrate cells include insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.

[00258] Plant cell cultures can also be utilized as hosts. See, e.g., US Patent Nos. 5.959.177. 6,040,498, 6,420,548, 7,125,978. and 6,417,429.

[00259] Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g, in Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR" CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines such as YO, NSO and Sp2 / 0. kkk

[00260] This description and exemplary embodiments should not be taken as limiting. For the purposes of this specification and appended claims, unless otherwise indicated, all numbers expressing quantities, percentages, or proportions, and other numerical values used in the specification and claims, are to be understood as being modified in all instances by the term “about,” to the extent they are not already so modified. “About” indicates a degree of variation that does not substantially affect the properties of the described subject matter, e.g., within 10%, 5%, 2%, or 1%. Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. EXAMPLES

[00261] The following examples are provided to illustrate certain disclosed embodiments and are not to be construed as limiting the scope of this disclosure in any way. Example 1: Construction of mammalian expression vectors encoding fusion proteins.

[00262] Coding sequences for all protein domains including linker sequences were synthesized as an entire gene (Genscript, NJ). All synthetic genes were designed to contain a coding sequence for an N-terminal signal peptide (to facilitate protein secretion), a 5° Kozak sequence, and unique restriction sites at the 5’ and 3’ ends. These genes were then directionally cloned into the mammalian expression vector pcDNA3.1 (Invitrogen, Carlsbad, CA). Examples of fusion protein constructs are listed in table SA. Site directed mutagenesis was performed using standard molecular biology techniques and appropriate kit (GeneArt, Regensburg).

[00263] Table 5A. Exemplary cytokine prodrug constructs | Name SEQ ID NO Features Construct | A Construct | 101 | m IL2-2x(SG4) - MMPcs1 — 2x (G4S) — IL2Ralpha — mIgG1 Fc B Construct | 102 | m IL2(C140S)- 2x(SG4) — MMPcs1 — 2x(G4S) — IL2Ralpha — Cc mlgG1 Fo(T252M)- 6xHIS 104 Construct | D 106 Construct | E {03 Construct | F 804 Construct | G 805 Construct | H R06 Construct | Vv 807 Construct | w R37 | Construct | 838 3 m IL2(C1408)- 2x(SG4) —- MMPcs1 — 2x(G4S) — soluble IL2Ralpha — mIgG1 F¢(T252M)- 6xHIS | Hu IL2(C125S)- 2x(SG4) - MMPcs1 — 2x(G4S) — IL2Ralpha — hu IgG1 Fc — 6xHIS h IL2(C1258)-2x(SG4) -MMPcs1-2x(G4S)-chimeric IL2Ra(sushi mouse)-hIgG1 Fc | hIL2 (C1258)-2x(SG4)-MMPecs1-2x(G4S)-hIL2Ra (1-219)- GSGGGG-hu IgG1 Fe | hIL2 (C1258)-2x(SG4)-MMPcs1-2x(G4S)-hIL2Ra (1-178)- GSGGGG-hu IgG1 Fe | hIL2 (C1258)-2x(SG4)-MMPcs1-4x(G4S)-hIL2Ra (1-219)- GSGGGG-hu IgG1 Fe | hIL2 (C1258)-2x(SG4)-MMPcs1-6x(G4S)-hIL2Ra (1-219)- GSGGGG-hu IgG1 Fc | h IL2(C1258)-2x(SG4) -MMPcs1-2x(G4S)-hIL2Ra(1-219; M25I)- hIgG1 Fe-6xHis | h IL2(C1258)-2x(SG4) -MMPcs1-2x(G4S)-hIL2Ra(1-219;L42V)- hIgG1 Fe-6xHis {08 Construct | J Construct | X m IL2(C1408)- 2x(SG4) - MMPik — 2x(G4S) — mIL2Ralpha (1- 215)- mu IgG1 Fe | Construct | 809 | m IL2(C1408)- VRIQRKKEKMKET- MMPcs1-2x(G4S)-mIL2Ra Y (1-215)- mu IgG1 Fe Construct | 810 | m IL2- 2x(SG4) - MMPIk — 2x(G4S) — mIL2Ralpha (1-215) mu Zz 1gG1 Fe Construct | 811 m IL2-SGG — FHRRIKA- MMPcs1-2x(G4S)-mIL2Ra (1-215)- mu AA IgG1 Fe Construct 812 m IL2-SGG —- FHRRIKA- MMPscr-2x(G4S)-mIL2Ra (1-215)- mu BB 1gG1 Fe Construct | m IL2 — 2x(GHHPH)- MMPcs1-2x(G4S)-mIL2Ra (1-215)- mu CC 1gG1 Fe Construct | m IL2 — 2x(GHHPH)- MMPscr-2x(G4S)-mIL2Ra (1-215)- mu DD IgG1 Fe Construct | m IL2 - SGG- GGWSHW- MMPcs1-2x(G4S)-mIL2Ra (1-215)- EE mu IgG1 Fc Construct | m IL2 -SGG- GGW SHW- MMPscr-2x(G4S)-mIL2Ra (1-215)- mu FF IgG1 Fe Construct | m IL2 -SGG- KLWVLPK- MMPcs1-2x(G4S)-mIL2Ra (1-215) GG mu IgGl Fe Construct | m IL2 -SGG- KLWVLPK- MMPscr-2x(G4S)-mIL2Ra (1-215)- HH mu IgGl Fe Construct | m IL2 — LHERHLNNN - MMPcs1-2x(G4S)-mIL2Ra (1-215)- mu I IgG1 Fe Construct | m [L2 — LHERHLNNN - MMPscr-2x(G4S)-mIL2Ra (1-215)- 1 1 1gG1 Fe Construct | m IL2 - VRIQRKKEKMKET- MMPscr-2x(G4S)-mIL2Ra (1- KK 215)- mu IgGl Fe Construct | m IL2- 2x(SG4) - MMPcs1 - FHRRIKAGGS — mIL2Ralpha (1- LL 215)- mu IgG1 Fe Construct | m IL2- 2x(SG4) —- MMPscr — FHRRIKAGGS — mIL2Ralpha (1- MM 215)- mu IgG1 Fe Construct | m IL2 —2x(SG4)-MMPcs1-2x(GHHPH)-mIL2Ra (1-215)- mu NN 1gG1 Fe Construct | m IL2 -2x(SG4)-MMPscr-2x(GHHPH)-mIL2Ra (1-215)- mu IgG1 00 Fc Construct | m IL2- 2x(SG4) - MMPcs1 —- GGWSHWGGS — mIL2Ralpha (1- PP 215)- mu IgG1 Fe Construct | m IL2- 2x(SG4) — MMPscr — GGWSHWGGS — mIL2Ralpha (1- QQ 215)- mu IgG1 Fe Construct | m IL2- 2x(SG4) - MMPcs1 — KLWVLPKGGS — mIL2Ralpha (1- RR 215)- mu IgG1 Fe Construct | m IL2- 2x(SG4) —- MMPscr—- KLWVLPKGGS — mIL2Ralpha (1- SS 215)- mu IgG1 Fe Construct | m IL2- 2x(SG4) - MMPcs1 —- LHERHLNNNG — mIL2Ralpha (1- TT 215)- mu IgG1 Fe Construct m IL2- 2x(SG4) —- MMPscr — LHERHLNNNG — mIL2Ralpha (1- uu 215)-mu IgG1 Fe Construct | m IL2 —- SGGGGGHHPH- MMPcs1- 2x(G4S)-mIL2Ra- mu IgG1 vv Fc Construct | m IL2 - GHHPHSGGGG- MMPcs1-2x(G4S)-mIL2Ra- mu IgG1 WwW Fc Construct | | m IL2 —2x(SG4)-MMPcs1-GHHPHGGGGS-mIL2Ra- mu IgGl Fc XX Construct | m IL2 -2x(SG4)-MMPcs1-2x(G4S)-mIL2Ra- mu IgG1 Fe- YY 2x(GHHPH) Construct | m IL2 —2x(SG4)-MMPcs1-2x(G4S)-mIL2Ra- mu IgG1 Fc- zz (GHHPH) Construct | M Construct | N Construct | 0 Construct | P Construct | Q Construct | AAA Construct | BBB Construct | ccc Construct | DDD Construct | EEE Construct | FFF Construct | m IL2 —2x(SG4)-MMPcs1-2x(G4S)-mIL2Ra- mu IgG1 Fc- zz (GHHPH) Construct | h IL2(C1258)-2x(SG4) -MMPcs1-2x(G4S)-hIL2Ra(1-219; L SGSL39-42ELV)-hIgG1 Fe-6xHis Construct | h IL2(C1258)-2x(SG4) -MMPcs1-2x(G4S)-hIL2Ra(1-219; DD4- K 5LY)-hIgG1 Fe- 6xHis Construct | hIL2 (C1258)-2x(SG4)-MMPcs1-2x(G4S)-hIL2Ra (1-192)-hu M 1gG1 Fc-6xHis Construct | hIL2 (C1258)-2x(SG4)-MMPcs1-2x(G4S)-hIL2Ra (1-192)- N GSGGGG-hu IgG1 Fc -6xHis Construct | hIL2 (C1258)-2x(SG4)-MMPcs1-2x(G4S)-hIL2Ra (1-192 / M25T)- 0 GSGGGG-hu IgG1 Fc -6xHis Construct | hIL2 (C1258)-2x(SG4)-MMPcs1-2x(G4S)-hIL2Ra (1-192 / L42V)- P GSGGGG-hu IgG1 Fc - 6xHis Construct | hIL2 (C1258)-2x(SG4)-MMPcs1-2x(G4S)-hIL2Ra (1-192 / DAL, Q D5Y)-GSGGGG-hu IgG1 Fc - 6xHis Construct | h IL2 (C1258)- 2x(SG4)- MMPcs1-2x(G4S)-hIL2Ra(M25I)- AAA GSGGGG- hu IgG1 Fc (LALA) Construct | h IL2 (C125S)- 2x(SG4)- MMPscr-2x(G4S)-hIL2Ra(M25I)- BBB GSGGGG- hu IgGl Fc (LALA) Construct | h IL2 (C125S)- 2x(GHHPH)- MMPscr-2x(G4S)-hIL2Ra(M251)- CCC GSGGGG- hu IgG1 Fc (LALA) Construct | h IL2 (C125S)- 2x(GHHPH)- MMPcs1-2x(G4S)-hIL2Ra(M25I)- DDD GSGGGG- hu IgGl Fc (LALA) Construct | h IL2 (C125S)- VRIQRKKEKMKET- MMPcs1-2x(G4S)- EEE hIL2Ra(M251)-GSGGGG- hu IgG1 Fc (LALA) Construct | h IL2 (C125S)- VRIQRKKEKMKET- MMPscr-2x(G4S)- FFF hIL2Ra(M251)-GSGGGG- hu IgG1 Fc (LALA) Construct m IL2(C1408)- 2x(SG4) - MMPscr— 2x(G4S) — mIL2Ralpha (1- GGG 215)-mlgG1 Fe Example 2: Expression and purification of fusion proteins. Transient expression of fusion proteins

[00264] Different mammalian cell expression systems were used to produce fusion proteins (ExpiCHO-S™, Expi293F™ and Freestyle CHO-S™, Life Technologies). Briefly, expression constructs were transiently transfected into cells following manufacturer’s protocol and using reagents provided in respective expression kits. Fusion proteins were then expressed and secreted into the cell culture supernatant. Samples were collected from the production cultures every day and cell density and viability were assessed. Protein expression titers and product integrity in cell culture supernatants were analyzed by SDS- PAGE to determine the optimal harvesting time. Cell culture supernatants were generally harvested between 4 and 12 days at culture viabilities of typically >75%. On day of harvest, cell culture supematants were cleared by centrifugation and vacuum filtration before further use. Purification of fusion proteins

[00265] Fusion proteins were purified from cell culture supernatants in either a one- step or two-step procedure. Briefly, Fc domain containing proteins were purified by Protein A affinity chromatography (HiTrap MabSelect SuRe, GE Healthcare). His-tagged proteins were first purified on a Nickel-agarose column (Ni-NTA Agarose, Qiagen), followed by anion ion exchange chromatography (HiTrap Capto Q ImpRes, Sigma). All purified samples were buffer-exchanged and concentrated by ultrafiltration to a typical concentration of > 1 mg / mL. Purity and homogeneity (typically >90%) of final samples were assessed by SDS PAGE under reducing and non-reducing conditions, followed by immunoblotting using an anti-His or anti-Fc antibody. Purified proteins were aliquoted and stored at -80°C until further use. Fig. 1 shows examples of successfully purified fusion proteins. Example 3: Cleavage of fusion protein by MMP proteases

[00266] Recombinant MMP9 and / or MMP2 (R&D Systems) was first activated with p- aminophenylmercuric acetate and this activated protease or equivalent amount of activating solution without the protease was used to digest or mock digest the fusion protein for 1 hr, 2hr, 4 hr and overnight (18-22 hr) at 37 C. Cleavage assays are set up in TCNB buffer: 50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% Brij-35 (w / v), pH 7.5. Digested protein was aliquoted and stored at -80°C prior to testing. Aliquots of digests were subsequently analyzed by SDS-PAGE followed by Western blotting to evaluate the extent of cleavage. Digests were also assessed in functional assays such as CTLL-2 proliferation and HEK-Blue Interleukin reporter assays. As shown in Figs. 2A-E, essentially complete cleavage by MMP9 protease of the fusion proteins with functional site is seen after overnight incubation. In contrast, proteins containing a scrambled MMP cleavage site are not cut (Fig 2E). Example 4: Detection of mouse IL-2 / IL-2Ra fusion proteins and mouse IL-2 by ELISA

[00267] We developed an ELISA assay to detect and quantify fusion proteins comprising IL-2 and IL-2Ra moieties. Wells of a 96-well plate are coated overnight with 100uL of a rat anti-mouse IL-2 monoclonal antibody (JES6-1A12; ThermoFisher) at 1 mg / ml in PBS. After washing, wells are blocked with TBS / 0.05% Tween 20 / 1% BSA, then fusion proteins and / or unknown biological samples are added for 1hr at room temperature. After washing, an anti-mouse IL-2Ra biotin-labelled detection antibody (BAF2438, R&D systems) is added and binding is detected using Ultra Strepavidin HRP (ThermoFisher). The ELISA plate was developed by adding the chromogenic tetramethylbenzidine substrate (Ultra TMB, ThermoFisher). The reaction is stopped by addition of 0.5M H2S04 and the absorbance is read at 450-650 nm.

[00268] We developed a second ELISA assay to detect and quantify mouse IL-2 and / or fusion proteins comprising an IL-2 moiety. Wells of a 96-well plate are coated overnight with 100uL of a rat anti-mouse IL-2 monoclonal antibody (JES6-1A12; ThermoFisher) at 1 mg / ml in PBS. After washing, wells are blocked with TBS / 0.05% Tween 20 / 1% BSA, then fusion proteins and / or unknown biological samples are added for 1hr at room temperature. After washing, an anti-mouse IL-2 biotin-labelled detection antibody (JES6-5H4, ThermoFisher) is added and binding is detected using Ultra Strepavidin HRP (ThermoFisher). The ELISA plate was developed by adding the chromogenic tetramethylbenzidine substrate (Ultra TMB, ThermoFisher). The reaction is stopped by addition of 0.5M H2S04 and the absorbance is read at 450-650 nm. This assay is able to simultaneously detect both free mouse IL-2 as well as mouse IL-2 in the context of pro-drug fusion proteins. Example 5 : IL-2, IL-2Ra,6xHistidine and Fc Immunoblot analyses

[00269] Untreated and digested fusion proteins were evaluated for cleavage products by Western blot. The following monoclonal antibodies were used: rat anti-mouse IL-2 antibody (JES6-1A12; ThermoFisher), goat anti-mouse IL-2 polyclonal antibody (AF-402- NA; R&D systems), mouse anti-6xHis monoclonal antibody (MA1-21315, ThermoFisher), Anti-mIgG Fc HRP conjugated (ThermoFisher cat# A16084), and Anti-human IL2 antibody (Invitrogen, cat# MAS5-17097, mouse IgG1). Detection was performed using either a goat anti-rat HRP-conjugated antibody, Donkey Anti-goat HRP-conjugated antibody or Goat Anti-mouse HRP conjugated (Jackson Immuno Research, West Grove, PA) and developed using the SuperSignal West Femto Maximum sensitivity detection reagent (ThermoFisher) following the manufacturer's recommendations. Example 6: IL-2 functional cell-based assays

[00270] IL-2 activity was measured using either CTLL-2 cells (ATCC) or the reporter cell line HEK Blue IL2 (Invivogen, San Diego). In brief, for the CTLL-2 assay a titration of untreated and digested samples is added to 40 000 CTLL-2 cells per well in 100 ul medium in a 96-well plate and incubated at 37C in 5% CO2 for 18-22 hr. At the end of this period, 50ug / well Thiazolyl Blue Tetrazolium Bromide (MTT) (Sigma-Aldrich) was added and the plate was incubated for 5 hr at 37C in 5% CO2. Cells were lysed with 100 ul / well 10% SDS (Sigma) acidified with HCI, incubated at 37C for 4hr, and absorbance was read at 570 nm. Recombinant human or mouse IL-2 (Peprotech and R&D systems respectively) was used as a positive control. Figs. 3A-B, 3K-L and 3N-P show examples of untreated and digested fusion proteins evaluated in CTLL-2 proliferation assay.

[00271] HEK-Blue™ IL-2 cells are specifically designed to monitor the activation of the JAK-STAT pathway induced by IL-2. Indeed, stimulation with human or murine IL-2 triggers the JAK / STATS pathway and induces secreted embryonic alkaline phosphatase (SEAP) production. SEAP can be readily monitored when using QUANTI-Blue™, a SEAP detection medium. These cells respond to human and murine IL-2. For the HEK Blue assay, untreated and digested samples are titrated and added to 50 000 HEK Blue cells per well in 200 ul medium in a 96-well plate and incubated at 37C in 5% CO2 for 20— 24 hr. The following day, levels of SEAP are measured by adding 20uL of cell supernatant to QuantiBlue reagent, followed by 1-3h incubation at 37C and reading absorbance at 630nm. Figures 3C-J, 3Q-Y and Table 5B-5C show results obtained from IL2 fusion proteins tested in HEK Blue IL2 assay.

[00272] Table 5B. Construct F +MMP | -MMP cavomars | 505" | 2 | orp pmmaencs ConstructE | 0.0073 | 0.103 [4 ConstructL | 0.0061 | 0.0453 | 73 ConstructK | 0.0055 | 0.0933 | 17 Construct] | 0.0059 | 0.1264 | 21 Construct F | 0.0078 2 Construct] | 0.0074 | 03165 | 43

[00273] Table 5C. +MMP | -MMP | | CANDIDATE | EC50 EC50 (nM) (nM) Construct AA 0.01088 | 0.4423 Construct Y 0.0109 1.232 Construct CC 0.013 0.66 Construct EE 0.0066 [118 Construct GG 0.0072 0.14 Construct I 0.009 0.489 Construct AAA | 0.0089 0.23 Construct DDD | 0.0094 0.181 Construct EEE | 0.0069 0.149

[00274] Aggregation, stability, and homogeneity of Construct E, Construct M, and Construct N were compared using Coomassie-stained SDS-PAGE analysis (Fig. 3M). Construct M and Construct N showed decreased aggregation and greater stability and homogeneity, consistent with there being an improvement resulting from deletion of O- glycosylation sites. Example 7: In vitro serum stability of fusion protein

[00275] Construct B was incubated at 37C for up to 72h with serum collected from 8 weeks old female C57BL / 6 naive and MC38 tumor bearing mice respectively (n=2 per serum type, tumor volume > 3000mm3 at time of collection), in order to examine both non-specific cleavage as well as MMP-specific off-target cleavage. Samples were collected at Oh, 4h, 8h, 24h, 48h and 72h and the intact non-MMP cleaved fusion protein was quantified using an in- house developed sandwich ELISA. Results (see Fig. 4) show that the levels of fusion protein are stable in both serum types, indicating 1) a lack of off-target protein cleavage up to 72 hrs and 2) no active MMPs in circulation. Example 8: Pharmacokinetic evaluation of fusion protein in non-tumor bearing mice

[00276] For this study, C57BL / 6 8-10 weeks old female mice (Jackson Labs) were assigned to different groups (3 mice per treatment group). Mice received a single dose of fusion protein via IV injection (3,5mg / kg). 3 mice / group / time point were bled at the following time points: pre-dose (Oh), 10 min, 30 min, 1h, 4h, 12h, 24h, 48h, 72h, 96h and 120h post dose. Blood samples were collected in Eppendorf tubes and processed to serum, then stored at -80C until testing. Samples were then evaluated by ELISA to quantify intact fusion protein levels. Mean serum concentrations of fusion protein were plotted over time and PK parameters were calculated using WinNonlin 7.0 (non-compartmental model) as shown in Fig 5. Example 9: In vivo efficacy of fusion proteins in syngeneic MC38 colorectal cancer model a. Intra-tumoral injection of Construct A

[00277] Pilot PK data indicates that Construct A is rapidly cleared from circulation (~ 30-fold drop in serum levels within 30 min of IV injection). This is common for small therapeutic proteins whose molecular weight is below the renal glomerular filtration cut-off of ~ 60-70kDa. Hence, we reasoned this fusion protein was not amenable to systemic IV dosing for our POC in vivo efficacy study. Instead, we chose a direct intra-tumoral delivery design with 3 arms: vehicle, recombinant human IL-2 (r hIL2) and Construct A (n=3 mice / arm). IL-2 has previously demonstrated anti-tumor activity in a variety of syngeneic models by direct tumor injection, and based on this data, we selected to dose r hIL2 at Sug / day (equivalent to 50 000 U / day. Construct A was dosed at 70ug / day, which represents a 5 molar excess compared to recombinant IL-2 to compensate for the EC50 difference observed in the CTLL-2 assay. All agents and vehicle were injected daily into subcutaneous MC38 tumor mass (~200mm?’ in size upon initiation of dosing) growing on the flank of C57BL / 6 mice for 12 days with 2-day holiday after first 5 injections (total of 10 injections). Tumors and body weights were measured twice a week for the duration of the study. Tumor volumes were calculated using the following equation: (longest diameter * shortest diameter?) / 2. As shown in Fig.6A, remarkable anti-tumor activity was observed for Construct A. Indeed, a complete elimination of tumor was observed in Construct A treatment group while no tumor regression was observed in either vehicle or r hIL2 treatment groups. When ‘cured’ Construct A-treated mice were re-inoculated with MC38 tumor cells (10° cells on opposite flank) on Day 40, no tumor mass was established a month after re-challenge suggesting the existence of a ‘memory’ immune response in these mice (fig. 6B). b. Systemic IV injection of Construct B

[00278] The objective of this study is to evaluate efficacy of Construct B in the MC38- bearing female C57BL / 6 mice. For this study, C57BL / 6 6-8 weeks old female mice (Jackson Labs) were subcutaneously inoculated with MC38 cells (10° cells / animal), and when the average tumor volume reached about 80 mm?>, animals were randomized into 2 groups based on tumor volumes (8 mice per treatment group). Animals were dosed according to the following study design: [ Group | Treatment N | Dose Dosing Frequency | Dose Level | Dose Route & Duration (mpk) Volume (ul) ta Vehicle Control [8 | IV Q3D for 21D NA 100 2 Construct B 8 [IV Q3D for 21D 10 100

[00279] Mice were dosed over a 21 day period then further observed for an additional week. Tumors and body weights were measured twice a week for the duration of the study. Tumor volumes were calculated using the following equation: (longest diameter * shortest diameter?) / 2. Fig.7 shows the mean tumor volume over time for both groups (Fig. 7a) and individual body weights of vehicle and treated (Fig.7B) animals.

[00280] The results showed excellent efficacy for the treatment group, with 92% inhibition of tumor growth at Day 21, while no adverse effect was observed. Remarkably, out of 8 cases, 3 complete tumor regressions (‘cures’) occurred in the colorectal cancer syngeneic setting Example 10: Evaluation of immune cell populations by immunohistochemistry (IHC) in MC38 colorectal cancer samples

[00281] The objective of this study is to evaluate immune targets in tumor samples by THC. See below for details: CD4 + Foxp3 double immunofluorescence staining CD8, CD25, CD3, CD4 and CD335 single IHC staining

[00282] Note that prior to performing IHC, H&E staining was ran for all control and Construct B treated tumors to check the tissue quality.

[00283] 7 tumor samples were selected from the systemic in vivo efficacy study and formalin-fixed paraffin embedded (FFPE) blocks were prepared following standard embedding process. Model type: MC38 Group Treatment Number of FFPE blocks | 1 Vehicle, IV, Q3D for 21 days | 4 |2 Construct B, 10 mg / kg, IV, Q3D for 21 days | 3

[00284] The following antibodies were used: | cpa | ell |25220 | Rabbit IgG mAb | Mouse Signaling | Foxes | Cell . | 12653 | Rabbit IgG mAb | Mouse Signaling | cps | ell . | 98941 | Rabbit 1G mAb | Mouse Signaling CD25 | cps | Sell | 99940 | Rabbit IgG mAb | Mouse Signaling R&D AF2225- | CD335 aE | Goat IgG pAb Antibody | Company | Cat# Type Reactivit) | cps Coll ine | 25229 | Rabbit 1sG mAb | Mouse Signaling | Foxp3 can ing | 12653 | Rabbit IgG mAb | Mouse ignaling | cps Cell 1 gg041 | Rabbit 1gG mAb | Mouse Signaling CD25 abcam ab227834 | Rabbit IgG mAb | Mouse | cps Cell 199040 | Rabbit 1gG mAb | Mouse Signaling R&D AF2225- | CD335 SP | Goat IgG pAb Mouse | Leica | DS9800 Ta | Goat IgG pAb | Mouse Anti-rabbit Poly-HRP-IgG (<25pg / mL) containing 10% DS9800 | (v / v) animal serum in tris- buffered saline / 0.09% ProClin™ | 950 (ready-to-use Anti-goat Poly-HRP-IgG MP-7405 | (<25pug / mL) containing 10% v / v) animal serum in tris- Bond Polymer ; Refine Lien Detection ImmPRESS HRP Anti- | Vector Goat buffered saline (ready-to-use) and House serum (2.5% | Isotype control Cell Signaling Je | PerkinElmer | NEL742001KT Rabbit (DAIE) mAb IgG TRITC TSA(Red) FITC . | TSA (Green) | PerkinElmer | NEL741001KT Fluorescent T | double stainin, Fluorescent T | double stainin,

[00285] FFPE blocks were sectioned with a manual rotary microtome (4 um thickness / section) and optimized IHC assay protocols for all the antibodies were used. All stained sections were scanned with NanoZoomer-S60 Image system with 40x magnification. High resolution picture for whole section was generated and further analyzed.

[00286] Scoring Method: All the images were analyzed with HALO™ Image Analysis platform. The whole slide image was analyzed and necrosis area was excluded. The total cells and IHC positive cells were counted. IHC score is presented as the ratio of the positive cell counts against the total cell numbers within whole section and shown in Fig 8. Results show that there is a significant increase in tumor infiltrating immune cells post Construct B treatment. Example 11: In vivo MMP activity evaluation in diverse syngeneic tumor models.

[00287] We assessed the degree of MMP activity in the models in vivo utilizing an MMP-activatable fluorescent probe, MMPSense 680™. This probe is optically silent in its intact state and becomes highly fluorescent following MMP-mediated cleavage and is designed to be used as a real-time in vivo imaging tool (Perkin Elmer). Following a single dose IV injection of the probe to tumor-bearing mice, fluorescent images were captured over 6 days and the fluorescence intensity in tumor area, which is directly proportional to MMP activity present, was quantified (Figure 9). All models showed intrinsically different levels of MMP activity. Example 12: In vivo efficacy of Construct B in diverse syngeneic tumor models.

[00288] For the efficacy studies, C57BL / 6 or BALB / c mice were subcutaneously inoculated with malignant cells and when the average tumor volume reached on average 90 mm?, animals were randomized into 2 groups based on tumor volumes (n=10 mice per treatment group). Mice were dosed intravenously every 3 days (Q3D) at 20mg / kg. Tumors, body weights and clinical observations were measured / collected twice a week for the duration of the study. Tumor volume is shown in FIGs 10A-D, 11A, 124, and 13B-C. Robust anti-tumor activity was observed in several models, notably 49% tumor growth inhibition (TGI) was observed at D12 in the BI6F10 melanoma model and 58% tumor TGI at Day 10 in the aggressive Ras / Myc transformed RM-1 prostate cancer model (Figure 10C-D and Table 6). Notably, no signs of toxicity, including body weight loss and elevated levels of liver and / or kidney enzymes, were noted and clinical observations were normal in these models. Liver and kidney enzyme results corresponding to FIGs 11A and 12A are shown in FIGs 11B-D and 12B-D, respectively.

[00289] Table 6. Cancer i Dosing Max type | strain | Model Regimen TGI % T test | MMP score handle do Sdiildiiais dt tt id ™ Stl l ah SH Ub el bl Sia Bi SS SC i dia Eos i a Ei de 11B-D and 12B-D, respectively.

[00289] Table 6. Cancer 3 Dosing Max type | strain | Model Regimen TGI % T test | MMP 20mpk, IV | 43 _ | Breast | BALB / c EMTO6 | (a) 0 | P=0.0006 | HIGH 20mpk, IV | 49 _ | Melanoma | cs7BLIS | BI6F10 | ou oi2) | P=0.0004 | Low 20mpk, IV | 46 P= | colorectal | BALB / c CT-26 | Q3D | (D13) | 00114 | MED / ] 1 EE 1 20mpk, IV | 46 P- | colorectal | BALB / c | e126 = | Hel | MED / HIGH 1ompk, IV | 92 P< | colorectal | cs7BLIs | MC-38 Fi 1% fom | MED 20mpk, IV | 58 P< NOT | prostate | cs7BLG | RMI bi Zn om Fo ns P values represent unpaired t test (graphpad prism) between vehicle and Construct B groups on Day of max TGIL.

[00290] The difference in efficacy between MC38 and B16F10 models may in part be due to the lower MMP activity measured in B16F 10 tumors, resulting in less functional IL-2 being released in the TME relative to the MC38 setting (Figure 13A). Example 13: Next generation retention linker peptide binding assay

[00291] A series of peptides comprising an MMP cleavable site with or without the addition of a tumor retention sequence were synthesized and conjugated to the fluorophore EDANS (5-((2-Aminoethyl)amino)naphthalene-1-sulfonic acid) (custom synthesis, ThermoFisher). Table 7 shows the list of peptides. These peptides were then tested for their ability to bind ECM proteins such as heparin, fibronectin and collagen which are found in abundance in the tumor stroma.

[00292] Table 7. SEQ ID NO Sequence Target of retention motif’ 901 l66GSGGGGPLGVRG-* None (1% gen) 902 locGHHPHGPLGVRG-* fpr dependent heparin 903 lovrigrRKKERMKE T-* heparin boa FHRRIKAGPLGVRG-* heparin 907 [sGGsGGGPAALIGG* None (1% gen) 913 oe WSHWGPLGVRG-* fp dependent fibronectin 914 [ L WVLPKGPLGVRG-* |cotiagen v 915 [6GGSGLHERHLNNN-* I ollagen I Underlining indicates MMP cleavage site. Bold italics indicates retention motif when present. -* represents Edans fluorophore conjugated to peptide.

[00293] All binding assays were set up in 10mM TrisHCI pH 7.5 and / or 10mM TrisHCI pH 6. Peptides (20uM) were incubated on a shaker for 2hrs at room temperature with agarose cross-linked to heparin or control agarose beads (Sigma and Pierce respectively). The beads were then washed 4 times and resuspended in 100uL of binding buffer in a black 96- well plate. Peptide binding was quantified by measuring the fluorescence of samples using excitation / emission spectra of EDANS (Ex 340 / Em 490). Fig 14A shows that several next generation MMP linker peptides containing heparin binding motifs bind to the heparin- agarose beads while 1% generation MMP linkers lacking these retention sequences do not. One such peptide displays enhanced binding to heparin at pH6 (the pH of tumors) vs pH 7.5 (pH of normal tissues) (Fig 14B).

[00294] For fibronectin and collagen binding assays, streptavidin coupled magnetic beads (Mag Sepharose, Cytiva and Dynabeads, ThermoFisher, respectively) were first incubated with biotin-labelled fibronectin (Cytoskeleton) or biotin-labelled collagen IV (Prospec) for 1 Hr with gentle shaking. Following multiple washes, the ECM-coated beads were then incubated with Edans Peptides (20uM) for 2 hours at room temperature with shaking in neutral or acidic binding buffer. Beads were then washed and resuspended in 100uL of binding buffer in a black 96-well plate. Peptide binding was quantified by measuring the fluorescence of samples using excitation / emission spectra of EDANS (Ex 340 / Em 490). Fig 14D shows that peptide 13 is able to bind fibronectin and displays enhanced binding at pH6 (the pH of tumors) vs pH 7.5 (pH of normal tissues). Fig 14F shows that peptide 14 strongly binds collagen IV while peptide 15 binds to a lesser extent. Example 14: Next generation tumor retention IL-2 fusion protein binding assays

[00295] A series of IL-2 fusion proteins comprising tumor retention sequences in the linker regions were designed and successfully manufactured (Table 3 and Figs 1C-D). These proteins were then tested for their ability to bind ECM proteins such as heparin, fibronectin and collagen which are found in abundance in the tumor stroma.

[00296] 96-well plates were coated with 25 ug / mL of Heparin-BSA conjugate (provided by Dr. Mueller, Boerhinger Ingelheim) or control BSA for 18-22h at room temperature on shaker (350rpm). After washing, wells are blocked with PBS-0.05% Tween 20 / 1% BSA for 90 min, then fusion proteins are titrated in 1% BSA / PBS-0.05% Tween 20 pH 7.5 and / or pH 6 and added for 2hr at room temperature with shaking. After washing, an anti-mouse IL-2 biotin-labelled detection antibody (JES6-5H4, ThermoFisher) is added and binding is detected using Ultra Strepavidin HRP (ThermoFisher). The plate was developed by adding the chromogenic tetramethylbenzidine substrate (Ultra TMB, ThermoFisher). The reaction is stopped by addition of 0.5M H2S04 and the absorbance is read at 450-650 nm. IL-2 fusion variants Construct Y and Construct CC at acidic pH bind heparin in dose- dependent manner and with higher affinity than Construct B (Fig 14C). Strikingly, Construct CC preferentially binds heparin at acidic pH and shows the most robust binding with EC50 ~ 10nM, while Construct B’s binding is much weaker with > 100-fold higher EC50 value.

[00297] A similar plate-based assay was developed to interrogate binding of IL-2 fusion variants to fibronectin. 96-well plates were coated with 4 ug / mL of fibronectin (Sigma) or control BSA for 18-22h at room temperature on shaker (350rpm). After washing, wells are blocked with protein-free blocking buffer (Pierce) for 90 min, then fusion proteins are titrated in blocking buffer-0.1% Tween 20 pH 7.5 and / or pH 6 and added for 1hr at room temperature with shaking. After washing, an anti-mouse IL-2 biotin-labelled detection antibody (JES6-5H4, ThermoFisher) is added and binding is detected using Ultra Streptavidin HRP (ThermoFisher). The plate was developed by adding the chromogenic tetramethylbenzidine substrate (Ultra TMB, ThermoFisher). The reaction is stopped by addition of 0.5M H2S04 and the absorbance is read at 450-650 nm. Construct EE preferentially binds fibronectin at acidic pH and shows dose-dependent binding, while no binding is observed at pH 7.5 (Fig 14E). No significant binding of Construct B is seen in either neutral or acidic conditions.

[00298] To test binding to collagen, a pulldown assay using agarose cross-linked to collagen (Sigma) was performed. IL-2 fusion proteins were incubated with collagen-agarose or control agarose beads for 18-22h at 4C with gentle rotation in 1% BSA / PBS-0.05% Tween 20. After washing, proteins bound to the beads were eluted by resuspending beads in SDS sample buffer (Life Technologies). Bound proteins were then separated by SDS-PAGE on 4-12% BisTris gradient gel followed by immunoblotting with goat anti-mouse IL-2 polyclonal antibody (AF-402-NA; R&D systems). Donkey Anti-goat HRP-conjugated antibody was used for detection (Jackson Immuno Research, West Grove, PA) and the blot was developed using the SuperSignal West Femto Maximum sensitivity detection reagent (ThermoFisher) following the manufacturer’s recommendations. The blot image is shown in Fig 14G. Construct GG and Construct II were specifically bound by collagen-agarose beads, while no IL-2 fusion protein bound the control agarose beads. Quantitation of the blot using Bright imaging system (Invitrogen), shows that although the fraction of bound Construct GG and Construct II was low (< 1% of input), it was 2.5 and 1.4-fold higher than the fraction of bound Construct B (Table 8).

[00299] Table 8. [om Normalized finput (2%) Bound loz 3amecsian ound (% input) 30s 0.3% I 191 0.7% bs Construct IB 16707 Construct GG ®] r Construct I =o bar [0.4% La Example 15: Next generation retention linker IL-2 fusion proteins show greater retention in tumor in vivo.

[00300] We assessed the levels of IL-2 fusion proteins present in tumors in vivo by utilizing fluorescently labelled proteins and real-time whole-body imaging. Non-cleavable Construct GGG and Construct DD were conjugated to Dylight 650 probe according to the manufacturers protocol (Dylight 650 Antibody labeling kit, ThermoFisher). We confirmed the conjugation did not significantly alter the proteins’ binding to heparin. BALB / c mice were subcutaneously inoculated with EMT6 breast cancer syngeneic model and when the average tumor volume reached 240 mm?, animals were randomized into 3 groups based on tumor volumes (n=2 mice per treatment group). Table below shows study design: Spe Group Treatment N Dose Dosing Dose Level | Dose Route Frequency | (mg / kg) Volume & Duration mL / k 1 2 IV Once NA 4 2 2 IV Once 3 4 GGG-DY650 En Construct DD- | 2 v Once 8 4 2 | GGG-DY650 Construct DD- | 2 DY650

[00301] Following a single dose of the labeled IL-2 fusion proteins to tumor-bearing mice, fluorescent images (excitation 640 / emission 680 consistent with Dylight 650 probe ex / em spectra) were captured over 96 hrs on an IVIS system (PerkinElmer, IVIS Lumina Series III) and are shown in Figure 15A. The fluorescence intensity in tumor area was quantified across the groups, average background tumor fluorescence (group 1) was subtracted from group 2 and 3 values at each time-point, and data was normalized to the initial fluorescence intensity of same amount of each labeled protein. Figure 15B shows that the tumor-associated fluorescence with group 3 is roughly 2-fold higher than that of group 2 at each of the time- points tested. This signifies next generation retention linker Construct DD accumulates and is retained in tumors at 2-fold higher levels compared to 1! generation IL-2 fusion protein Construct GGG. Example 16: Next generation retention MMP-Linker leads to increased levels of drug and IL2 in tumors and serum in vivo.

[00302] We quantified levels of full-length IL2-IL2Ra fusion proteins and IL-2 in tumor samples collected during pre-clinical efficacy studies comparing Construct B and retention linker IL-2 fusion drugs (see example 17).

[00303] Tumors (n=3 per group) were collected 24h after the last dose injection, flash frozen and stored at -80C until further processing. Tumor lysates were generated using tissue extraction reagent (ThermoFisher) supplemented with protease and phosphatase inhibitors and standard techniques and protein concentrations were determined using the BCA assay (Pierce).

[00304] Lysates were tested with in-house ELISAs to measure full-length IL-2 fusion proteins (IL-2 capture / IL-2Ra detection) and IL-2 fusion proteins + free IL-2 (IL-2 capture / IL-2 detection). Free IL-2 levels in tumor were calculated by subtracting drug levels from the drug + IL-2 data set. Results were normalized to 1 mg of tumor lysate and mean values are shown in Figs 15 C-H. Levels of Construct CC (20mg / kg dose) in tumor are roughly 3-fold higher compared to Construct B levels, despite Construct B being dosed at 40mg / kg (Fig C). Drug level comparison in samples from the 10mg / kg dosing cohort shows highest levels present in collagen binding Construct GG treated tumors (Fig 15F). This indicates that retention linker technology may lead to a robust increase in drug amounts in tumor in vivo. Likewise, IL-2 levels in Construct CC, Construct GG and Construct II treated tumors are elevated compared to Construct B treated tumors (Fig 15E / H). This implies that next generation retention linker technology is able to retain in TME both full-length drug and released IL-2 post-cleavage.

[00305] The equivalent serum samples (n=3 per group) were also tested with in-house ELISAs to quantify full-length IL-2 fusion drugs and results are shown in fig 15I-K. 24 hrs after dosing, circulating drug levels of Construct B (40mg / kg) and Construct CC (20mg / kg) are roughly similar despite the dosing difference, whilst in the 10mg / kg cohort, Construct GG and Construct II drug levels in serum are roughly 5-fold and 3-fold higher than Construct B serum levels (Fig 15J). Additional serum samples collected at Day 17 (Construct B 20mg / kg) and Day 21 (Construct Y 20mg / kg), 4 days and 8 days respectively after the last IV injection, were assayed for full-length IL-2 fusion drug. Fig. 15 K shows that Construct Y drug levels in circulation are strikingly more than 10-fold higher than Construct B despite serum being collected 4 days later. Collectively, these data indicate retention linker technology leads to increased levels of drug in circulation. Example 17: In vivo efficacy of retention linker IL-2 drugs in B16F10 syngeneic model

[00306] In a first efficacy study, C57BL / 6 mice were subcutaneously inoculated with B16F10 melanoma cells and when the average tumor volume reached on average 70-90 mm?, animals were randomized into 5 groups based on tumor volumes (n=6 mice per treatment group). Mice were dosed intravenously every 3 days (Q3D) for a total of 5 doses according to following design: Group | Treatment N | Dose _ Q3D for 14 ! | 1 reg | 6 | v days (5 NA | 4 Vehicle doses) Moll Lid | 2 | Construct B | 6 | v | days (5 | 20 | 4 NOLL PLA | 3 | Construct B | 6 | v | days (5 | 40 | 8 MDL ly | 4 | Construct ¥ | 6 [v | days (5 | 2 | 4.45 Construct i fold | |'s | So | 6 | v | days 5 20 5 Dosing Dose Level Dose Frequency (mg / kg) Volume & Duration mL / k Q3D for 14 days (5 NA | 4 doses; Q3D for 14 days (5 | 20 | 4 doses; Q3D for 14 days (5 | 40 | 8 doses, Q3D for 14 days (5 | 20 | 445 doses Q3D for 14 days (5 | 20 | 5 doses

[00307] Tumor volumes were measured twice a week for the duration of the study. Mean tumor volume is shown in FIGs 16A. Anti-tumor activity was observed in all treatment groups, however the most robust tumor growth inhibition (TGI) was observed in the retention linker drugs Construct Y and Construct CC (77 and 78% respectively) compared to ~ 60% TGI in Construct B treated groups (regardless of dose, Table 9).

[00308] Table 9. TGI (%) | Group | Drug | Dose | ste) | 3a | P value |D13 | 2 | ha | 20mg / kg pr.43 p-0002 Construct 3 20mg / kg construct | 3 | - | 40mg / kg [58.44 p-0019 Construct 7 40mg / kg construct | 4 | o | 20mg / kg [76.59 o.001 Construct v 20mg / kg construct | | - | 20mg / kg [77.84 o.0002 Construct 20melk im; cc 8 P values represent unpaired t test (graphpad prism) between vehicle and Test article groups on Day 13.

[00309] In a second efficacy study in the same model, C57BL / 6 mice were subcutaneously inoculated with B16F10 melanoma cells and when the average tumor volume reached on average 70-90 mm? animals were randomized into 5 groups based on tumor volumes (n=6 mice per treatment group). Mice were dosed intravenously every 3 days (Q3D) for a total of 5 doses according to following design: Dose | Group | Treatment | N | Route | 1 | PBS-Vehicle | 6 | v days (5 NA | 5 | 2 | Construct B oo . [6 |v Jase 10s | 3 | Construct EE | 6 v TE I Q3D for 14 | 10 5 | 4 | Construct GG | 6 | v days 5 , Ty 5 fomman [sv |CmEle TTS Dosing Dose Level Dose Frequency (mg / kg) Volume & Duration mL / k; Q3D for 14 days (5 NA | 5 doses Q3D for 14 days (5 10 | 5 doses Q3D for 14 | 10 3 days (5 doses Q3D for 14 | 10 5 days (5 doses Q3D for 14 | 10 5 days (5 doses’

[00310] Tumor volumes were measured twice a week for the duration of the study up until Day 20, 7 days following the fifth dose. On Day 20, mice received an additional dose of drug, animals were sacrificed 24hrs later and tissues and blood (processed to serum) were collected and stored at -80C for further testing. Mean tumor volume is shown in FIGs 16B. Only modest anti-tumor activity was observed with Construct B at 10mg / kg in this aggressive model (27% TGI Day 15, Table 10). Strikingly, at equivalent dosage all retention linker IL-2 fusion drugs showed superior TGI (Table 10). In particular, collagen binding drugs Construct GG and Construct II (10mg / kg dosing) showed robust tumor control similar to what was previously observed for Construct B at twice higher dose (57% TGI Day 15 Table 10 compared to 61% TGI Day 13 Table 9 respectively). Furthermore, after a dosing holiday of 7 days Construct B showed diminished efficacy whilst all retention linker drugs maintained similar levels of tumor control at Day 20. Collectively, Figs 16A-B demonstrate that retention linker IL-2 drugs have superior anti-tumor efficacy in a pre-clinical melanoma model. This is most likely due to the higher levels of both circulating drugs in serum and resident drug in TME, which can exert prolonged anti-tumor activity even after an extended dosing holiday.

[00311] Table 10. Group | Drug Dose TGI (%)D15 | TGI (%) D20 [12.02 7.61 lea.70 [5 [Construct IT | 10mg / kg [57.68 68.52 2 Construct B | 10mg / kg [27.43 3 Construct EE | 10mg / kg [39.32 4 Construct GG | 10mg / kg [57.18 5 Construct IT | 10mg / kg [57.68 Example 18: IFN-y levels in tumor samples

[00312] IFN-y cytokine levels in tumor lysates (n=3 per group) were measured using a Luminex kit according to manufacturer’s protocol (Invitrogen). Results were normalized to 1 mg of lysate and mean values are shown in Fig 17A / B. Elevated levels of IFN-y were measured in all retention linker IL-2 drug treated tumors compared to Construct B treated tumors. IFN-y was undetectable in vehicle treated tumors.

Claims

We claim: L, A protease-activated pro-cytokine comprising: a cytokine polypeptide sequence; a inhibitory polypeptide sequence capable of blocking an activity of the cytokine polypeptide sequence; a linker between the cytokine polypeptide sequence and the inhibitory polypeptide sequence, the linker comprising a protease-cleavable polypeptide sequence; and a targeting sequence, wherein the targeting sequence is configured to bind an extracellular matrix component, an integrin, or a syndecan; or is configured to bind, in a pH-sensitive manner, an extracellular matrix component, IgB (CD79b), an integrin, a cadherin, a heparan sulfate proteoglycan, a syndecan, or a fibronectin; or the targeting sequence comprises the sequence of any one of SEQ ID NOs: 180-662 or a variant having one or two mismatches relative to the sequence of any one of SEQ ID NOs: 180-662. z The protease-activated pro-cytokine of the immediately preceding claim, further comprising a pharmacokinetic modulator.

3. The protease-activated pro-cytokine of the immediately preceding claim, wherein the pharmacokinetic modulator comprises an immunoglobulin constant domain.

4. The protease-activated pro-cytokine of claim 2, wherein the pharmacokinetic modulator comprises an immunoglobulin Fc region.

3. The protease-activated pro-cytokine of the immediately preceding claim, wherein the immunoglobulin is a human immunoglobulin.

6. The protease-activated pro-cytokine of any one of claims 4-5, wherein the immunoglobulin is IgG.

7. The protease-activated pro-cytokine of the immediately preceding claim, wherein the IgG is IgG1, 1gG2, IgG3, or IgG4.

8. The protease-activated pro-cytokine of claim 2, wherein the pharmacokinetic modulator comprises an albumin.

9. The protease-activated pro-cytokine of the immediately preceding claim, wherein the albumin is a serum albumin.

10. The protease-activated pro-cytokine of any one of claims 8-9, wherein the albumin is a human albumin.

11. The protease-activated pro-cytokine of claim 2, wherein the pharmacokinetic modulator comprises PEG.

12. The protease-activated pro-cytokine of claim 2, wherein the pharmacokinetic modulator comprises XTEN.

13. The protease-activated pro-cytokine of claim 2, wherein the pharmacokinetic modulator comprises CTP.

14. The protease-activated pro-cytokine of any one of claims 2-13, wherein the protease-cleavable polypeptide sequence is between the cytokine polypeptide sequence and the pharmacokinetic modulator.

15. The protease-activated pro-cytokine of any one of claims 2-13, wherein the pharmacokinetic modulator is between the cytokine polypeptide sequence and the protease- cleavable polypeptide sequence.

16. The protease-activated pro-cytokine of any one of the preceding claims, comprising a plurality of protease-cleavable polypeptide sequences.

17. The protease-activated pro-cytokine of the immediately preceding claim, wherein the cytokine polypeptide sequence is flanked by protease cleavable polypeptide sequences.

18. The protease-activated pro-cytokine of the immediately preceding claim, having the structure PM-CL-CY-CL-IN (from N- to C-terminus or from C- to N-terminus), where PM is the pharmacokinetic modulator, each CL independently is a protease-cleavable polypeptide sequence, CY is the cytokine polypeptide sequence, and IN is the inhibitory polypeptide sequence.

19. The protease-activated pro-cytokine of any one of the preceding claims, comprising the targeting sequence, wherein the targeting sequence is between the cytokine polypeptide sequence and the protease-cleavable polypeptide sequence or one of the protease-cleavable polypeptide sequences.

20. The protease-activated pro-cytokine of any one of the preceding claims, wherein the cytokine polypeptide sequence comprises a modification to prevent disulfide bond formation, and optionally otherwise comprises wild-type sequence.

21. The protease-activated pro-cytokine of any one of the preceding claims, wherein the cytokine polypeptide sequence has at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of a wild-type cytokine polypeptide sequence or to a cytokine polypeptide sequence in Table 1.

22. The protease-activated pro-cytokine of the immediately preceding claim, wherein the cytokine polypeptide sequence is a wild-type cytokine polypeptide sequence.

23. The protease-activated pro-cytokine of any one of the preceding claims, wherein the cytokine polypeptide sequence is a monomeric cytokine, or wherein the cytokine polypeptide sequence is a dimeric cytokine polypeptide sequence comprising monomers that are associated covalently (optionally via a polypeptide linker) or noncovalently.

24. The protease-activated pro-cytokine of any one of the preceding claims, wherein the inhibitory polypeptide sequence comprises a cytokine-binding domain.

25. The protease-activated pro-cytokine of the immediately preceding claim, wherein the cytokine-binding domain is a cytokine-binding domain of a cytokine receptor or a cytokine-binding domain of a fibronectin.

26. The protease-activated pro-cytokine of claim 24, wherein the cytokine-binding domain is an immunoglobulin cytokine-binding domain.

27. The protease-activated pro-cytokine of the immediately preceding claim, wherein the immunoglobulin cytokine-binding domain comprises a light chain variable domain and a heavy chain variable domain that bind the cytokine.

28. The protease-activated pro-cytokine of any one of claims 26-27, wherein the immunoglobulin cytokine-binding domain is an scFv, Fab, or VHH.

29. The protease-activated pro-cytokine of any one of the preceding claims, wherein the protease-cleavable polypeptide sequence is recognized by a metalloprotease, a serine protease, a cysteine protease, an aspartate protease, a threonine protease, a glutamate protease, a gelatinase, an asparagine peptide lyase, a cathepsin, a kallikrein, a plasmin, a collagenase, a hKl, a hK10, a hK 15, a stromelysin, a Factor Xa, a chymotrypsin-like protease, a trypsin-like protease, a elastase-like protease, a subtilisin-like protease, an actinidain, a bromelain, a calpain, a caspase, a Mir 1-CP, a papain, a HIV-1 protease, a HSV protease, a CMV protease, a chymosin, a renin, a pepsin, a matriptase, a legumain, a plasmepsin, a nepenthesin, a metalloexopeptidase, a metalloendopeptidase, an ADAM 10, an ADAM17, an ADAM 12, an urokinase plasminogen activator (uPA), an enterokinase, a prostate-specific target (PSA, hK3), an interleukin-1b converting enzyme, a thrombin, a FAP (FAP-a), a dipeptidyl peptidase, or dipeptidyl peptidase IV (DPPIV / CD26), a type II transmembrane serine protease (TTSP), a neutrophil elastase, a proteinase 3, a mast cell chymase, a mast cell tryptase, or a dipeptidyl peptidase.

30. The protease-activated pro-cytokine of any one of the preceding claims, wherein the protease-cleavable polypeptide sequence comprises the sequence of any one of SEQ ID NOs: 700-741, or a variant having one or two mismatches relative to the sequence of any one of SEQ ID NOs: 700-741.

31. The protease-activated pro-cytokine of any one of the preceding claims, wherein the protease-cleavable polypeptide sequence is recognized by a matrix metalloprotease.

32. The protease-activated pro-cytokine of any one of the preceding claims, wherein the protease-cleavable polypeptide sequence is recognized by MMP-1.

33. The protease-activated pro-cytokine of any one of the preceding claims, wherein the protease-cleavable polypeptide sequence is recognized by MMP-2.

34. The protease-activated pro-cytokine of any one of the preceding claims, wherein the protease-cleavable polypeptide sequence is recognized by MMP-3.

35. The protease-activated pro-cytokine of any one of the preceding claims, wherein the protease-cleavable polypeptide sequence is recognized by MMP-7.

36. The protease-activated pro-cytokine of any one of the preceding claims, wherein the protease-cleavable polypeptide sequence is recognized by MMP-8.

37. The protease-activated pro-cytokine of any one of the preceding claims, wherein the protease-cleavable polypeptide sequence is recognized by MMP-9.

38. The protease-activated pro-cytokine of any one of the preceding claims, wherein the protease-cleavable polypeptide sequence is recognized by MMP-12.

39. The protease-activated pro-cytokine of any one of the preceding claims, wherein the protease-cleavable polypeptide sequence is recognized by MMP-13.

40. The protease-activated pro-cytokine of any one of the preceding claims, wherein the protease-cleavable polypeptide sequence is recognized by MMP-14.

41. The protease-activated pro-cytokine of any one of the preceding claims, wherein the protease-cleavable polypeptide sequence is recognized by more than one MMP.

42. The protease-activated pro-cytokine of any one of the preceding claims, wherein the protease-cleavable polypeptide sequence is recognized by two, three, four, five, six, or seven of MMP-2, MMP-7, MMP-8, MMP-9, MMP-12, MMP-13, and MMP-14.

43. The protease-activated pro-cytokine of any one of the preceding claims, wherein the protease-cleavable polypeptide sequence comprises the sequence of any one of SEQ ID NOs: 80-94 or a variant sequence having one or two mismatches relative to the sequence of any one of SEQ ID NOs: 80-90.

44. The protease-activated pro-cytokine of the immediately preceding claim, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 80 or a variant sequence having one or two mismatches relative thereto.

45. The protease-activated pro-cytokine of any one of claims 1-43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 81 or a variant sequence having one or two mismatches relative thereto.

46. The protease-activated pro-cytokine of any one of claims 1-43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 82 or a variant sequence having one or two mismatches relative thereto.

47. The protease-activated pro-cytokine of any one of claims 1-43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 83 or a variant sequence having one or two mismatches relative thereto.

48. The protease-activated pro-cytokine of any one of claims 1-43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 84 or a variant sequence having one or two mismatches relative thereto.

49. The protease-activated pro-cytokine of any one of claims 1-43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 85 or a variant sequence having one or two mismatches relative thereto.

50. The protease-activated pro-cytokine of any one of claims 1-43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 86 or a variant sequence having one or two mismatches relative thereto. 51 The protease-activated pro-cytokine of any one of claims 1-43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 87 ora variant sequence having one or two mismatches relative thereto. 52: The protease-activated pro-cytokine of any one of claims 1-43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 88 or a variant sequence having one or two mismatches relative thereto.

53. The protease-activated pro-cytokine of any one of claims 1-43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 89 or a variant sequence having one or two mismatches relative thereto.

54. The protease-activated pro-cytokine of any one of claims 1-43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 90 or a variant sequence having one or two mismatches relative thereto.

55. The protease-activated pro-cytokine of any one of claims 1-43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO: 80-89 or 90.

56. The protease-activated pro-cytokine of any one of claims 1-43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO:

91.

57. The protease-activated pro-cytokine of any one of claims 1-43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO:

92.

58. The protease-activated pro-cytokine of any one of claims 1-43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO:

93.

59. The protease-activated pro-cytokine of any one of claims 1-43, wherein the protease-cleavable polypeptide sequence comprises the sequence of SEQ ID NO:

94.

60. The protease-activated pro-cytokine of any one of the preceding claims, wherein the targeting sequence comprises the sequence of any one of SEQ ID NOs: 180-662, or a variant having one or two mismatches relative to the sequence of any one of SEQ ID NOs: 180-662.

61. The protease-activated pro-cytokine of the immediately preceding claim, wherein the targeting sequence comprises the sequence of any one of SEQ ID NOs: 180-662.

62. The protease-activated pro-cytokine of any one of the preceding claims, wherein the targeting sequence binds to denatured collagen.

63. The protease-activated pro-cytokine of any one of claims 1-61, wherein the targeting sequence binds to collagen.

64. The protease-activated pro-cytokine of any one of claims 62-63, wherein the collagen is collagen I.

65. The protease-activated pro-cytokine of any one of claims 62-63, wherein the collagen is collagen II.

66. The protease-activated pro-cytokine of any one of claims 62-63, wherein the collagen is collagen III.

67. The protease-activated pro-cytokine of any one of claims 62-63, wherein the collagen is collagen IV.

68. The protease-activated pro-cytokine of any one of claims 1-61, wherein the targeting sequence binds to integrin.

69. The protease-activated pro-cytokine of the immediately preceding claim, wherein the integrin is one or more of a1p1 integrin, 02p1 integrin, a3p1 integrin, a4p1 integrin, a5P1 integrin, a6pB1 integrin, a7B1 integrin, a9B1 integrin, a4f7 integrin, avp3 integrin, avPS integrin, aIIbB3 integrin, ollIbP3 integrin, cMP2 integrin, or allbp3 integrin.

70. The protease-activated pro-cytokine of any one of claims 1-61, wherein the targeting sequence binds to von Willebrand factor.

71. The protease-activated pro-cytokine of any one of claims 1-61, wherein the targeting sequence binds to IgB.

72. The protease-activated pro-cytokine of any one of claims 1-61, wherein the targeting sequence binds to heparin.

73. The protease-activated pro-cytokine of the immediately preceding claim, wherein the targeting sequence binds to heparin and a syndecan, a heparan sulfate proteoglycan, or an integrin, optionally wherein the integrin is one or more of a1B1 integrin, a2pB1 integrin, 31 integrin, a4P1 integrin, a5P1 integrin, a6P1 integrin, a7P1 integrin, a9B1 integrin, a4p7 integrin, avp3 integrin, avB5 integrin, allbp3 integrin, oIIIbP3 integrin, aMpB2 integrin, or oIIbB3 integrin.

74. The protease-activated pro-cytokine of any one of claims 72-73, wherein the syndecan is one of more of syndecan-1, syndecan-4, and syndecan-2(w).

78. The protease-activated pro-cytokine of any one of claims 1-61, wherein the targeting sequence binds to a heparan sulfate proteoglycan.

76. The protease-activated pro-cytokine of any one of claims 1-61, wherein the targeting sequence binds to a sulfated glycoprotein.

77. The protease-activated pro-cytokine of any one of claims 1-61, wherein the targeting sequence binds to hyaluronic acid.

78. The protease-activated pro-cytokine of any one of claims 1-61, wherein the targeting sequence binds to fibronectin.

79. The protease-activated pro-cytokine of any one of claims 1-61, wherein the targeting sequence binds to cadherin.

80. The protease-activated pro-cytokine of any one of the preceding claims, wherein the targeting sequence is configured to bind its target in a pH-sensitive manner.

81. The protease-activated pro-cytokine of the immediately preceding claim, wherein the targeting sequence has a higher affinity for its target at a pH below normal physiological pH than at normal physiological pH, optionally wherein the pH below normal physiological pH is below 7, or below 6.

82. The protease-activated pro-cytokine of the immediately preceding claim, wherein the targeting sequence has a higher affinity for its target at a pH in the range of 5-7, e.g. 5-5.5,5.5-6, 6-6.5, or 6.5-7, than at normal physiological pH.

83. The protease-activated pro-cytokine of any one of the preceding claims, wherein the targeting sequence comprises one or more histidines, e.g., 1,2, 3,4, 5,6, 7, 8,9, or 10 histidines.

84. The protease-activated pro-cytokine of any one of the preceding claims, wherein the targeting sequence comprises the sequence of any one of SEQ ID NOs: 641-662, or a variant having one or two mismatches relative to the sequence of any one of SEQ ID NOs: 641-662.

85. The protease-activated pro-cytokine of the immediately preceding claim, wherein the targeting sequence comprises the sequence of any one of SEQ ID NOs: 641-662.

86. The protease-activated pro-cytokine of any one of claims 80-86, wherein the targeting sequence is configured to bind, in a pH-sensitive manner, an extracellular matrix component, IgB (CD79b), an integrin, a cadherin, a heparan sulfate proteoglycan, a syndecan, or a fibronectin.

87. The protease-activated pro-cytokine of the immediately preceding claim, wherein the extracellular matrix component is hyaluronic acid, heparin, heparan sulfate, or a sulfated glycoprotein.

88. The protease-activated pro-cytokine of claim 86, wherein the targeting sequence is configured to bind a fibronectin in a pH-sensitive manner.

89. The protease-activated pro-cytokine of any one of the preceding claims, wherein the cytokine polypeptide sequence is an interleukin polypeptide sequence.

90. The protease-activated pro-cytokine of any one of the preceding claims, wherein the cytokine polypeptide sequence is capable of binding a receptor comprising CD132.

91. The protease-activated pro-cytokine of any one of the preceding claims, wherein the cytokine polypeptide sequence is capable of binding a receptor comprising CD122.

92. The protease-activated pro-cytokine of any one of the preceding claims, wherein the cytokine polypeptide sequence is capable of binding a receptor comprising CD25.

93. The protease-activated pro-cytokine of any one of the preceding claims, wherein the cytokine polypeptide sequence is an IL-2 polypeptide sequence.

94. The protease-activated pro-cytokine of the immediately preceding claim, wherein the IL-2 polypeptide sequence has at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of any one of SEQ ID NOs: 1-4.

95. The protease-activated pro-cytokine of the immediately preceding claim, wherein the IL-2 polypeptide sequence comprises the sequence of any one of SEQ ID NOs: 1-4.

96. The protease-activated pro-cytokine of any one of claims 93-95, wherein the IL-2 polypeptide sequence is a human IL-2 polypeptide sequence.

97. The protease-activated pro-cytokine of the immediately preceding claim, wherein the IL-2 polypeptide sequence comprises the sequence of SEQ ID NO:

1.

98. The protease-activated pro-cytokine of any one of claims 93-95, wherein the IL-2 polypeptide sequence comprises the sequence of SEQ ID NO:

2.

99. The protease-activated pro-cytokine of any one of claims 93-98, wherein the inhibitory polypeptide sequence comprises an IL-2 binding domain of an IL-2 receptor (IL- 2R).

100. The protease-activated pro-cytokine of the immediately preceding claim, wherein the inhibitory polypeptide sequence comprises an amino acid sequence having at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of any one of SEQ ID NOs: 10-19.

101. The protease-activated pro-cytokine of the immediately preceding claim, wherein the IL-2R is a human IL-2R.

102. The protease-activated pro-cytokine of any one of claims 93-98, wherein the inhibitory polypeptide sequence comprises an IL-2-binding immunoglobulin domain.

103. The protease-activated pro-cytokine of any one of claims 93-98, wherein the IL-2-binding immunoglobulin domain is a human IL-2-binding immunoglobulin domain.

104. The protease-activated pro-cytokine of the immediately preceding claim, wherein the IL-2-binding immunoglobulin domain comprises a VL region comprising hypervariable regions (HVRs) HVR-1, HVR-2, and HVR-3 having the sequences of SEQ ID NOs: 33, 34, and 35, respectively, and a VH region comprising HVR-1, HVR-2, and HVR-3 having the sequences of SEQ ID NOs: 36, 37, and 38, respectively.

105. The protease-activated pro-cytokine of any one of claims 102-104, wherein the IL-2-binding immunoglobulin domain comprises a VL region comprising an amino acid sequence having at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of SEQ ID NO: 32 and a VH region comprising an amino acid sequence having at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of SEQ ID NO:

33.

106. The protease-activated pro-cytokine of the immediately preceding claim, wherein the IL-2-binding immunoglobulin domain comprises a VL region comprising the sequence of SEQ ID NO: 32 and a VH region comprising the sequence of SEQ ID NO:

33.

107. The protease-activated pro-cytokine of any one of claims 102-104, wherein the IL-2-binding immunoglobulin domain is an scFv.

108. The protease-activated pro-cytokine of the immediately preceding claim, wherein the IL-2-binding immunoglobulin domain comprises an amino acid sequence having at least 80, 85, 90, 95, 97, 98, or 99 percent identity to the sequence of SEQ ID NO: 30 or 31.

109. The protease-activated pro-cytokine of the immediately preceding claim, wherein the IL-2-binding immunoglobulin domain comprises the sequence of SEQ ID NO: 30o0r31.

110. The protease-activated pro-cytokine of claim 1, comprising the sequence of any one of SEQ ID NOs: 803-852.

111. A pharmaceutical composition comprising the protease-activated pro-cytokine of any one of the preceding claims.

112. The protease-activated pro-cytokine or pharmaceutical composition of any one of the preceding claims, for use in therapy.

113. The protease-activated pro-cytokine or pharmaceutical composition of any one of the preceding claims, for use in treating a cancer.

114. A method of treating a cancer, comprising administering the protease- activated pro-cytokine or pharmaceutical composition of any one of the preceding claims to a subject in need thereof.

115. Use of the protease-activated pro-cytokine or pharmaceutical composition of any one of claims 1-110 for the manufacture of a medicament for treating cancer.

116. The method, use, or protease-activated pro-cytokine for use of any one of claims 113-115, wherein the cancer is a solid tumor.

117. The method, use, or protease-activated pro-cytokine for use of the immediately preceding claim, wherein the solid tumor is metastatic and / or unresectable.

118. The method, use, or protease-activated pro-cytokine for use of any one of claims 113-117, wherein the cancer is a PD-L1-expressing cancer.

119. The method, use, or protease-activated pro-cytokine for use of any one of claims 113-118, wherein the cancer is a melanoma, a colorectal cancer, a breast cancer, a pancreatic cancer, a lung cancer, a prostate cancer, an ovarian cancer, a cervical cancer, a gastric or gastrointestinal cancer, a lymphoma, a colon or colorectal cancer, an endometrial cancer, a thyroid cancer, or a bladder cancer.

120. The method, use, or protease-activated pro-cytokine for use of any one of claims 113-119, wherein the cancer is a microsatellite instability-high cancer.

121. The method, use, or protease-activated pro-cytokine for use of any one of claims 113-120, wherein the cancer is mismatch repair deficient.

122. A nucleic acid encoding the protease-activated pro-cytokine of any one of claims 1-110.

123. An expression vector comprising the nucleic acid of claim 121.

124. A host cell comprising the nucleic acid of claim 121 or the vector of claim 123.

125. A method of producing a protease-activated pro-cytokine, comprising culturing the host cell of claim 124 under conditions wherein the protease-activated pro- cytokine is produced.

126. The method of the immediately preceding claim, further comprising isolating the protease-activated pro-cytokine.

127. A method of boosting T regulatory cells and / or reducing inflammation or autoimmune activity, comprising administering the protease-activated pro-cytokine of any one of claims 1-110 to an area of interest in a subject, e.g, an area of inflammation in the subject.

128. A method of treating an inflammatory or autoimmune disease or disorder in a subject, comprising administering the protease-activated pro-cytokine of any one of claims 1- 110 to an area of interest in a subject, e.g., an area of inflammation or autoimmune activity in the subject.

Images